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Preface
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This PhD project was supported by “Associazione Italiana per la Ricerca sul Cancro”
(AIRC) regional grant 2005-2007 and carried out in cooperation with Professor Luisa
Bracci’s research group from the Department of Molecular Biology at University of
Siena.
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Chemotherapy has been the main modality for medical treatment of cancer for decades.
Traditional cytotoxic drugs work primarily through the inhibition of cell division,
affecting cancer cells and certain normal tissues. As a result, this treatment cause
myelosuppression and have also gastrointestinal, cardiac, hepatic, renal, neurologic and
respiratory toxicity. Cancer chemotherapy is limited not only by toxicity to normal
cells, but also by intrinsic or acquired multi-drug resistance (MDR) of tumor cells.
Because of the rapid elimination and widespread distribution of drugs into non-targeted
organs and tissues, the drug needs to be administered in large quantities, which, even
non considering the economic issue, complicates the drawback of non-specific toxicity.
Consequently, chemotherapy often involves a complex compromise between possible
benefits and anticipated side effects. Therefore, the selective targeting of tumor cells is
the goal of modern cancer therapy aimed at overcoming this non-specific toxicity.
Targeted therapy block the proliferation of cancer cells by interacting with specific
molecules which may be present in normal tissues, but they are mutated or over-
expressed in tumors. The main advantages of targeted drug delivery systems consists in
the more specific delivery of cytotoxic agents to tumor expressing receptors and
subsequently a more selective killing of cancer cells. Moreover, the sparing of normal
tissues from the harmful side effects of systemic therapy with a reduced peripheral
toxicity, allows to avoid the necessity of dose escalation overcoming the intrinsic
resistance of some tumors to chemotherapeutic agents.
Antibodies, especially monoclonal human or humanized antibodies (mAbs) against
tumor antigens, were the first, and so far the mainly, used as vectors of conjugated
moieties for targeted tumor therapy or diagnosis. The recent approval of antibodies such
as Herceptin (1998) for breast cancer, Erbitux (2004) and Avastin (2004) for colorectal
cancer have revolutionized chemotherapy. Although unmodified mAbs may show some
therapeutic potency, their affect tend to be various and ultimately not curative when not
used in combination with classical chemotherapy. These antibodies need to be
administered to patients in massive doses to be effective, thus leading to serious side
effects. As a result, mAbs have been armed with drugs, toxins or radionuclides opening
the door to the clinical use of targeted tumor therapy. Among new anticancer drugs
approved by U.S. Food and Drug Administration (FDA) since 2000, fifteen have been
targeted therapies, compared with only five traditional chemotherapeutic agents.1
Although traditional cytotoxic drugs remain the treatment of choice for many
malignancies, targeted therapies are now a component of treatment for many types of
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cancer. Despite all the advancements, most tumor-specific drugs which have undergone
registration or are undergoing clinical or preclinical trials (among them almost 20 are
immuno-conjugates2) are devoid of cytotoxic activity and ability to kill or damage
tumor cells.
The effect of these therapies is mainly cytostatic, so not curative, and consist in the
retardation of tumor growth or reduction of tumor mass. The main drawbacks on the
use of immunoglobulins as tumor targeting agents are the instability of the conjugate
and suboptimal pharmacokinetics and biodistribution of the mAb, as their non-specific
uptake by the liver and reticuloendotelial system.
Most hormonal approaches to target cytotoxic agents and radioisotopes to cancers are
now based on peptides. Peptides became potential vectors for tumor targeting when
receptors for different endogenous peptides were observed to be expressed and over-
expressed in different human tumours.3 In particular the finding that somatostatin
receptors are expressed on the plasma membrane of several human neuroendocrine
tumors opened the way for peptide receptor targeting.4,5 As tumor targeting agents,
peptides have several advantages over antibodies8, including:
o better organ or tumor penetration and more efficient cellular internalisation,
because the antibody molecules are relatively large and might not reach easily
the tumor.
o greater stability (long storage at room temperature)
o lower manufacturing costs (recombinant production takes approximately twice
as much, in terms of time and costs than chemical synthesis) and more uniform
batch-to-batch production parameters, due to the advances in solid-phase
peptide synthesis
o fewer and less expensive regulatory requirements (chemical synthesis versus
recombinant production) and easier and quicker authority approval.
For these reasons, peptide-derived drugs are now widely used for tumor therapy and
diagnosis.6-8 DOTATOC and OctreoScan, modified somatostatin analogues
conjugated to a metal chelator, are currently used for respectively the therapy and
diagnosis of neuroendocrine tumors in humans. Nonetheless, the applications are just
limited to neuroendocrine tumors that express sufficient somatostatin receptors. Other
regulatory peptides are now candidates as tumor-targeting agents, (such as neurotensin,
lutheinizing peptides, gastrin realising peptides, bombesin analogues, substance P,
glucagon-like peptide 1). Moreover an increasing number of tumors can be addressed
by ‘magic-bullet’ (‘peptide-bullet’) strategy, conjugating peptides with functional units
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(diagnostic or cytotoxic moieties) which can be specifically delivered into the tumor
cell by internalization of the receptor-ligand complex by endocytosis (Figure 1).
Figure 1. Endocytosis for intracellular drug delivery: 1. Binding of drug delivery unit to a specific ligand;
2. Formation of endosome; 3. Endosome-lysosome fusion; 4. Degradation of the endodomal content by
lysosomal enzyme; 5. Endosomal escape, and subsequent delivery of drug to the cytoplasm.
Neurotensin (NT) is a 13-amino acids regulatory peptide, sharing significant similarity
in its C-terminal portion of amino acids with several other neuropeptides (Figure 2).
This region is responsible for the biological activity as neurotransmitter while the N-
terminal portion has a modulatory role. Neurotensin is distributed throughout the
central nervous system, with highest levels in the hypothalamus, amygdala and nucleus
accumbens. It induces a variety of effects, including: analgesia, hypothermia and
increased locomotor activity. It is also involved in regulation of dopamine pathways. In
the periphery, neurotensin is found in endocrine cells of the small intestine, where it
leads to secretion and smooth muscle contraction.
Figure 2. QLYENKPRRPYIL: Neurotensin (NT)
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Three different receptors for neurotensin (NTR1, NTR2, and NTR3) have been
discovered, cloned and studied so far.9,10 Neurotensin receptors, in particular the high-
affinity NTR1, are expressed in several human tumors, such as small cell lung cancer
and colon, pancreatic, and prostate carcinomas (Table 1).4,8,10,11 Over 75% of all ductal
pancreatic carcinomas were reported to overexpress neurotensin receptors, whereas
normal pancreas tissue, pancreatitis, and endocrine pancreas do not.12
Table 1
TUMOR TYPE COLON PANCREAS PROSTATE LUNG
NT Expression &
Synthesis
Yes Yes Yes Yes
NTR1 Expression Yes Yes Yes Yes
NTR2 Expression No No No _
NTR3 Expression Yes Yes Yes _
MAPK Activation Yes Yes _ Yes
Proliferative stimulus Yes Yes Yes Yes
Neurotensin is considered the best possible candidate for peptide based therapy of
exocrine pancreatic carcinomas,8 due to the high incidence and density of neurotensin
receptors in these tumors, and of whole the gastrointestinal tract cancers in general.
Unfortunately the use of protein and peptides, as Neutotensin, in therapy is hampered
by their short half-life, due to physiological degradation by peptidases and proteases.
A truncated COOH-terminal fragment NT(8-13:RRPYIL), fundamental for the
interaction peptide-receptor, is slightly more stable than NT while maintaining
neurotensin receptor affinity. However, the half-life of NT(8-13) is still too brief for
tumor targeting in vivo.13
To circumvent this problem, various neurotensin analogues have been synthesized,
including linear peptides,13-15 cyclic peptides,16 and non-peptide molecules,17 but
chemical modification of the native peptide may radically modify receptor affinity and
specificity. Prof. Luisa Bracci’s group previously reported that synthesis in branched
form (Figure 3) increased the biostability of certain peptides, including neurotensin,
obtaining promising results in vitro and in vivo both for diagnostic and therapeutic
purposes.18,19
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Figure 3 Schematic MAP representation
Synthesis of bioactive peptides in Multiple Antigen Peptide (MAP) dendrimeric form
can result in increased half-life, due to acquired resistance to protease and peptidase
activity. MAPs, introduced for the first time by Dr. James Tam, have a peptidyl core of
radially branched lysine residues onto which peptides can be added using standard
solid-phase chemistry (Figure 4).20 MAPs can be more efficient than monomeric
peptides in diagnostic applications and moreover have the possibility to be conjugated
to various Functional Units such as fluorophores, photosensitizers, cytotoxic groups or
chelators for radioisotopes.
Figure 4 Peptide tetramer with three-lysine branched core
The in vitro and in vivo efficiency of dendrimeric peptides like MAPs is generally
ascribed to their multimeric nature, which enables polyvalent interactions.
In order to test the possible influence of peptide length, number of peptide copies, and
steric hindrance on branched peptide stability to peptidases, the monomeric, two-
branched and tetra-branched forms of NT and NT(8–13) were synthesized and their
stability, after incubation with human plasma and serum was compared. A correlation
was made between the number of peptide copies in branched neurotensin and NT(8–13)
and stability in plasma and serum. Prof. Bracci found that the tetra-branched form of
neurotensin and its short analogue NT(8–13) were stable in both human plasma and
serum for 24 h, whereas the two-branched for 5 h and and the monomeric analogues
were degraded in roughly 5 h (Tables 2 and 3).19
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Table 2. Stability of monomeric, dimeric and tetra-branched NT in plasma and serum
PLASMA SERUM
PEPTIDE 2h 5h 24h 2h 5h 24h
QLYENKPRRPYIL + - - + - -
(QLYENKPRRPYIL)2
K
+ + - + + -
(QLYENKPRRPYIL)4
K2K
+ + + + + +
Table 3 Stability of monomeric, dimeric and tetra-branched NT(8-13) in plasma and serum
PLASMA SERUM
PEPTIDE 2h 5h 24h 2h 5h 24h
RRPYIL + - - + - -
(RRPYIL)2K + + - + + -
(RRPYIL)4K2K + + + + + +
The tetrameric form has also receptor affinity, which in the case of tetrabranched NT(8-
13), is even higher than that of the monomeric peptide,18,19 probably due to the
polyvalent interactions.
As expected, the native and short peptide have similar resistance to plasma and serum
proteases, because most proteolytic enzymes that inactivate NT have their cleavage
sites in the short NT(8–13) sequence (Figure 5),21 the longer sequence of NT does not
introduce new sites.
Figure 5. Neurotensin specific cleavage enzymes
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In order to determine whether multimericity or branched structure contributes to peptide
stability, linear and branched multimeric peptides were compared. Tetrameric peptides
showed a dramatic difference in proteolytic resistance. The linear tetramer was very
labile being cleaved by blood proteases like the linear monomer (Table 4), whereas the
branched tetramer was stable up to 24 h in plasma and serum. This established that, as a
general rule, multimeric branched forms are more stable than the corresponding
monomeric forms and that multimericity progressively enhances the stability of
peptides. Peptidases acting on small endogenous peptides are mainly Zn
metallopeptidases like neurolysin, the catalytic centre of which is located in a deep
channel, to which only small peptides have access (Figure 6).22,23 Although binding of
the peptide in the catalytic pocket may still be possible, the cleavage site may be
geometrically unreachable by catalytic residues, especially in tetrabranched peptides
that, unlike two-branched ones, cannot achieve an extended conformation. As a result,
the steric hindrance may limit their access to the cleavage site of these peptidases,
lengthening the peptide half-life, with obvious advantages for their use as drugs.
Figure 6 shows Neurolysin (white) and tetrabranched NT (orange) as seen parallel (A) and perpendicular
(B) to the major axis of the groove containing the catalytically active zinc site of the enzyme.
The possibility to form supramolecular aggregates is another feature of branched
peptides probably accounting for their increased stability.
Tetrabranched peptides may arrange their four arms in parallel structures stabilized by
intramolecular H-bonding of the backbone. This structure would resemble that of self-
assembling β-sheet peptides. Prof Bracci’s group analyzed the presence of aggregates in
branched peptide in solution using gel filtration, finding that the tetrabranched NT(8–
13) monomer might be in equilibrium with a small aggregate of four or five units.19
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The formation of small aggregates might decrease the rate of proteolysis and has to be
taken into account for the increased half-life of branched peptides.
As already suggested, the finding of new specifically targeted cytotoxic drugs is an
important challenge in cancer research, where receptor-specific small peptides may
have major potential applications, provided that they are stabilized to overcome their
degradation by plasma proteases. Prof. Bracci’s results indicate that synthesis in
dendrimeric form may be a general method to increase in vivo stability of bioactive
peptides and so a step forward on this direction.
On the basis of these observations in 2005 “Associazione Italiana per la Ricerca sul
Cancro” (AIRC) granted to three groups, including that of my tutor at the University of
Florence, a research project titled “Selection and development of new molecules for
tumor therapy and in vivo diagnosis”. The Florence unit used part of this grant for the
present PhD course. The aim of the project was to set up a general method for the
design and synthesis of peptide molecules for tumor targeting, both for therapy and for
in vivo imaging. These new molecules have been designed as dendrimeric neurotensin
derivatives carrying functional units as fluorophores, photosensitizer, cytotoxic drugs
and chelators for radionuclides. The project is based on the data reported above,
demonstrating that peptides in such a dendrimeric form are particularly suitable for in
vivo use because they acquire a notable resistance to degradation by proteolytic
enzymes, though maintaining or even increasing their natural biological activity.
Neurotensin and its functional fragment, synthesised as tetramers, offers even
accessible linking units for coupling of functional moieties.
Figure 7. Functional Units conjugated to the dendrimeric carrier
Results obtained with tetra-branched NT(8-13) bound to biotin or fluorescein
demonstrate that it fully retains its binding activity on neurotensin specific receptor on
HT-29 (colon adenocacinoma) tumor cell line.24 These outcomes bring new
perspectives to the use of dendrimeric NT(8-13) as a carrier, multifunctional targeting
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molecule, where cancer detection, screening, diagnosis and therapy are obtained by
means of the same molecule, with no modification in target binding, but ‘simple
exchange’ of functional units. Since cancer cells are very different from one another in
terms of drug sensibility, not only in different tumors, but in different patients and
stages of the disease, this approach prefigures the synthesis of a number of constructs
conjugated with different chemotherapeutics. Bracci’s group has set up a general
method allowing conjugation by standard solid-phase peptide synthesis. The C-
terminal lysine’s side chain was functionalized with the chemotherapeutics spaced by a
PEG (polyethylenglycol) moiety, chosen in consideration of synthetic and biological
issues. The hindrance of the branched peptide might impair the access of the activated
chemotherapeutic and therefore give poor reaction yields. Moreover the drug moiety, if
closely linked to the branched peptide, might impair receptor recognition and, for slow
realizing compounds, the closeness of branched peptide might compromise drug-target
interaction inside the cell. The pending amino group is then coupled to Functional
Units, carrying an accessible COOH group, so that the synthesis can be led in
succession, directly on the resin support.
Figure 8. Conjugation procedure
The choice of linker’s structure to be inserted between tetrabranched NT and the
Functional Unit is fundamental because in the case of cytotoxic molecules the link has
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to be broken preferably upon internalization into the tumor cell. In other words the
conjugate can be regarded as a ‘prodrug’, defined as non-toxic form of active drug
which is converted in the body into the active species either chemically or
metabolically.25 Non-specific prodrugs are activated systematically (e.g. in plasma) and
are normally employed to improve solubility or pharmacokinetic properties. In contrast,
tumor-activated prodrugs aim to improve specificity of action of cytotoxins, by
providing non-toxic forms that can distribute systemically but which are specifically
activated to the toxic form only or preferably in tumor tissue. The activation step makes
use of some unique physiological, metabolic or genetic differences between tumour and
normal cells, such as different oxygen, ligands and enzymes concentrations.26 We
decide to use disulfide or ester linkage as covalent bonds suitable for safety delivering
the drug inside the cell where the releasing of the anticancer agent occurs respectively
by reaction with citoplasmatic thiols (for example glutathione, GSH) or by hydrolysis
(mediated by ubiquitous esterases). The preparation of selected conjugated pro-drugs,
drugs and diagnostic tools have been the main challenge of this PhD project. As it will
be described in the following sections, we have synthesized a variety of carboxylic
derivatives decorating the most common anticancer drugs (Combretastatin A-4 (CA4),
Tirapazamine (TPZ), 6-Mercaptopurine (6-MP), 5-Fluoro-2’-deoxyuridine (5-FdUrd),
Gemcitabine, Monastrol) and metal chelators (DOTA) (Figure 9).
Figure 9. Common anticancer drugs which have been modified during this PhD.
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The accessible COOH groups have been then coupled with the NH2 group, introduced
ad hoc on the tetrameric peptide, by standard solid phase peptide synthesis.
The synthetic results obtained as well as the anti-tumour activity of these derivatives,
once conjugated to the tetrameric peptide NT(8-13), will be reported in this thesis.
Results and Discussion
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1. Synthesis of modified drugs
1.1 Chelating agents (DOTA analogues)
Current interest in the clinical use of chelating agents as vehicles for metals in
biological systems has led to the synthesis and study of a large number of new cyclic
polioxa or polyaza ligands. One class that has shown great promise for clinical
applications is the polyazamacrocyclic polycarboxilate ligands.27 Particularly, 1,4,7,10-
tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic acid (DOTA) (Figure 10) and its
analogues became a subject of universal interest because they form stable complexes
with a wide variety of metal ions. Furthermore metal-DOTA complexes have been
shown to be kinetically inert under physiological conditions.28
Figure 10 DOTA and octa-coordination around a metal
Among metal ions which can be strongly encapsulated by DOTA, radiometals such as
111In(III), 67Ga(III) and 99mTc(VII) have physical properties which are well suited for
tumor imaging, while 90Y(III), 67Cu(II), 186Re(VII) and 177Lu(III) have cytotoxic
properties which can be exploited for therapy.
Paramagnetic ions, as Gd(III), are instead generally exploited for Magnetic Resonance
Imaging (MRI), which is a technique able to visualize intact opaque organisms in three
dimensions and, therefore, provide an alternative to light microscopy and
radiopharmaceutical methods.29 The image is based upon the NMR signal from the
water’s proton, where the signal intensity in a given volume element is a function of the
water concentration and relaxation times (T1 and T2). Gadolinium-based contrast agents
for MRI enhance tissue contrast by increasing the relaxation rate (1/T1) of water protons
and are widely used in clinical diagnostics.
One of the major problems in conventional contrast agents and radiopharmaceuticals is
that they are primarily extracellular with an aspecific biodistribution.
Results and Discussion
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For these reasons, the next generation of contrast agents will include systems able to
recognize specific molecules on the cellular surface that act as early reporters of a given
pathology. The targeting of over-expressed membrane receptors with specific
radiopharmaceuticals is already a well-established diagnostic method in nuclear
medicine for several types of tumors. A somatostatin radioligand, DOTA-[D-Phe1-
Tyr3]-octreotide (DOTATOC), has been the first synthesized for therapeutic purposes,
because of its stable and easy labeling with 90Y. Starting from this successful
compound, the number of peptide-metal chelate based molecular sensors, diagnostic
and therapeutic agents is rapidly increasing and is becoming one of the most
challenging areas of research.30
Considering our perspectives in peptide targeted tumor therapy we decided to conjugate
a chelating agent to our carrier and exploit its efficacy on detecting or killing of tumors,
once complexed with an appropriate metal. For this purpose we selected, as a suitable
chelating agent, DOTA because of the promising results obtained and the opportunity
of direct coupling between the petide’s free amine and its carboxylic functionalities.
In literature is reported that DOTA-modified peptides are generally synthesized either
in solution31 or on solid support32 attaching the DOTA residue to a free amine of the
resin bound peptide. DOTA or a derivative can be both directly attached to the peptide
or a linker may be included between the peptide chain and the chelator. The selection of
the linker is dependent on the desired pharmacokinetic and chelating properties of the
conjugate. Based on this, we designed the synthesis of three DOTA derivatives 1-3
(Figure 11) functionalised with a single pending carboxylic acid moiety to permit their
coupling with the free amino group of the dendrimeric peptide using standard solid
phase peptide synthesis. The carboxylic acids not to be involved in the coupling, were
protected as t-Bu esters, to overcome side reactions by polyactivation of the four
carboxylic groups of DOTA, and easily deprotected during the final acid cleavage of
the modified peptide from the solid support.
Figure 11 The three DOTA derivatives synthesized
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As a suitable common starting material, 1,4,7,10-tetraazacyclododecane-1,4,7-tris(tert-
butylacetate) 4, was prepared, as shown in Scheme 1, reacting in dimethylacetamide
(DMA) tert-butylbromoacetate (3 eq.) with a solution of tetraazacyclododecane (1 eq.),
commercially available as cyclen, and Na(CH3COO) (3 eq.). The tert-butyl ester of
DO3A (1,4, 7,10-tetraazacyclododecane-1,4,7-triacetic acid) 4 was obtained by
precipitation after 20 days under stirring in 55% yield (Scheme 1).
Scheme 1
The derivative 1 was obtained, as previously reported,31 by adding benzylbromoacetate
to compound 4 in DMF in the presence of NaH. The reaction mixture was then stirred
for a day at room temperature (r.t.), then a solution of 5% citric acid was added and the
mixture extracted with chloroform. The product obtained was purified by flash
chromatography to yield N-(benzylcarboxymethyl)-1,4,7,10-tetraazacyclododecane-
N’,N’’,N’’’-triacetic acid tri-tert-butyl ester 5. A mixture of this compound and 10%
Pd/C was hydrogenated in methanol under a positive H2 atmosphere for 6 hours to yield
the modified DOTA macrocycle 1 in 50% yield (meant for two reactions) (Scheme 2).
Scheme 2
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With the aim to modulate the linker between the chelating moiety and the targeting
peptide and so hopefully improve the chelating ability, we designed the synthesis of
derivative 2 where a benzyl group is interjected.
Compound 2 was synthesised with a similar procedure to the one reported above, but
using another halogenated compound, which has been prepared expressly by heating a
suspension of 4-chloromethylbenzoic acid in benzyl alcohol, which works both as
solvent and reagent, in acidic conditions. The crude product obtained was purified by
column chromatography to give the desired benzyl derivative 6.
The benzyl ester of 4-chloromethylbenzoic acid 6 (1 eq.) was added to a solution of 4 (1
eq.), and 3 eq. of K2CO3, in dry MeCN at 60 °C. After 2 days, the suspension obtained
was filtered through celite and concentrated, giving DO3A derivative 7 without further
purification. The following hydrogenation was performed at high pressure, 50 psi of H2,
for 60 hours, to obtain benzyl derivative 2 after purification by column chromatography
in an overall 50% yield of two reactions (from 4 to 2) (Scheme 3).
Scheme 3
Structure of compounds 1 and 2 ensure a selective and efficient coupling with the
dendrimeric peptide, as it is shown in chapter 3, through the formation of a single amide
linkage. However this will cause a lower ability of encapsulating metals due to the lack
of a free carboxylic acid group when compared with unmodified DOTA. (Figure 12)
Results and Discussion
17
Figure 12 Complexation
Therefore we planned to synthesize the DOTA derivative 3, by modification of
previous methods,34 which contemporarily ensures the possibility of an active coupling,
using the standard solid phase peptide chemistry, and an octa-coordination around the
selected metal once the t-butyl esters have been hydrolyzed.
Operatively, starting from the commercially available L-glutamic acid-5-benzylester (1
eq.), using a method analogous to Holmberg,32 a suspension with sodium bromide (3
eq.) in a cooled 1N solution of bromidric acid was made and sodium nitrite (2 eq.) was
added portionwise. The yellow solution was stirred for 2 hours and finally 560 μL of
98% sulfuric acid were added, followed by diethylether. The crude product was purified
by flash chromatography to obtain bromoacid 8 in 82% yield.
The protection of the free carboxylic group was obtained adding dropwise a solution of
tert-butyltrichloroacetimidate (TBTA) (2 eq.) in cyclohexane to a solution of 8 (1 eq.)
in CHCl3. During the addition a white precipitate formed, which was dissolved by the
addition of DMA before adding a catalytic amount of boron trifluoridiethyl etherate
(0.1 eq.). The reaction mixture was stirred for three days at r.t.. Flash chromatography
was then necessary to isolate bromoester 9 in 50% yield.
The following coupling with the macrocyclic ring was performed as usual, in mild basic
conditions. A mixture of 4 (1 eq.) and K2CO3 (3 eq.) was stirred in dry acetonitrile at 60
°C for 10 min before adding dropwise, over a period of 40 min, a solution of 9 (2 eq.) in
dry acetonitrile. After 42 hours under stirring at 60° C the yellow solution was filtered
through celite and concentrated. The residue was chromatographed to obtain benzyl
ester 10 isolated in 59% yield. Eventuallly 10 was dissolved in absolute ethanol and
hydrogenated over 10% Pd/C under a positive H2 atmosphere for 48 hours to give the
desired product 3 in 79% yield without the necessity of a further purification (Scheme
4).
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Scheme 4
As it is shown in Scheme 4 this derivative (3) can be conjugated to the dendrimeric
peptide without affecting its complexation ability, because, like for DOTA, an octa-
coordination around the metal, resulting in a compact square-antiprism involving four
nitrogen atoms in one plane and the four oxygen atoms in a second plane, is perfectly
available.
Results and Discussion
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1.2 Cytotoxins
Cytotoxic chemotherapeutic agents are defined as anticancer drugs that kill cells and
especially cancer cells. Almost six decades separate us from the first clinical application
of an antitumor drug. Nearly all major achievements in cytotoxic therapy were made in
early stages, 20-30 years ago, when anticancer drugs such as Cisplatin, Doxorubicin,
Cyclophosphamide, 5-Fluorouracil, Tamoxifen, 6-Mercaptopurine, etc., were
developed.
Today a large variety of registered and under clinical trials cytotoxins are used in the
treatment of malignant tumors. Among these drugs we selected the most useful, taking
in consideration the type of tumors where the neurotensin receptors (NTRs) are over-
expressed (Table 1), and at the mean time the most suitable to be synthetically modified
in order to be conjugated to the targeting dendrimer.
The selection regarded efficient but non-specific chemotherapeutics from some of the
most common anticancer classes, such as antimetabolites, bioreductive drugs and
mitosis inhibitors, with the aim to transform them into tumor selective drugs. The
simple exchange of Functional Units allowed to test a wide variety of different
cytotoxins with different mechanism of action, cytotoxicity and problems, therefore
increasing the chances of success.
Results and Discussion
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1.2.1 Antimetabolites
Antimetabolites are substances bearing a close structural resemblance to ones required
for normal physiological functioning, and exerting their effect by interfering with the
utilization of the essential metabolites. In the cell, antimetabolites are mistaken for the
metabolites they resemble, and are processed in the cell in a manner analogous to the
normal compounds. The presence of the 'decoy' antimetabolites prevents the cells from
carrying out vital functions and the cells are unable to grow and survive. In cancer
treatment they can be used, as they interfere with DNA production and, therefore cell
division and tumor growth. Because cancer cells spend more time dividing than other
cells, inhibiting cell division harms tumor cells more than other cells. Even if the
clinical application of these drugs have shown an inadequate selectively which brings
serious side effects, antimetabolites can be used for their high cytotoxicity as Functional
Units in tumor-targeting systems.35
a) The antimetabolite 6-Mercaptopurine (6-MP) 11 is a synthetic analogue of the
natural purine, adenine, where the amine group is replaced by a thiol (Figure 13).
Figure 13
The biological activity of 6-MP is complex and involve cellular metabolism in several
ways. Two of 6-MP metabolites, 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-
thioinosine (T-IMP), inhibit nucleotide interconversions and de novo purine synthesis,
thereby blocking the formation of purine nucleotides and inhibiting DNA replication.
This agent is also incorporated into DNA in the form of deoxythioguanosine, which
results in the disruption of DNA replication. In addition, mercaptopurine is converted to
6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase;
MMPRs are also potent inhibitors of de novo purine synthesis.
6-MP has been widely used as a chemotherapeutic agent and, to a lesser extent, as an
immunosuppressant for almost five decades. The drug is still used in the treatment of a
variety of conditions, including leukemias, limphomas, adenocarcinomas,36
rheumatologic disorders and prevention of rejection following organ transplantation.
However, oral absorption of 6-MP is erratic with only 10-50 % of the administered dose
reaching the systemic circulation. The limiting factors in the use of mercatopurine are
the very short half-life in plasma (0.5-1.5 h) and its very variable bioavailability (about
Results and Discussion
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16 %). Moreover, severe bone marrow toxicity, with a subsequent risk of infections,
anaemia and bleeding, and liver toxicity are associated with 6-MP treatment. Strategies
to circumvent these problems have included the design of prodrugs that might decrease
the systemic toxicity of 11 while ensuring its delivery to the target tissue.
Prodrugs are biologically inert or substantially inactive forms of the parent or active
compound, where the release rate of the active drug is influenced especially by the type
of bond joining the parent drug to the modifier.
Glutathione (GSH) is an ubiquitous compound that is important in cellular defense
mechanism and amino acid transport. Elevated GSH content and levels of glutathione
S-transferases (GSTs), GSH peroxidase and GSH reductase (GR) were detected in
many tumors compared with the healthy tissues.37 Moreover, increased levels of GSH
were associated to drug resistance. This condition has been useful to design 6-MP
prodrugs such as azathioprine (AZA) 12, that has been shown to be superior to 6-MP as
an immunosuppressant, whereas its therapeutic index against leukaemia and
adenocarcinoma is similar to that of 11. AZA has now replaced 6-MP in the treatment
of organ transplant patients and other structural analogues have been exploited as
anticancer drugs. The biological activity of AZA and its structural analogues (AVTP,
13, and PTA, 14) is due to their GSH-mediated metabolism to 6-MP.36,38 Gunnarsdottir
and Elfarra have characterized the metabolism of cis-3-(9H)-purin-6-ylthio)acrylic acid
(PTA, 14), targeting tumors with up-regulated GSH levels. Structurally, PTA is a
propenoic acid conjugate of 6-MP and a Michael acceptor that undergoes addition-
elimination reaction with nucleophiles to yield the parent drug.
Figure 14
6-MP is formed via two distinct pathways, in the first 11 is obtained indirectly via the
formation and further metabolism of S-(9H-purin-6-yl)glutathione (PG) 15, the major
metabolite formed in the reaction between PTA and GSH after the attack on the C-6 of
the purinic ring (Scheme 5).
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Scheme 5
In the second pathway, 6-MP was formed directly from PTA through an addition-
elimination reaction with GSH, as is shown in Scheme 6. This mechanism is dependent
on the GSH concentration and on pH and it can occur in a non-enzymatic way.
Scheme 6
Therefore, the presence of a carboxylic moiety and the ability to release 6-MP
preferably into the cancer cells, due to the high levels of GSH and its enzymes, make
PTA a suitable prodrug to be coupled to our targeting peptide.
We decided to synthesise compound 14 by modification of previous methods,38 because
with the amount of MeONa reported in literature, 3 eq., we obtained the undesired
product 16, resulting from the bis-addition of the methoxide, onto the propiolic acid,
with a subsequent low yield of 14 (Scheme 7).
Scheme 7
Instead, adding a stoichiometric amount of a freshly prepared solution of MeONa (1
eq.) in dry MeOH and propiolic acid sodium salt (1 eq.) to a suspension of 11 (1 eq.) in
dry MeOH, acid 14 precipitated as pure product in 43% yield, after the addition of HCl
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1N until pH 2. This procedure allowed the achievement of only the Z isomer (Scheme
8).
Scheme 8
We have also verified the formation of PTA from the ethyl propiolate using the same
strategy shown in Scheme 7, with stoichiometric amounts of sodium methoxide, led to
derivative 17, generated from a trans-esterification to the corresponding methyl ester, in
14% yield. The alkaline hydrolysis and following acidification gave 14 quantitatively as
a mixture of E and Z isomers (Scheme 9).
Scheme 9
Since the efficiency of the linker in releasing the drug is crucial for this kind of prodrug
and since releasing of 6-MP from PTA is quite slow,36 possibly because the propenoic
acid moiety is ionized at physiological pH slowing the Michael addition, we decided to
prepare other types of 6-MP derivatives differently conjugated to the carrier peptide.
For this reason, we studied the properties of a structural analog of PTA, 6-(2-
acetylvinylthio)purine AVTP 13 (Figure 4) where the sulfur is conjugated to a butenone
moiety. This α,β-unsaturated ketone undergoes a more efficient addition-elimination
reaction with GSH than PTA, to yield 6-MP.
Therefore, we designed the synthesis of an α,β-unsaturated prodrug with general
structure 18, bearing a carboxylic group to allow the conjugation to the branched
peptide. We imagined to obtain this type of molecules by the same addition between an
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electron-poor alkyne and the thiolate group of 6-MP observed in Scheme 7. The
retrosynthetic Scheme 10 shows the designed procedure.
Scheme 10
After browsing all the commercial sources of carboxyaldehydes we selected methyl-4-
formylbenzoate as the first suitable starting material to verify our retrosynthetic
scheme. Ethynyl magnesium bromide (1 eq.) was reacted with methyl-4-
formylbenzoate (1 eq.) in THF at -78 °C to give the correspondent secondary alcohol
19 in 69% yield, without affecting the ester function. The oxidation to ketone 20 was
carried out in 97% yield, following a mild and chemoselective oxidation strategy,39
adding catalytic amounts of 2,2,6,6-tetramethylpiperidin-1-yloxy (TEMPO) to a
solution of 19 and trichloroisocianuric acid (TCICA) in CH2Cl2. The reaction mixture
was stirred for 3 min at r.t. then simply filtered through celite (Scheme 11).
Scheme 11
Once obtained the desired alkyne 20 was subjected to the usual reaction with ionized 6-
MP, as shown in Scheme 12, but the crude product, where reasonably there was
compound 21, was insoluble in all the solvents tried, even after deprotection of the ester
group by alkaline hydrolisys. Probably the benzene ring considerably reduces the low
mercaptopurine’s solubility and this would have been a big disadvantage especially in
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the next peptide coupling. We therefore realized that another suitable α,β-unsaturated
modified prodrug had to be exploited.
Scheme 12
To circumvent the problem caused from the benzene ring we decided to introduce an
alkylic chain on the sulphur atom of 6-MP. Commercially available ethyl-6-
hydroxyhexanoate was quantitatively oxidised to the corresponding aldehyde 22 again
with trichloroisocianuric acid (TCICA) (1 eq.) and catalytic amount of 2,2,6,6-
tetramethylpiperidin-1-yloxy (TEMPO) in CH2Cl2. Reaction of the aldehyde 22 (1 eq.)
with ethynyl magnesiumbromide (1 eq.) at -78°C in THF allowed the preparation of
propargylic alcohol 23 (43%) which was purified by flash chromatography. The alkyne
24 containing an α,β-unsaturated carbonyl group was eventually obtained using the
above described oxidation method adding TEMPO and TCICA to a solution of 23 in
CH2Cl2 at 0 °C. The reaction mixture was stirred at r.t. for 20 h, diluted with CH2Cl2,
filtered through celite and after purification by flash chromatography we obtained 24 in
quantitative yield. Finally, the addition of the 6-MP thiolate, generated in the presence
of MeONa, to the acetylenic group gave the prodrug derivative 25 (47%), which has a
good solubility in organic solvents as we expected (Scheme 13).
Scheme 13
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Disappointingly in spite of all the efforts done in both acidic or basic conditions, as
reported in Scheme 14, we couldn’t isolate the desired acid 26.
Scheme 14
On the other hand an advanced hydrolysis of derivative 24 to its corresponding acid
offered a solution to these deprotecting problems, but the so prepared acid did not react
with 6-MP to give 26.
After all these attempts that in any case led to insoluble or undesired compounds, an
α,β-unsaturated prodrug (27) was obtained starting from succinic anhydride. In
literature is reported the preparation of α,ω-ketoacids by reaction of a Grignard reagent
with a cyclic anhydride.41
Succinic anhydride (1 eq.) was desymmetrizated as mono-t-butyl ester 28 by the
addition of N-hydroxy succinimide (NHS) (0.3 eq.), 4-dimethylaminopyridine (DMAP)
(0.1 eq.), tert-butanol (3 eq.) and triethylamine (TEA) (0.3 eq.).42 After one day under
reflux the crude was purified by flash chromatography to give 28 in 73% yield. This
carboxylic acid was activated utilizing the standard peptide coupling strategy, adding
O-benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate (HBTU) (1 eq.)
and N,N-diisopropylethylamine (DIPEA) to its solution in dry DMF. Then a solution of
N,O-dimethylhydroxylamine 29 was added to the activated acid 28 and stirred for 3 h to
obtain the corresponding Wienreb amide 30 in 76% yield without further purification.
The reaction of 30 with an excess (5 eq.) of ethynyl magnesium bromide in THF
afforded the alkynyl-γ-ketoester 31 in 47% yield. Michael addition of 6-MP anion to
the electron poor triple bond of 31 followed by acid hydrolysis of the t-butyl ester group
of 32 with TFA in CH2Cl2, allowed the isolation of compound 27 in 84% yield (Scheme
15).
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Scheme 15
The last reaction described in Scheme 15 demonstrated the stability of the ketoacid 27
in TFA, which is a fundamental requirement for all the molecules that we prepared. In
fact TFA is the reagent used at the end of the process for the cleavage of the conjugated
peptide from the resin support.
We have imagined another GSH-mediated mechanism for the releasing of 6-MP from a
reductively activated prodrug of 11 possible with the introduction of a disulfide linkage
(Scheme 16).43 Along similar lines Vrudhula et al.44 have synthesized several C2’-
disulfide Taxol (paclitaxel) derivatives, based on the similar notion that the disulfide
bond could be reduced to free thiol in the hypoxic environment of the tumor site. As
shown below we designed a 6-MP derivative with general formula 33 with an alkylic
chain separating the disulfide linkage and the carboxylic moiety. The releasing of 11
inside tumor cells should take place through a simple thiol-disulfide exchange with, for
example GSH, considering the elevated levels in the tumor tissue of endothiols.
Scheme 16
The desired disulfide was so prepared by two different strategies both starting from
dithiobutyrric acid 34 which was protected as methyl (35) and benzyl ester (36) both by
a Fischer direct esterification and as t-butyl ester (37) by the formation of the
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corresponding acyl chloride. Initially we hypothesized a reaction between a
thiolsulfonate acting as an electrophile and the sulfur of 6-MP used as the nucleophile.
Derivatives 35 and 36 were so oxidized with m-CPBA (meta-chloroperoxybenzoic acid,
2.2 eq) in CH2Cl2 for 8 h. The opaque solution was washed with a 10% solution of
sodium thiosulfate and twice with a saturated solution of sodium carbonate. The residue
obtained was purified by flash chromatography to give thiolsulfonate 38 and 39. The
same reaction conduced on t-butyl ester 37 instead didn’t allow the isolation of the
desired thiolsulfonate 40 (Scheme 17).
Scheme 17
The derivatives 41 and 42 were prepared reacting for 12 h thiolsulfonates 38 and 39
with 6-MP 11 in dry DMF, at 60°C in the presence of TEA (1 eq.). The crude was
diluted with a saturated solution of ammonium chloride, extracted with EtOAc and the
organic layer was washed with water. The residue was purified by flash
chromatography to yield the mercaptopurine derivatives 41 and 42.
All the various attempts to hydrolyze the methyl ester function, run both in basic and
acid conditions as well as in the presence of aluminum chloride (AlCl3) and N,N-
dimethylaniline, failed. In the same way the hydrogenation in neutral conditions of 42
gave as the unique product the 6-MP. The reason was clearly the high instability of
purinic disulfides regardless of the reaction conditions.
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Scheme 18
While trying to obtain compound 41 in high yields, we designed another strategy45,46
where the same product can be obtained by a two-step sequence as it follows.
To a solution of ester 35 in dry toluene was added dropwise a solution of SO2Cl2 (1eq.)
in toluene dry at -15 °C. The reaction mixture was stirred for 20 minutes, the formation
of the sulfenyl chloride was verified by titration with cyclohexene. The solution of the
sulfenic species obtained (roughly 15 eq.) was added dropwise to a suspension of 6-MP
11 (10 eq.) in pyridine. The reaction mixture was stirred at 84 °C for 2 h and later
purified by flash chromatography to give 41 in a whole yield of 27% (Scheme 19).
Scheme 19
As already reported we couldn’t deprotect 41 because of the instability of the disulfide
linkage under both acid and basic ester-cleavage conditions. So we tried this strategy,
just tested on derivative 35, without protecting carboxylic group, to overcome the above
reported problems using an ester as starting material. This synthetic pathway started
with the preparation of a sulfenyl chloride which can react with the 6-MP sulfur atom.
Operatively, to a cooled solution of 11-mercaptoundecanoic acid (2 eq.) in dry toluene a
solution of SO2Cl2 (1 eq.) was added, the mixture was stirred for 15 min, then nitrogen
was then bubbled inside to eliminate residual traces of SO2 and HCl. Before undergoing
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the next reaction we verified again the effective formation of sulfenyl chloride product
by titration with cyclohexene. This allowed us verifying the actual formation of the
expected sulfenic species and estimating a 46% yield for the first reaction. The so
obtained sulfenyl chloride was heated with a suspension of 11 (1 eq.) in dry pyridine to
give disulfide 44 in 30% yield (for two reactions) (Scheme 20).
Scheme 20
b) 5-Fluoro-2’-deoxyuridine (5-FdUrd, 45) was synthesized in 1979 by Cook et
al.57 It is commonly called doxifluridine or Furtulon® and has a molecular structure
consisting of a molecule of 5-Fluorouracil (5-FU) to which a pseudopentose is bonded
in position 1 (Figure 15). Doxifluridine represented an important improvement in terms
of tumor selectively, efficacy and safety from 5-FU. Compound 22 cannot be
phosphorylated and therefore incorporated into nucleic acids without pre metabolic
transformation into 5-FU.
Figure 15 5-FdUrd
The rationale for its development has been the need of the enzyme Thymidine
Phosphorylase (TP), a tumor-associated angiogenesis factor,47 for cleavage into 5-FU,
and thus activation. The high level of this enzyme in tumors and in the intestinal tract
compared with normal proliferating tissues48 gave an enhanced selectivity. However,
very high activity of TP is found in normal human liver, thus the liver toxicity.
5-FdUrd has a relevant role in the treatment of metastatic cancers, either by exerting an
appropriate antitumor activity via blocking thymidylate synthase to inhibit DNA
synthesis or by incorporation of its metabolite (5-Fluorouracyl) into DNA or RNA.49
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Although clinically effective, 5-FdUrd exhibits various side effects as a result of its
action on highly mitotic tissues such as the gastrointestinal tract and bone marrow.
Further, doxifluridine like most other nucleoside anticancer agents, suffers from low
and erratic oral absorption. Strategies that can improve the oral absorption and reduce
toxicity can be of a great benefit, therefore the synthesis of a proper linker will be
useful for this purpose.50 Previous studies demonstrated that ester derivatives of 5-
FdUrd undergo hydrolysis to effectively release 45 under physiologic conditions and
thereby produce a considerable antitumor effect.51 Considering that esters are the most
common prodrugs used,52 we choose to follow this strategy, inserting a succinate linker,
on the 5-FdUrd structure, as a suitable covalent bond able of a safety release of the
cytotoxic molecule 45 by both enzymatic and non-enzymatic hydrolysis.
Synthesis, as reported in literature,53 started by protecting the primary alcohol with 4,4’-
dimethoxytriphenylmethylchloride (DMTrCl) (1.5 eq.), to overcome possible side
reactions in the next coupling with succinic anhydride. DMAP (1.5 eq.) and succinic
anhydride (4.0 eq.) were then added to a solution of 46 in dry CH2Cl2. The desired acid
47 was obtained as the unique product in 99% yield, by simple series of basic and
acidic extractions to remove impurities (Scheme 21).
Scheme 21
The deprotection of ether function on primary alcohol is not necessary at this stage
because the removal of DMTr group will occur contemporary with cleavage of the
modified peptide from the solid support at the end of the process.
c) Gemcitabine is a difluorinated analog of the naturally occurring nucleoside
deoxycytidine. 5-Fluorouracil has long been the only available drug that offered some
promise in the palliative treatment of advanced pancreatic cancer, but objective
responses were rarely achieved. The moderate activity of fluorouracil may therefore
explain the unsatisfactory results reported for fluorouracil-containing adjuvant regimens
in patients undergoing pancreatectomy.
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Figure 16 Gemcitabine
The development of gemcitabine is considered a major advance in the treatment of
pancreatic cancer. Gemcitabine has a good safety profile with a low incidence of
toxicities and has shown significant clinical activity in a variety of solid tumors. In
1997, Burris et al. reported54 the first results of a phase III study that demonstrated
significant improvements both in survival and clinical benefit (pain relief, improved
performance status, or both) with single agent gemcitabine compared with fluorouracil
as first-line chemotherapy for advanced pancreatic cancer.55 Now gemcitabine is a drug
used to treat certain types of breast, pancreatic, ovarian, and lung cancer and is being
studied in the treatment of other types of cancer. Gemcitabine is metabolized
intracellularly by nucleoside kinases to the active diphosphate (dFdCDP) and
triphosphate (dFdCTP) nucleoside metabolites that interfere with DNA replication,
arresting tumor growth. The mechanism of action as well as the structure of
gemcitabine and 5-fluoro-2’-deoxyuridine are very similar one to each other, so we
decided to use the same strategy adopted before. The primary alcohol of 48 was
protected with DMTrCl (1.5 eq.), affecting also the amine group and then the secondary
alcohol of 49 was coupled with succinic anhydride to obtain the desired acid 50 as the
unique product in 15% yield (of two reactions), which is ready to be conjugated to the
targeting carrier (Scheme 22).
Scheme 22
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As well as for derivative 47, the ether deprotection is not necessary for 50 because it
will occur while cleaving the conjugated peptide from the solid support at the end of the
process.
1.2.2 Bioreductive drugs
Hypoxia specific cytotoxins, also known as bioreductive drugs, are compounds that
undergo reductive metabolism under low oxygen conditions to produce toxic
products.56 The rationale for their use in cancer is the hypoxia associated with tumors.
Robust tumor growth requires the presence of a local vascular network that supplies
oxygen and nutrients. Hypoxia occurs as a result of poor blood supply, and therefore
oxygenation, due to the faster development of the highly proliferating mass of tumour
cells than the vasculature.57 It is well established that many solid tumors contain
significant regions which are poorly oxygenated (hypoxic) and this is directly correlated
with disease progression and patient survival. Furthermore, the hypoxic cells are often
resistant to non-surgical treatments of cancer, primarily radiation and anticancer drugs.
This hypoxic condition increases the levels of reductive enzymes and nucleophyles,
such as GSH and this is a fact to take in consideration while designing new molecules
for cancer therapy (as we showed for 6-MP).58
There is currently an impressive interest in exploiting tumor hypoxia to produce
cytotoxins from prodrugs which selectively attack chemo- and radio-resistant hypoxic
tumor cells.59
a) The drug tirapazamine 25 (3-amino-1,2,4-benzotriazine 1,4-dioxide, TPZ) is
the most clinically advanced bioreductive, hypoxia selective prodrug.60
Figure 17 Tirapazamine
TPZ is the lead compound in the class of benzotriazine-di-N-oxides, but the real
mechanism of action is still unclear.
Is something of a paradox that TPZ promotes free radical oxidative cleavage of DNA,
yet it is more active in the absence than in the presence of molecular oxygen. On the
basis of these observations it has been proposed a dual mechanism of action.61 First, in
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a bioreductive process TPZ generates high oxidative free radicals which break DNA as
it is shown in Scheme 23. Molecular oxygen quenches this process by accepting an
electron from TPZ radical, hence the greater activity of the drug in hypoxic conditions.
Scheme 23 Generation of free radicals from TPZ
As an alternative mechanism, TPZ reacts directly with DNA sugar radicals followed by
oxidation of DNA, thus it is the drug and not oxygen which oxygenates DNA-centered
radicals (Scheme 24).
Scheme 24 Reaction between DNA and TPZ
By these ways TPZ is able to kill hypoxic cells 50-200 times more effectively than well
oxygenated cells, depending on the cell line.
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TPZ has a quite low aqueous solubility, and a combination of rapid metabolism and
slow extra-cellular diffusion combine to limit its ability to penetrate into hypoxic
tissues. Moreover, in contrast to most animal studies, clinical studies report a wide
variety of acute toxicities. Even if systematic clinical examinations of long-term
toxicity have not yet been performed, is clear that there is necessity for a way to
improve bioavaibility and tumor selectivity.
Therefore we designed TPZ derivatives, with similar or improved drug abilities, to be
conjugated with the targeting peptide. For this purpose the introduction of a carboxylic
acid on the molecule’s skeleton by an appropriate linker is necessary, as for all the
drugs reported in this thesis.
The choice of a versatile or permanent linker between the peptide and the drug can also
be useful to predict the mechanism of action of TPZ. In any case we used the chloride
52, prepared by modifications of previous methods62, as the key starting material.
2-Nitroaniline (1 eq.) and cyanamide (5 eq.) were heated together with stirring at 100°C
until a deep red melt formed. The reaction was cooled at 50 °C and concentrated HCl
was added dropwise. The reaction mixture was warmed at 100 °C, stirred for 4 h, then
made strongly alkaline by the careful addiction of a 30% solution of NaOH. After the
solution was heated again for 3 h, crystals formed on cooling which were collected and
washed with water and diethylether to give 3-amino-1,2,4-benzotriazine-1-oxide 53 as a
yellow solid in 72% yield.
A solution of 53 (1 eq.) in trifluoroacetic acid (TFA) was cooled at 5°C. Over a period
of 15 min sodium nitrite (3 eq.) was added portionwise. The reaction mixture was
stirred at r.t. for 4 h, poured onto ice/water and stirred 30 min. After filtration, the
precipitate was washed with water and dried to give 3-hydroxy-1,2,4-benzotriazine-1-
oxide 54. Chloride 52 was finally obtained by adding DMF (3 eq.) and phosphorous
oxychloride (7 eq.) directly to 54. The mixture was refluxed for 1 h, then poured on ice
and the precipitate formed filtered. The crude product was recristyllized from methanol
to give 52 in 50% yield (for two reactions) (Scheme 25).
Scheme 25
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After obtaining the key intermediate 52, the chloride atom was substituted by a
coupling reaction with an amine under basic conditions. The amine choice permitted
synthesis of TPZ-derivatives with different properties and utilizations.
Firstly to a solution of methyl-6-aminohexanoate (3 eq.) in CH2Cl2 a solution of 52 (1
eq.) and TEA (2 eq.) in CH2Cl2 was added. The reaction mixture was stirred for 116 h at
r.t. and distilled to dryness in vacuo. The residue was purified by flash chromatography
with 50/1= CH2Cl2 /MeOH as eluent to obtain 1-oxide 55 in 75% yield.
We have optimized the oxidation reaction, after various disappointingly attempts using
MCPBA63 or the commonly sold solutions of H2O2 (30 and 50%),64 as reported in
literature. The best result was obtained when we treated a solution of 50% H2O2 in
MeOH with Na2SO4 to increase its oxydizing properties. A solution of the treated H2O2
(20 eq.) in MeOH was added to a stirred solution of trifluoroacetic anhydride (20 eq.) in
dry CH2Cl2 at 5 °C. After 10 min stirring at r.t. the oxidizing agent, tri-fluoroperacetic
acid, was formed, then cooled to 5 °C before adding of a solution of 55 (1 eq.) and
trifluoroacetic acid (9 eq.) in dry CH2Cl2. After 4 days under stirring the red solution
was diluted with EtOAc and washed with a saturated solution of NaHCO3. The organic
phase was dried and concentrated to give the red coloured 1,4-dioxide 56 in 90% yield
(Scheme 26).
Scheme 26
Ester hydrolysis of 56 to free acid 57 was achieved either in acid or basic conditions. In
fact adding 37% HCl (35 eq.) to a solution of 56 (1 eq.) in dioxane and stirring at r.t. for
48 h, we obtained 57 in 83% yield, after purification by flash chromatography.
Otherwise, we added 1M LiOH (10 eq.) to a solution of 56 (1 eq.) in 1/1=THF/MeOH.
The mixture was stirred for 5min and 1M HCl was added until pH 5. The acid aqueous
phase was extracted several times with EtOAc and the combined organic layer was
dried and the solvent evaporated to obtain again 57 but this time in 98% yield without
further purification (Scheme 27).
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Scheme 27
With the aim to have an active linker, between TPZ and the dendrimeric peptide, able to
release the drug in hypoxic conditions, we decided to prepare a disulfide containing
TPZ-analogue. Unlike 6-MP derivative 44, here the sulfur-sulfur bond does not directly
involve the pharcophore part of the molecule but it is separated by an alkyl chain.
Starting again from the chloride 52, the conjugation was carried out in the presence of
N-Boc-1,6-hexanediamine, adopting the same conditions reported before for the
synthesis of 55, to give derivative 58 in 90% yield. The oxidized product 59 was
prepared, with a 99% yield, using treated H2O2 with the same procedure shown before,
confirming its efficiency. Once it was obtained, the red compound 59 was dissolved in
MeOH and gaseous HCl was bubbled inside for 2 min. The solution instantly became
yellow and was stirred for 17 h at r.t., diluted with water and extracted several times.
The aqueous phase was basified by adding a saturated solution of NaHCO3 and
extracted many times with CHCl3. These final recollected organic layers were dried and
concentrated to give the amine 60 in 55% yield. Finally adopting the strategy usually
utilized for the standard solid phase conjugation, the carboxylic group of dithiobutirric
acid (1 eq.) was activated by adding to its solution in dry DMF, HBTU (1 eq.) and
DIPEA (2 eq.). After stirring for 10 min this solution was added to a solution of 60 (1
eq.). The reaction mixture was stirred for 6 h, acidified to pH 5 with 1N HCl and
diluted with CHCl3. The two phases were separated and the organic layer was washed
with water, dried and concentrated. The crude product was then purified in a TLC plate
to obtain 61 in 55% yield (Scheme 28).
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Scheme 28
The high instability of disulfide molecules, already noticed in the case of 6-MP
derivatives, forced us to verify the behaviour of this specific molecule 61 in the acid
conditions used during the already mentioned peptide cleavage. We therefore
demonstrated the stability of 61 in 99% TFA for 18 h.
b) β-Hydroxy Lapachone (62)
Mass screening programs of natural products by the National Cancer Institute have
identified the quinone moiety as an important pharmacophoric element for cytotoxic
activity.65 Naturally occurring naphthoquinones comprise an important class of natural
products with a wide range of biological activity66 arising from their ability to cause
DNA modification via redox cycling of the quinone moiety and the generation of
reactive oxygen species. In the structurally diverse naphthoquinone natural products,
dihydropyranonaphthoquinones (α- and β-lapachones) have attracted special attention
because of their promising antitumor ability,67 among various other bioactivities.
Figure 18
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Heterocyclic naphthoquinones of the lapachone family are found as minor components
in the stem bark of many trees of the Tabebuia genus in Central and South America.68
α-Lapachones have a wider distribution than β-lapachones, and are additionally found
in Ekmanianthe longiflora in America and in Capalta ovata trees in many east Asian
countries. Among these pyranonaphthoquinones, β-lapachone derivatives have so far
received the most extensive investigations, mainly owing to their stronger antitumor
activity. β -lapachone exerts its anti-tumor effect by indirect actions of inducing p53-
independent apoptosis and cell cycle arrest mediated through altered activities of cell
cycle control regulatory proteins, including down-regulating retinoblastoma protein
(pRB), a transcriptional repressor target at transcription factor E2F-1, as well as induces
expression of cyclin dependent kinase inhibitor 1A (CDKN1A or p21). Both E2F-1 and
p21 are required for G1/S-phase transition during cell cycle. This agent also inhibits
DNA topoisomerase I by a mechanism distinct from that of camptothecin, and thereby
blocks the formation of a cleavable complex leading to enzyme inhibition and prevent
DNA repair. Furthermore, beta-lapachone could induce reactive oxygen species in vivo,
and result in cytotoxicity acting as a bioreductive drug.69
As already reported for the prodrug synthesis of other cytotoxins, we exploited the
presence of a hydroxyl group on the structure of β-hydroxy lapachone 62 by succcinate
formation. The synthetic procedure started from the commercially available lapachol
(63), which was treated with MCPBA (1.2 eq.) in CH2Cl2 for a day to yield the drug 62
(57%). The next coupling with succinic anhydride gave prodrug 64 in quantitative yield
without further purification (Scheme 29).
Scheme 29
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1.2.3 Mitosis Inhibitors
There is a considerable interest in the discovery and development of novel small
molecules able to affect tubulin polymerization. Such compounds impair dynamic
microtubule elements of the cell cytoskeleton responsible for the formation of the
mitotic spindle and required for proper chromosomal separation during cell division.70
Current drugs that inhibit cell proliferation, such as paclitaxel and docetaxel, are
standard treatments for many types of cancers, but these drugs also target other proteins
that are essential to important cellular functions and thus, their use is limited by side
effects. More recently, it has been established that some tubulin binding agents
selectively target the vascular system of tumors. These compounds induce
morphological changes in the endothelial cells of the tumor’s blood vessels, resulting in
their occlusion and interruption of blood flow.71 These agents has been termed
antivascular agents, in contrast with antiangiogenic agents, which can act by inhibiting
proliferation of new tumor vasculature. Vascular targeting drugs instead specifically
and rapidly act on preexisting tumor blood vessels.
a) Combretastatin A-4 (65), isolated from the bark of the South African tree
Combretum caffrum, is a potent antimitotic and cytotoxic agent which strongly inhibits
the polymerization of tubulin by binding to the colchicine site.72
Figure 19 Combretastatin A-4 (CA4) and its prodrug Combretastatin A-4 phosphate (CA4P)
It is also able to elicit irreversible vascular shutdown within solid tumors, leaving
normal vascolature intact, behaving as an antivascular agent. Combretastatin A-4
inhibits cell growth even at low nanomolar concentartions and exhibits inhibitory
effects on multidrug resistant cancer cell lines.
A prodrug of 65, its water soluble phosphate derivative (CA4P), is now in phase II of
clinical trials73 and a wide number of its analogues have been synthesized and
evaluated.74 Its structural simplicity, along with its ability to selectively damage tumor
neovascolature, makes CA4 of a great interest for medicinal chemistry applied to cancer
treatment.
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Total synthesis and introduction of the suitable linker will allow the delivery of the drug
by the branched-peptide. We imagined to exploit the same releasing mechanism
adopted for 5-FdUrd, gemcitabine and lapachone derivatives (47, 50 and 64)
transforming the free phenolic OH of 65 in a functionalized ester. Combretastatin was
prepared by a modification of previous methods75 developed by Pettit et al., that
exploits a Wittig reaction between aldehyde 66 and corresponding ylide of 67 as the
key step.
The synthesis of the phosphonium salt 67 started from the reduction of 3,4,5-
trimethoxybenzaldehyde (1.0 eq.) by the addition of NaBH4 (1.2 eq.) in MeOH at 0 °C
to yield benzyl alcohol 68 in 88% yield. To a solution of 68 (1.4 eq.) in dry CH2Cl2,
cooled to -5 °C, a solution of PBr3 (1.0 eq.) in dry CH2Cl2 was added dropwise to give
69 in 96% yield. Finally, a solution of triphenylphosphine (1 eq.) in toluene was added
to a solution of bromide 69 (1 eq.). The reaction mixture was stirred for 24 h at r.t. and
the precipitate formed filtered and dried to obtain phosphonium bromide 67 in 62%
yield (Scheme 30).
Scheme 30
Aldehyde 66 had to be protected to undergo the Wittig reaction and we choose tert-
butylsilyl (TBDMS) as protecting group. To a solution of isovanillin (1.0 eq.) in dry
DMF, DIPEA (2.0 eq.) and TBDMSCl (1.6 eq.) were added. The crude product,
obtained after 4 h of reaction, was purified by flash chromatography to give 66 in 98%
yield.
A suspension of phosphonium bromide 67 (1.0 eq.) in dry THF under nitrogen was
cooled to -23 °C and retained at that temperature for 2 h. Butyllithium (1.0 eq.) was
added dropwise, the resultant orange solution was stirred at the same temperature for 1
h and finally 66 (1.04 eq.) was added. The reaction mixture was stirred at -23 °C for 4 h
and at r.t. for 18 h, ice-water was added and two phases separated. The aqueous phase
was washed with Et2O and the etheral solution added to the THF layer. The combined
organic phase was washed with water and dried. The crude product was purified by
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flash chromatography to give both the desired Z product 70 in 61% yield and a 20% of
the corresponding E product. The careful control of temperature is critically correlated
with the obtainment of an excess of Z. Deprotection of 70 (1 eq.) occurred in dry THF
in the presence of TBAF.3H2O (1 eq.) after 20 min stirring. The residue was then
chromatographed to obtain the natural product CA4 (65) in 77% yield (Scheme 31).
Scheme 31
The next reaction with succinic anhydride, led as usual with DMAP in CH2Cl2, gave
ester 71, as verified by NMR analysis, but this derivative resulted instable even in silica
gel, making impossible not only the purification but also the coupling with the
dendrimeric peptide. Since the other succinate derivatives prepared (47, 50 and 64)
were stable even in extremely acid conditions, we realised that the aromatic ring
promote the ester cleavage because it stabilizes the resulting phenate ion. Therefore, we
imagined the formation of a more stable ester, just increasing the chain length. Glutaric
anhydride (4 eq.) was added to a solution of combretastatin 65 (1 eq.) in dry CH2Cl2.
The mixture was stirred for 16 h at r.t., refluxed for 24 h and poured onto
ice/water/NaHCO3. The suspension was washed several times to remove other glutaric
derivatives and give the desired acid 72 in 50% yield. This product is much more stable
than the corresponding compound obtained by the reaction with succinic anhydride, so
could be used for the next coupling (Scheme 32).
Results and Discussion
43
Scheme 32
Many of the prodrugs synthesised to be coupled to the targeting unit, count a realising
in vivo of the corresponding drugs. Since it is difficult to demonstrate the effective
release in an animal system, we thought to prepare other derivatives with a non-
cleavable ether bond, instead of an ‘active’ ester function. These molecules can’t
undergo neither enzymatic nor non-enzymatic hydrolysis and so can be used as a
‘control’ to effectively demonstrate the importance of the linker in our molecules. For
this purpose we synthetised derivative 73 by modifications of the previous method.
Isovanillin was functionalized with tert-butylbromoacetate and directly utilized for the
next Wittig reaction with the same ylide used previously.
Operatively, to a solution of 3-hydroxy-4-methoxybenzaldehyde (1 eq.) in dry CH3CN,
was added K2CO3 (3 eq.). The mixture was heated while adding a solution of t-
butylbromoacetate (1 eq.) and stirred for a day to give tert-butyl 2-(5-formyl-2-
methoxyphenoxy)acetate 74 with 88% yield after aqueous work up. A homogeneous
suspension of phosphonium bromide 67 (1 eq.) in dry THF under nitrogen was cooled
to -23 °C and retained at that temperature for 2 h. Butyllithium 1.6 M in hexane (1 eq.)
was added dropwise, the resultant orange solution was stirred at the same temperature
for 1 h and finally 74 (1.04 eq.) was added dropwise. The reaction mixture was stirred
at -23 °C for 4 h and at r.t. for 18 h, After aqueous washings, the crude product was
purified by flash chromatography to give both the Z (75) and the E stilbenes in 13 and
15% yield respectively. Finally the hydrolysis of 75 (1 eq.) was carried in 1M LiOH (10
eq.) in a 1/1=THF/MeOH mixture to give acid 73 in 83% yield without further
purification.
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Scheme 33
b) Monastrol, a 4-(3-hydroxyphenyl)-2-thione derivative, is the first specific
small molecule inhibitor of the vertebrate kinesin-5 subfamily KSP (human kinesin
spindle protein), also known as HsEg5.76 It is cell-permeable, and its effect on dividing
cells is to bring about collapse of pre-existing bipolar spindles and cell cycle arrest with
a monopolar spindle. The cocrystal structure of the monastrol-bound KSP motor
domain complex revealed that monastrol is an allosteric inhibitor that binds to an
induced-fit pocket 12 Å away from the ATP binding pocket. Monastrol is not
competitive with ATP but is competitive with microtubules in inhibition of the KSP
ATPase.77 For this mechanism of action is the first small-molecule inhibitor of mitosis
that does not target tubulin.
Figure 20 Monastrol
Its analogue ispinesib (Cytokinetics) is currently being studied in multiple phase II
clinical trials. Because KSP is not involved in non-mitotic processes, such as neuronal
transport, ispinesib may be less likely to cause the peripheral neuropathy often
associated with the tubulin-targeting agents. To allow the coupling with branched
neurotensin, racemic monastrol 76 was decorated at the phenolic OH with a carboxylic
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acid group trough and ‘active’ ester link in 77 and a permanent ether bond in 80.
Monastrol can be efficiently prepared in high yield (95%) via a Yb(OTf)3 catalysed
three components Biginelli reaction.78 The use of the Lewis acid Yb(OTf)3 as the
promoter instead of the three component system CuCl/AcOH/BF3.Et2O, usually
adopted in this type of reaction, is due to the incompatibility of this system with the
sulfurated version, employing thiourea.79 Operatively ethyl acetoacetate (1 eq.), 3-
hydroxybenzadehyde (1 eq.) and thiourea (3 eq.) were mixed together in THF and
Lewis acid (0.1 eq.) was added. The reaction mixture was refluxed for 2 h, to afford
monastrol 76 by aqueous work up followed by flash chromatography. The reaction of
76 (1 eq.) with glutaric anhydride (3 eq.) in dry CH2Cl2 under basic conditions (DMAP,
3 eq.) allowed the preparation of derivative 77 (56%) with the required pending
carboxylic acid, purified by simple acid/basic washings (Scheme 34).
Scheme 34
The reaction of 3-hydroxybenzaldehyde with t-butylbromoacetate, used to introduce the
ether link, followed by the condensation under the reaction conditions used above,
allowed the isolation of the modified Biginelli adduct 79 (15%, non-optimized) which
was transformed into the ether linked acid derivative 80 (50%) by hydrolysis with TFA
in CH2Cl2 (Scheme 35).
Scheme 35
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In summary the synthetic efforts made allowed the prepation and isolation of fifteen
different carboxylic acid derivatives, shown in Figure 21, with chelating or anti-tumor
activity to be adopted as Functional Units in our targeting system.
Figure 21 Carboxylic acid derivatives prepared during these three years.
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2. 6-MP release from prodrugs
We synthesized three 6-MP derivatives 14, 27, 43 which are supposed to be prodrugs,
biologically inert or inactive molecules which are able to release the active drug in vivo.
Solid tumors are often in an hypoxic environment where GSH is normally abundant.42,43
Pro-drugs as 14 and 27, in the presence of nucleophiles like GSH that promote an
addition-elimination reaction on the double bond, release 6-MP. Derivative 43 instead
releases 6-MP by a thiol-disulfide exchange.
Figure 22 6-MP derivatives
In order to corroborate these findings, compounds 14, 27 and 43 were incubated at
37°C in a phosphate buffer solution (pH = 7.4) in the presence of 1, 5 and 15
equivalents of GSH. These three concentrations had been chosen because they represent
respectively the average concentration of GSH in normal cells, tumor cells and high
hypoxic cells. The release of 6-MP, in all the three solutions incubated at 37 °C, was
measured by HPLC at different time intervals.
Disulfide 43 was extremely reactive with nucleophiles and after 5 min, 77% of 6- MP
was already released. Moreover the release of 6-MP was observed even in absence of
GSH. In fact after 3 h of incubation of derivative 43 in buffered solution the 6-MP
release was 50%. The instability of the compound was incompatible even with the
conditions required for the resin cleavage (i.e. 95% TFA). We therefore gave up with
the development of 43 and of any disulfide analogue.
Compound 14, on the other hand, came out to be far too stable, since in the presence of
15 equivalents of GSH, after 18 h it only released 10% of 6-MP.
Satisfactorily, the most interesting releasing profile was shown by 27, in fact the
derivative 27 released 86% of 6-MP after 135 min in the presence of 1 equivalent of
GSH (Figure 23, squares) and complete release after 30 min with 5 equivalents of GSH
(Figure 23, rhombus). The possibility to modulate the release of the drug as function of
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cellular endothiols concentration is an important feature of the pro-drug that was then
carried forward for further characterization.
Figure 23 Release (%) of 6-MP at 37 °C with concentrations of 27 1 mM and in presence of GSH at 1 mM
(blue rhombus) ad 5 mM (red squares) concentrations
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3. Conjugation to branched peptides (NT4)
We have synthesized, as we described in chapter 1, a variety of carboxylic derivatives
decorating the most common anticancer drugs [Combretastatin A-4 (CBTST),
Tirapazamine (TPZ), 6-Mercaptopurine (6-MP), 5-Fluoro-2’-deoxyuridine (5-FdUrd),
Gemcitabine, Monastrol (MON)] and metal chelators (DOTA). The accessible COOH
groups of these Functional Units should be then coupled with the tetrameric NT
peptide in order to provide a tumor targeting system for diagnostic or therapeutic
applications.
The conjugation with the NH2 group, introduced ad hoc on the dendrimer, was carried
out by standard solid phase synthesis for most of the derivatives prepared.
Operatively, peptide synthesis was performed on a MultiSynTech Syro automated
multiple peptide synthesizer (Witten Germany), employing 9-
fluorenylmethoxycarbonyl (Fmoc) chemistry with 2-(1H-benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU) / N,N-diisopropylethylamine
(DIPEA) activation. Side chain protecting groups were trityl for His, 2,2,4,6,7-
pentamethyldihydro-benzofuran-5-sulfonyl for Arg, tert-butyl ether for Ser and Tyr,
tert-butyl ester for Asp and Glu, and tert-butyloxycarbonyl for Trp. Considering the
large variety of molecules to be conjugated with the dendrimeric peptide, prof. Bracci’s
group tested different approaches to find the most simple and versatile way to prepare
tetramers. Tetra-branched analogues were synthesized on resin NovaSyn TGR. A
mixture of 5 eq. of Fmoc protected aminoacid, 5 eq. of HBTU dissolved in DMF and 10
eq. of DIPEA were added to the resin beads. The reaction was automatically performed
at r.t. for 40 minutes and the coupling step repeated twice. After each aminoacid
addition the Fmoc protecting group was removed with a 40% solution of piperidine in
DMF and extensively washed with DMF before adding the next one. All tetrameric
peptides were built employing two consecutive Fmoc-Lys(Fmoc)-OH coupling steps to
form the branched core.
In particular, tetrabranched NT(8-13)-PEG derivatives of DOTA, [NT4(8-13)-1] 81 and
[NT4(8-13)-3] 82; 6-Mercaptopurine, [NT4(8-13)-14] 83 and [NT4(8-13)-27] 84; 5-
Fluorodeoxyuridine, [NT4(8-13)-47] 85; Gemcitabine, [NT4(8-13)-50] 86;
Tirapazamine, [NT4(8-13)-57] 87 and [NT4(8-13)-61] 88; Combretastatin, [NT4(8-13)-
72] 89 and [NT4(8-13)-73] 90; and Monastrol, [NT4(8-13)-77] 91 and [NT4(8-13)-80]
92 (Scheme 36), were synthesized with Fmoc-Lys(Dde)-OH as first coupling step and
Fmoc-β-Ala-OH as second coupling.
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Fmoc-Lys(Fmoc)-OH was used to build the three-lysine branched core. C-terminal
stepwise automated elongation [(Arginine (R), Arginine (R), Proline (P), Tyrosine (Y),
Isoleucine (I), Leucine (L)] was then carried out by the above described HBTU/DIPEA
method. Boc-Arg(Pbf)-OH was used as last amino acid of the neurotensin sequence, so
that the last step occurred selectively on the side chain arm. In fact, Dde protective
group was removed with 2% hydrazine for 10 min at room temperature and the free
amino group was coupled with all the new functional units, which are provided with a
carboxylic acid function. Moreover, the side chain amine group to be used for the
functional unit coupling was rendered more accessible stretching it with Fmoc-PEG-
OH. After deprotection of the Fmoc group on PEG, the functionalized peptide was
finished by activation and coupling of the carboxylic acid of the Functional Unit (R’-
OH).
Peptides were cleaved from the resin and deprotected by treatment with trifluoroacetic
acid (TFA) containing water and triisopropylsilane (95/2.5/2.5), and precipitated with
diethyl ether (Scheme 36).
The same procedure was also used to synthesized NT4(8-13)-Bio (Biotin) (Figure 24),
starting with Fmoc-Lys-Bio-OH as the first group attached to the solid support and the
spacer Fmoc-PEG-OH as second step.
Figure 24 NT4(8-13)-Bio
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Scheme 36
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All compounds were characterized by MS on a Ettan MALDI-TOF mass spectrometer
and purified by HPLC on a C18 Vydac column. [NT4(8-13)-57] 87 characterization has
been initially complicated, because the compound undergoes reduction of the
tirapazamine moiety by single or double oxygen extraction during MS analysis.
NT(8-13)4-PEG-DOTA 81 and 82 were then used to chelate 115In3+ in a typical
chelation reaction: the peptide and InCl3 were dissolved in acetate buffer pH 8 and
stirred for four hours at room temperature (Scheme 37).
Scheme 37
The reaction and purification procedures will be reproduced with 111In for
biodistribution experiments in mice.
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4. Cytotoxicity of drug-conjugated tetra-branched NT peptides
All the experiments have been carried out in three different cell lines to represent the
diverse tumors that over-express NT receptors (Table 1): HT-29 (colon
adenocacinoma), PANC-1 (pancreas epitheloid carcinoma) and PC-3 (prostate
carcinoma).
Our tumor targeting system is based on the specific delivery of the functional unit into
the tunor cell by peptide binding and subsequent internalization of the receptor-ligand
complex by endocytosis, as shown in Figure 1. In order to validate NT branched
peptides as possible targeting agents for therapy of either colon or pancreas or prostate
adenocarcinoma, binding of tetra-branched NT peptides to human tumor cell lines, was
analysed and their rate of internalization was quantified.
Peptide binding and internalization of tetra-branched NT(8-13) conjugated to Biotin
(NT(8-13)4-Biotin) was analysed by confocal microscopy in HT-29, PANC-1 and PC-3
cell lines. It was found that NT4 conjugated to different fluorophores or to biotin,
followed by fluorophore-conjugated streptavidin, specifically bind to the three cell
lines, which express the NT receptors.24 Peptide binding on membrane receptors was
observed after 30 minutes incubation at room temperature. Cells were then washed and
further incubated for 1, 2 or 4 hours to follow peptide internalization by confocal
microscopy as it is shown in Figure 25. Peptides are degraded inside the cells within 18
hours. Binding of tetra-branched NT(1-13) and NT(8-13) was clear in all the cell lines,
whereas that of corresponding monomeric peptides was scarcely evident, which
demonstrated the higher binding efficiency of branched peptides. NT(1-13) and NT(8-
13) branched peptides were completely internalized by the three cell lines, despite
different internalization rates among the cell lines. Internalization of both tetra-
branched NT(1-13) and NT(8-13) was quicker in PANC-1 and PC-3 than in HT-29
(Fig. 2). As a matter of fact HT-29 still showed a considerable amount of peptide on the
cell membrane after a 2-hour incubation, whereas in PANC-1 and PC-3, peptides were
completely internalized after a 1-hour incubation. No binding was observed either with
an analogously conjugated branched peptide containing an unrelated sequence
(DDHSVA) or with equivalent concentrations, in terms of peptide units, of the
conjugated monomeric NT(1-13) or NT(8-13) sequences.80
Drug-conjugated tetra-branched NT peptides’ internalization rate
PANC-1 cells were incubated with tetra-branched NT conjugated to Functional Units
and with the unrelated peptide (DDHSVA). Cells were centrifuged, washed and then
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lysed. The presence of uncleaved peptides was assessed by MALDI spectrometry both
in the cell supernate and in cell lysate. Functional Units were detected as uncleaved
molecules in cell supernate and cell lysate even after 48 h. Unrelated peptides were
found intact after 48 hours in the supernate and never detected in the lysed cells. Linear
NT(1-13) (Sigma) was detectable in cell supernate after 2 hours but was undetectable in
the lysed cells.
Figure 25 Binding and internalization in tumor cell lines. HT-29, PC-3 and PANC-1 were exposed for 30
minutes (time 0) to NT(8-13)4-Biotin or monomeric NT(8-13)-Biotin (M) followed by Streptavidin-Cy3.
Internalization of NT(8-13)4-Biotin was observed after 1, 2 and 4 hours of further incubation in medium at
37°C. Cell membrane was stained with Lectin-FITC.
The ability of tetrabranched peptides conjugated to a functional unit to bind cancer cell
lines through NT receptors, to be rapidly internalized in cells and still detectable after 4
hours, is an important feature for possible therapeutic applications of these molecules.81
Finally we tested the possible application of these new NT-based molecular tools,
conjugated to different drugs, for personalized therapy by determining their cytotoxicity
in different human cancers.
Cytotoxicity of drug-conjugated NT4 in different tumor cell lines
It is well known that classical chemotherapeutics used in the clinical practice have
different activity on different tumors. This is due to natural resistance of cancer cells to
the drugs, caused by different mechanisms, including a decreased uptake or increased
export of drugs by the cell, increased inactivation of drugs inside the cell or enhanced
repair of the DNA damage produced by DNA-alkylating agents.
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Previously reported cytotoxicity experiments, performed by the Prof. Bracci’s research
group on HT-29,24 demonstrated that conjugation of methotrexate (MTX) or of the
photosensitizer, chlorine-e6, to tetra-branched NT(8-13) produces pro-drugs like
molecules. Such molecules can no longer be transported across plasma membranes by
the mechanism of the corresponding free drug and can only be ‘activated’ via peptide-
receptor binding, thus profoundly decreasing non-specific drug toxicity.
Introduction of a novel, peptide receptor-mediated, mechanism of cell internalization of
the drug might allow by-passing natural mechanism of cell resistance. As already
shown in chapter 1, we designed and prepared several derivatives of different drugs,
commonly used in classical tumor chemotherapy. Almost all these molecules were
tested either as free drugs or conjugated to the tetra-branched NT(8-13) on HT-29,
PANC-1 and PC-3 tumor cell lines.
In details, HT-29, PANC-1 or PC-3 cells were plated at a density of 2.5 x 104 per well
in 96-well microplates. Different concentrations of free or NT(8-13)-conjugated drugs,
from 0.15 to 30 µmol/L, were added 24 h after plating. Cells were grown without
changing the medium for 6 days. Growth inhibition was assessed by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide. EC50 values were thereby
calculated by non-linear regression analysis using GraphPaD prism 3.02 software.2
The cellular toxicity of all the drug-conjugated NT4 was tested on the three cell lines
and compared with the cytotoxicity of corresponding free drugs and also with that of an
unrelated tetra-branched peptide (U4), identically conjugated to the same drug.
We must say first that 5-Fluorodeoxyuridine, monastrol and combretastatin have never
been proved to be inactivated by the conjugation, so at the state of the art it is not
known if 47, 72 and 77 are prodrugs or not. However it was necessary to know their
rate of drug release to identify the true cytotoxic species (free or conjugated drugs). For
this reason derivatives 72 and 77 were conjugated to NT4 via a bifunctional linker that
bears an ester bond, which should be released in vivo, at one end and an amide at the
other end, whereas 73 and 80 bifunctional linker bears a non-hydrolyzable ether bond at
one end and an amide at the other end. Stability of the conjugated molecule was then
assessed by incubation with HT-29 for different time intervals and the supernate and
cell lysate analysed by HPLC and MS resulting in a complete release of the drug moiety
after 2 hours (data not shown). The ester bond allows a faster release of the drug and
the branched derivatives were then classified as fast releasing 84, 85, 89 and 91 - and
slow releasing 83, 90 and 92 and their cytotoxicities compared.
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When cells were incubated with the fast releasing 85 and 89 peptide drugs in
experimental protocol of six days of incubation without washing (Figure 19 and 22)
part of the chemotherapeutic moiety was released outside the cell and internalized via a
different mechanism, probably by membrane diffusion. This was proved since unrelated
conjugated peptides had a cytotoxic effect that could only be ascribed to the release of
the 5-FdUrd 45, Combretastatin 65 or Monastrol 76, since we demonstrated that the
unrelated peptide cannot be internalized.24
The washing procedure was then essential to follow the activity of fast releasing
adducts so to exclude the additive effect of the released free drug.
Cytotoxicity of fast releasing drug-conjugated tetra-branched peptides was then
tested80,81 in HT-29, PANC-1 and PC-3 in experiments where cells were exposed to a 1
hour pulse of free or NT-conjugated drug, washed and incubated for 6 days or,
alternatively incubated for 6 days with the peptides, without additional washing. The
additional washing was performed in order to avoid diffusion of free drug inside the
cells during the following six days (Figure 20, 23, 25).
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Cytotoxicity of 83 and 84, derivatives of 6-Mercaptopurine. (Figure 26 and 27)
Mercaptopurine 11 itself is a chemotherapy drug that is most commonly used to treat
acute leukaemias but is also given as a treatment for some other types of cancer.
The cytotoxicity test for derivative 83, where its analog, PTA, is conjugated to the
dendrimeric neurotensin was evaluate as described above, in two cell lines HT-29 and
PANC-1. As expected, 6-MP derivative 83, a very slow releasing adduct, was
completely inactive in this in vitro model, as well as U4-6MP.
Figure 26 Cytotoxicity of conjugate [NT4-14] 83 (indicated like NT4-6MP in the figure) compared to the
unrelated conjugate U4-14 (indicated like U-6MP) and free 6MP
Regardless the promising releasing behaviour, 27 didn’t give the expected results, in
fact, the conjugated derivative (84) showed a cytotoxic activity comparable to 6-MP
itself. (Figure 27)
On the other hand, this behavior means that this derivative is effectively a pro-drug and
it is able to release 6-MP in this experimental model. Probably there are enzymatic or
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GSH-mediated mechanisms which permit the drug releasing both by neurotensin
peptide and its unrelated analog.
Figure 27 Cytotoxicity of conjugate [NT4-27] 84 (indicated like NT4-6MP in the figure) compared to the
unrelated conjugate U4-27 (indicated like U-6MP) and free 6MP
Cytotoxicity of 85, NT4(8-13) derivative of 5-Fluorodeoxyuridine. (Figure 28 and 29)
5-FdUrd (5-fluorodeoxyuridine) 45 as already said is a thymidylate synthase inhibitor,
it is transformed into different cytotoxic metabolites which are then incorporated into
DNA and RNA, finally inducing cell cycle arrest and apoptosis. Its principal use is in
colorectal and pancreatic cancers.
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Figure 28 Cytotoxicity of conjugate [NT4-47] 85 (indicated like NT4-5FU) compared to free 5FU
5-Fluorouracile was used as a control in the experiment of cytotoxicity and shows
analogue activity on PC-3, PANC-1 and HT-29 cell lines. The conjugated molecule
NT4-5FU showed increased activity with respect to the free drug especially on HT-29
where the IC50 drops to 1.0 nM, whereas in PC-3 and PANC-1, IC50 it is in the
micromolar range, respectively 3.8 µM and 1.6 µM.
An additional washing was performed in order to avoid the diffusion of free 5-FdU
released by hydrolysis of the ester bond of 85 during the 6 day incubation period and
the data obtained with this procedure are reported below (Figure 29).
Results and Discussion
60
Figure 29 Cytotoxicity of conjugate [NT4-47] 85 (indicated like NT4-5-FU) compared to free 5FU and the
unrelated conjugate U4-47 (indicated like U4-5FU) after washing
Free 5-FdU was completely ineffective in PANC-1 and PC-3 cell lines at the doses used
and slightly effective in HT-29. When conjugated to branched NT, it became effective
not only in HT-29, where the EC50 became 1.1e-007, with nearly two logs
improvement, but also in PANC-1 and PC-3 (Figure 29).
Results and Discussion
61
Cytotoxicity of 87, NT4(8-13) derivative of Tirapazamine. (Figure 30)
Tirapazamine 51 is selectively activated by multiple reductases to form free radicals in
hypoxic cells, thereby inducing single-and double-strand breaks in DNA, base damage,
and cell death. This agent also sensitizes hypoxic cells to ionizing radiation and inhibits
the repair of radiation-induced DNA strand breaks via inhibition of topoisomerase II.
Curreently, there are numerous clinical trials using this agent, alone or in combination,
in cervical cancer, non-small cell lung cancer, head and neck cancer, glioblastoma
multiforme, and ovarian carcinoma.
Figure 30 Cytotoxicity of conjugate [NT4-57] 87 (indicated like NT4-TPZ) compared to the free TPZ and
unrelated conjugate (U-TPZ).
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As we can see from Figure 30 free TPZ was more active than when it is conjugated to
the branched peptide, which therefore didn’t bring any advantage in PANC-1 and PC-3
cell lines. Interestingly conjugation to branched NT increased drug efficiency in HT-
29. We have to consider the bioreductive nature of TPZ, which is able to kill hypoxic
cells 50-200 times more effectively than well oxygenated cells. Therefore, this study
has to be repeated under hypoxic conditions to have a real evidence of the TPZ activity.
Moreover the cytotoxicity of the conjugated disulfide derivative of TPZ 88 has still to
be evaluated as well as its ability to effectively release the TPZ and consequently
increase the activity of the conjugate.
Cytotoxicity of 89, NT4(8-13) derivative of Combretastatine. (Figure 31 and 32)
Combretastatin A-4 inhibits cell growth even at low nanomolar concentrations and
exhibits inhibitory effects on multidrug resistant cancer cell lines.
Figure 31 Cytotoxicity of conjugate [NT4-72] 89 (indicated like NT4-CBST) compared to the free CBST.
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The strong toxic activity of the free drug is evident in these human tumors cell lines and
especially against PANC-1 and PC-3. The conjugated derivative NT4-72 preserves its
activity in the three cell lines and reflects the same trend, in facts, the IC50 is 3.5 µM
on HT-29 and drops to 0.5 and 0.4 nM respectively on PANC-1 and PC-3.
As for [NT4-47] 85 the additional washing was performed and the results compared.
Figure 32 Cytotoxicity of conjugate [NT4-72] 89 (indicated like NT4-CBST) compared to the unrelated
conjugate (indiacted like U-CBST) and free CBST after washing
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Compound 89 deserves major interest, since the activity of the drug is clearly increased
by conjugation to branched NT4 through a fast releasing linker (Figure 31) and this is
evident though the unfavourable conditions of the additional washing.
Cytotoxicity of 90, NT4(8-13) derivative of Combretastatin. (Figure 33)
Figure 33 Cytotoxicity of conjugate [NT4-73] 90 (NT4-O-CBST) compared to the unrelated conjugate
(U4-O-CBST) and free CBST
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Comparison of results obtained with Combretastatin derivatives 89 and 90, indicates
that this system works better if Combretastatin can be released inside the cell than
when it remains bound to the carrier peptide.
Cytotoxicity of 91, NT4(8-13) derivative of Monastrol. (Figure 34)
Monastrol and its analog Ispinesib selectively inhibits the mitotic motor protein, kinesin
spindle protein (KSP), resulting in inhibition of mitotic spindle assembly, induction of
cell cycle arrest during the mitotic phase, and cell death in tumor cells that are actively
dividing. They are undergoing multiple clinical trials for breast, prostate, ovarian and
other solid tumors or lymphomas.
Figure 34 Cytotoxicity of conjugate [NT4-77] 91 (indicated like NT4-MON) compared to the unrelated
conjugate (indicated like U4-MON) and free MON after washing
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Monastrol has a very poor cytotocity as a free drug for the three cell lines tested and its
activity is not increased by the conjugation to the peptide.
Cytotoxicity of 92, NT4(8-13) derivative of Monastrol. (Figure 35)
Figure 35 Cytotoxicity of conjugate [NT4-80 ] 92 (indicated like NT4-OMON) compared to the unrelated
conjugate (indicated like U4-OMON) and free MON
In the case of Monastrol, very poor in citotoxicity as a free drug, conjugation to NT4 by
an ether linkage, converts free drug inefficacy to moderate cytotoxicity of the
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conjugated drug. As we can see from Figure 34 and 35 the effect of the washing on the
activity of Monastrol is pronounced. We are planning to repeat the experiments in order
to find the best incubation interval before washing. Nevertheless in vivo studies will be
the most exhaustive to appreciate the releasing pattern of the drug.
In conclusion, as expected, the washing procedure, in [NT4-47] 85, [NT4-72] 89 and
[NT4-77] 91 experiments, lowers sensibly the resulting EC50 and this has to be taken
into account when considering the overall goodness of the tumor targeting peptide. To
have an idea of the loss of initial drug concentration, by means of the additional
washing, the behaviour of free CA-4 can be followed in Figure 31 and 32: free CA-4
for PANC-1 and PC-3 give 100% cell death at all tested concentrations, but when cells
are washed after 2 hours and re-incubated EC50 falls to 12 µM and 0.4 µM respectively
for PANC-1 and PC-3 .
All the experiments assessed that the conjugation to tetrabranched NT(8-13) profoundly
modified drug activity, which might result from the combination of both cell and drug
features, including: i) cell sensitivity to the drug; ii) drug mechanism of action; iii)
mechanisms of cell resistance to the drug; iv) efficiency of membrane transport of the
conjugated-drug. As expected, activities of the free drugs are very different from one
another and from cell line to cell line. In principle, the conjugation to tetrabranched NT
may produce as a result:
-an increase in drug specificity,
-an increase in drug activity,
-an increase in both specificity and activity or no improvement of the free drug.
When the free drug is very efficient, slow release conjugation to NT4 apparently
decreases drug efficiency (like in the case of Combretastatin derivative 90 in PANC-1
and PC-3). Interestingly, in other cases conjugation to branched NT can increase drug
efficiency (as for Monastrol derivative 92 in the three cell lines, Tirapazamine
derivative 87 in HT-29). Two negative examples of this type of conjugation are
represented by 83 [tetrabranched NT(8-13)-14] (slow release) and 91 [tetrabranched
NT(8-13)-77] (fast release) these two compounds gained no improvement compared to
the parent free drugs. Results with fast releasing tetra-branched NT are very interesting,
since in the case of both 5-Fluorodeoxyuridine and Combretastatin derivative,
respectively 47 and 72, the activity of the drug is clearly increased by conjugation to
branched NT4 (Figure 28-33). Comparison of results obtained with slow and fast
releasing molecules, indicate that fast releasing molecules can be even more active than
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slow-releasing compounds. A clear advantage of the branched peptide carrier is its
target specificity, demonstrated by the lack of activity on the three cell lines of any
drug, when coupled to an unrelated branched peptide.
Interestingly, cells that are not affected by a drug, such as PC-3 by 5-Fluorouracil itself,
can become sensitive to it, when conjugated to branched NT (Figure 28 and 29).
Changing the mechanism of membrane transport, by switching to a peptide receptor-
mediated mechanism, can deeply modify drug transport from outside to inside the cells.
Moreover, conjugation to branched peptides might as well impair mechanisms of drug
export from inside to outside the cell, entrapping the conjugated drug into the target
cell. This is extremely important for the therapy of tumors that over-express NT
receptors and do not respond to classical chemotherapy.
In conclusion, almost all our derivatives show very interesting profiles, in any case we
can see an increased selectivity and/or an increased activity.
Especially [NT4-47] and [NT4-72] have both increased their activity, and seem to be
very efficient cytotoxic agents, while the branched scramble peptide conjugated to 47
and 72 are inactive.
These two new promising molecules 85 and 89 will be so enrolled for the in vivo
studies, to determine the inhibition of tumor growth in nude mice bearing HT-29 tumor
xenografts.
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5. Nanoparticle therapeutics
During my PhD I had the opportunity to spend six months in the group of Professor
Vincent M. Rotello at University of Massachusetts, working on a project directed
towards the synthesis of nanoparticles to be used in therapeutic applications.
Nanomaterials are currently receiving considerable attention because of their potential
applications in biology and medicine. In particular, nanoparticles (NPs) are artificially
created structures in which all three dimensions are between 1 and 100 nm and which
are stable dispersed in solvent.82,84 Depending on material, size and shape, NPs possess
different functional properties. Some of these properties make them interesting as
contrast markers for imaging cancerous tissue (MRI), diagnostic tools,82 radiotherapy
enhancers, as well as drug and gene deliverers.83,84
Several methods have been proposed to target a tumor efficiently, exploiting some
useful characteristics of the newly formed vasculature. For example the enhanced
permeability and retention (EPR) phenomenon in tumors, where microvasculature
allows permeation of molecules and the absence of lymphatic drainage leads to
retention and accumulation of the delivered compounds in a tumor83 (Figure 36). In
EPR targeting, also called passive targeting, the therapeutic agent is subsequently
released locally and taken up by tumor cells to achieve its effect. In contrast, the tumor
receptor or antigen targeting, utilizing respectively peptides (like NT) and mAbs as
targeting agents, specifically aims the therapeutic agent at tumor cells (active targeting).
Figure 36 Passive and active targeting
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NPs exploiting either passive or active targeting are emerging as attractive candidates
for delivery of various payloads, which can be small drugs or large biomolecules, like
proteins, DNA or RNA.
Drug delivery
Many of the pharmacological properties of conventional (“free”) drugs can be improved
through the use of drug delivery systems (DDS) composed primarily of lipids and or
polymers.86 DDS are designed to alter the pharmacokinetics (PK) and biodistribution
(BD) of their associated drugs, or to function as drug reservoirs. Alterations in the BD
of DDS can occur through EPR effect (passive targeting).
Multifunctionality is the fundamental advantage of nanovectors86 for the cancer-specific
delivery of therapeutic and imaging agents. Primary functionalities include the
avoidance of biobarriers and biomarker-based targeting, and the reporting of therapeutic
efficacy. A huge number of nanovectors are now under study and the first examples,
liposome-encapsulated formulations of doxorubicin86 were approved more than ten
years ago for the treatment of Kaposi’s sarcoma, and are now used against breast cancer
and refractory ovarian cancer. Liposome carriers are to date the most effective, but they
do not provide control for the time of drug release and usually do not achieve effective
intracellular delivery of the drugs87, therefore limiting their potential, especially against
multidrug-resistant cancers. In contrast, inorganic nanoparticles generally possess
versatile properties suitable for cellular delivery, including wide availability, rich
functionality, good biocompatibility (low toxicity), potential capability of targeted
delivery and controlled release of carried drugs, thus offering a new appealing
alternative.83 Thus in the last decade an increasing efforts in research and development
have been devoted worldwide to various inorganic materials as novel carriers in the last
decade.
Gold nanoparticles (AuNPs) have been recently emerged as an attractive candidate for
drug and gene delivery applications for their functional versatility,88 biocompatibility,89
and low toxicity.90 Efficient release of these therapeutic agents is a prerequisite for
effective therapy. Both covalent and non-covalent approaches can be applied to these
DDSs. Recent studies have demonstrated release of payload, shown in Figure 37, by
intracellular thiols, as GSH.84,91 However controlled dissociation of drugs from covalent
conjugates is still a challenge for therapeutic applications.
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Figure 37 GSH-mediated payload release
During my period in the U.S.A. I have been involved in the synthesis of a thiol-
derivative of the ester prodrug of β-hydroxylapachone (LAP) 64 which was also
conjugated to the NT targeting peptide, see Chapter 1.2.2. We imagined the same
release of the cytotoxic molecule exploited for this type of conjugates, by both
enzymatic and non-enzymatic hydrolysis. In this case the release will occur after thiol-
exchange on the Au NPs by GSH.
β-hydroxylapachone (LAP) derivative 64 was functionalized with the previously
prepared1 protected thiol 94 affording the amide 95 which was then deprotected with
TFA to obtain the desired thiol 96 (Scheme 38).
This thiol will be used in the future to functionalize AuNPs and subsequently release
the covalently linked cytotoxic drug in vivo by a combined action of GSH and esterases.
Scheme 38
Non-covalent incorporation of drugs onto carriers can be achieved either by
encapsulation of hydrophobic drug molecules into non-polar cavities or by
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complexation between functional groups on the surface of NPs and drugs with opposite
charges. These non-covalent inclusions or complexes offer a variety of promising
advantages over the free drug molecules, such as enhanced water solubility and drug
stability, programmed release of drugs from the matrixes, and improved PD and PK
behaviors. This approach provides an alternative delivery strategy with the potential for
avoiding drug release and prodrug processing issues. Encapsulation methods, however,
are not without intrinsic limitations as inefficient drug loading and clearance by the
reticuloendothelial system (RES) remain a challenge. Interestingly, it has been shown
that smaller structures can evade RES capture and exhibit the ability to accumulate in a
broader range of tumors creating a necessity for nano-sized delivery vehicles.
We hypothesized that hydrophobic drugs would partition, as organic solutes do, into the
“hydrophobic pockets” inside monolayer of water-soluble AuNPs.
Figure 38
For this purpose we synthesized a variety of thiols, to functionalize AuNPs, featuring
two functional domains: a hydrophobic alkanethiol interior and a hydrophilic shell.
Initially we decided to prepare biocompatible AuNPs with a zwitterionic headgroup,
which minimize non-specific binding with biomolecules.92 The principle of stabilizing
small nanoparticles of less than 10 nm by zwitterionic ligands has been proved by
various studies.93
For the synthesis of the zwitterionic thiol ligands we started from 11-bromo-1-
undecanol (1 eq.) which was reacted, in the presence of 12 M NaOH, with
triphenylmethanethiol (1.2 eq.) in a ethanol/toluene mixture. The thioether 97 was
obtained in 99% yield after purification by column chromatography. Methanesulfonyl
chloride (1.5 eq.) was then added to a solution of 97 (1 eq.) and TEA (2 eq.) in CH2Cl2
to give sulfonyl derivative 98 in 80% yield. The tetraethylenglycol (TEG) functionality
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was then introduced heating 98 with TEG-OH in basic conditions, flash
chromatography was then necessary to isolate 99 (58%) (Scheme 39).
Scheme 39
TrS-C11-TEG-OH (99) was the key intermediate for the synthesis of various
functionalized thiols used in this study.
Methanesulfonyl chloride (1.5 eq.) was added to a solution of compound 99 (1 eq.) and
TEA (2 eq.) in CH2Cl2 to obtain sulfonyl derivative 100 in 89% yield without further
purification. The dimethylamine was then bubbled inside a solution of 100 in THF for 5
h, the reaction mixture was stirred overnight, washed with water to give tertiary amine
101 (85%). Finally the zwitteronic functionality was introduced by reaction with 1,3-
propanesulton in acetone. Purification by flash chromatography allowed to obtain
zwitterion 102 in 85% yield. Deprotection of the trityl group was carried out in CH2Cl2
with TFA/triisopropylsilane (TIPS) giving thiol 103 which is ready for the coupling
with the gold nanoparticles (Scheme 40).
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Scheme 40
We prepared other zwitterionic thiols with a different hydrophobic/hydrophilic ratio in
order to evaluate the changing of encapsulation’s ability of the resulting AuNPs. Two
ligands without TEG functionality were synthesized either with a C11 (104) or C16 (105)
alkyl chain.
In the case of 104 we prepared also the starting bromide 106 that is not commercially
available. We started from hexadecane-1,16-diol which was reacted with HBr in
cyclohexane to give bromide 106 quantitatively. The thio ether functionality was then
introduced by reaction with triphenylmethanethiol obtaining 107, which underwent the
next sulfonylation with methanesulfonyl chloride to give the activated derivative 108
(Scheme 41).
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Scheme 41
The two sulfonyl derivatives 98 and 108 were reacted with dimethylamine to obtain
109 and 110 which were transformed in the zwitterionic species 111 and 112 using 1,3-
propanesultone. Deprotection of the trityl group of 109 and 110 was carried out in
CH2Cl2 with TFA/triisopropylsilane (TIPS) giving the desired thiols 101 and 102, ready
for the coupling with the gold nanoparticles (Scheme 42).
Scheme 42
In order to obtain a wide hydrophobic pocket able to encapsulate big molecules we
decided to synthesized a thiol with a dendrimeric chain. We chose the same lysine
dendrimer adopted for the tetramerization of NT peptides for its versatility and
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biocompatibility. In this case the G1-lysine dendrimer was prepared in solution starting
from L-lysine methyl ester dihydrochloride (1 eq.) and Boc-Lys(Boc)-OH (2 eq.).
These two compounds were suspended in EtOAc in the presence of TEA (2 eq.), then
N-hydroxybenzotriazole (HOBT, 2 eq.) and dicyclohexylcarbodiimide (DCC, 2 eq.)
were added to activate the carboxylic acid of Lysine. Three lysine molecules were so
connected together in the G1-dendrimer 113, which was then deprotected on the methyl
ester in basic conditions (NaOH) to afford acid 114 (Scheme 43).
Scheme 43
Esterification of the key intermediate 99 (1 eq.) with the acid 114 (1.4 eq.) previously
activated with DCC (2 eq.) and DMAP (0.5 eq.), allowed the isolation of G1-
conjugated 115 in 99% yield, after the purification by flash chromatography (Scheme
44).
Scheme 44
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Eventually, deprotection of derivative 115 on the Boc functionalities and trityl group
was carried out directly with TFA/TIPS in CH2Cl2, allowing the isolation of thiol 116 in
quantitative yield (Scheme 45).
Scheme 45
Once obtained the desired thiols, these were used to conveniently functionalize AuNPs.
Gold nanoparticles, C5NP (~ 2 nm) were prepared by following the Brust-Schiffrin two
phase method using 1-pentanethiol as capping ligand. Ligand place exchange reaction
was then carried out, mixing 10 mg of C5 NP with 30 mg of thiol (1:3 in weight) in
CH2Cl2. After washing with diethylether the water-soluble functionalized gold
nanoparticles were dialysed in MilliQ water (Scheme 46). The effectiveness of the
place exchange was verified by the reversal solubility in water and 1H NMR analysis.
Scheme 46
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All the AuNPs synthesised resulted water soluble and stable for long time in solution.
In order to prepare AuNPs complexes with a guest compound, solvent displacement
method was carried out using water and acetone. An acetone solution of 10 mg of the
guest compound and aqueous solution of AuNP were mixed together. Then, acetone
was evaporated slowly. During the evaporation of the solvent, some guest compounds
were entrapped inside AuNP due to hydrophobic interactions while the residue
precipitated out. The particles were purified by multiple filtrations, through a
molecular weight cutoff filter until no absorbance of guest molecules in filtrate was
detected by spectrophotometer. The complexes were characterized by 1H NMR using
the signal of the broad peak of the guest molecule as indication of the entrapment into
the hydrophobic pocket of AuNP. In the case of AuNPZwit the entrapment of the guest
occurred only for NPs 117, but not for 118 and 119. Therefore the presence of a TEG
moiety is probably fundamental for the formation of the complexes.
Moreover AuNPs 117 didn’t form any complex with the guest compounds tried,
probably the hydrophobic pocket is too wide to retain the guest once entered.
AuNPZwit 117 were the only able to efficiently entrap guest compounds were,
therefore other studies were performed in order to test the stability and cytotoxicity of
these complexes.
We chose three different hydrophobic guest compounds: 4,4-difluoro-4-bora-3a,4a-
diaza-s-indacene (Bodipy) as a fluorescent probe, and the highly hydrophobic
therapeutics tamoxifen (TAF) and β-lapachone (LAP) as drugs.
The number of entrapped guest compounds per particle was calculated by measuring
the integrals from 1H NMR spectrum and NaCN-induced decomposition experiments.
The AuNPZwit-dye/drug complexes were stable in buffer for more than 1 month and to
dialysis, indicating a level of kinetic entrapment greater than the one observed with
dendrimers.94
Prof. Rotello’s group explored also the ability of the delivery systems to release the
payload in vitro. Initially a two-phase CH2Cl2-water system was adopted and
AuNPZwit-Bodipy released the dye into the organic phase probably via a particle-
interface process, since no AuNPZwit particle was observed in CH2Cl2. Afterwards the
delivery of the dye/drug to cells using human breast cancer cells (MC-7) was
determined by laser scanning microscopy (CLSM), transmission electron microscopy
TEM and inductively coupled plasma mass spectrometry (ICP-MS) (data not shown93).
Little or no cellular uptake of AuNPZwit was noticed while efficient delivery of the dye
to the cytosol was observed and an efficient cytotoxicity of the encapsulated drugs was
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demonstrated (Alamar blue assay). Notably AuNPZwit 115 itself was non-toxic but
once complexed with TAF and LAP acquired a comparable toxicity to the free drugs
making these systems suitable for targeting strategies.
Gene delivery
Gene therapy provides an ideal therapeutic for treatment of a variety of diseases, like
cancer and genetic disorders of both innate and acquired origin.95 Although viral
vectors are very effective, they have raised many safety concerns such as unpredictable
cytotoxicity and immune responses.96 Synthetic vectors, which include polymers, lipids,
nanomaterials and combinations thereof,97 although highly effective in vitro have a low
efficiency in vivo also due to their cell toxicity and immunogenicity. The effective
delivery vehicles should provide efficient protection of nucleic acids from degradation,
efficient cell entry and release of the nucleic acid in functional form. Gold nanoparticles
are particularly attractive scaffolds for gene delivery because they provide an high
surface-to-volume ratio and a controlled surface functionality, which allow tuning of
the charge and hydrophobicity.
Prof. Rotello’s group showed in earlier studies that quaternary ammonium-
functionalized cationic GNPs bind plasmid DNA through electrostatic interactions.98-99
The releasing of the bound DNA from these systems is regulated by manipulation of
intracellular GSH levels (like in Figure 37). These studies demonstrated that DNA
delivery efficiency and therefore their ability to condense DNA, strongly depends on
the structure of the head-groups. Amino-acid functionalized gold nanoparticles provide
a versatile scaffold for recognition and delivery of DNA and in particular the GNP-
LysG1 (Lysine Dendron) 121 was the most potent vector (Figure 39).99
In order to increase the transfection efficiency of these vectors we modified the thiol
ligand used to functionalize the GNPs. In particular we introduced a TEG functionality
into the alkyl chain trying to provide a better permeation.
Results and Discussion
80
Figure 39
Synthesis of derivative 122 started from the G1-Lysine dendron 114 and protected thiol
123. The activation of the carboxylic group with DCC allowed the conjugation with the
alcohol 123 and formation of the desired ester 124 in quantitative yield (Scheme 47).
Scheme 47
The deprotection was performed in two steps. Initially Boc protecting groups were
cleaved by the addition of TFA to a solution of 124 in CH2Cl2 to give free amine 125.
Then acetyl chloride was added to remove thioacetyl group, allowing the isolation of
thiol 122 in 86% yield without further purification (Scheme 48).
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Scheme 48
Once obtained the desired thiol, ligand place exchange reaction was carried out, mixing
10 mg of C5 NP with 30 mg of 122 (1:3 in weight) in CH2Cl2. After washing with
diethylether the water-soluble functionalized gold nanoparticles were dialysed in MilliQ
water (Scheme 46). The effectiveness of the place exchange was verified by the
reversal solubility in water and 1H NMR analyses.
FePt nanooparticles have never been exploited as gene delivery agents.
Their easy functionalization with different ligands on iron and platinum allows a better
tuning of the charge and hydrophobicity, making them interesting tools in DNA
delivery applications. Since PEI (polyethylenimines) has shown high transfection
efficiency both in vitro and in vivo and attracted great attention, we designed the
synthesis of PEI functionalized FePt NPs.
FePt NPs (~ 4 nm) were prepared by following the Shouheng Sun et al. method using
oleic acid and oleyl amine as capping ligands respectively for Fe and Pt.100
The functionalization of Fe can be achieved using either carboxylic acid or dopamine
groups while Pt can attach thiols or amines. We chose to prepare two dopamine
derivatives: 126, carrying a disulfide linkage, which should be able to release the DNA
by thiol-disulfide exchange with endogenous thiols like GSH, and 127, with a C8 alkyl
chain. The synthetic procedure started in both cases from a commercially available
dicarboxylic acids 34 or 128. One acid group was activated with N-hydroxysuccinimide
to give 129 and 130. The reaction with Boc-protected oligoethylamine 131, previously
synthesized as reported in the experimental part,101 in basic conditions afforded the
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corresponding amides 132 and 133 in quantitative yields without further purification.
The conjugation with dopamine of both the free acids and the deprotection of the Boc
protecting groups with TFA allowed the isolation of the PEI-Dopamine derivatives 126
and 127 (Scheme 49).
Scheme 49
In a typical experiment the FePt functionalize NPs were prepared by mixing 5 mg of
oleic acid and oleylamine stabilized FePt NPs with 10 mg of deprotected derivative of
99 in CH2Cl2. The mixture was stirred overnight then to the resulting SH-C11-TEG-OH
functionalized FePt NPs, 7.5 mg of DOP-PEI (126 or 127) were added and the reaction
mixture stirred for 2 days at 35 °C. The functionalized NPs 136 and 137 were then
purified by multiple filtrations through a molecular weight cut-off filter and dissolved
in water.
The introduction of SH-C11-TEG-OH provided a better water solubility (Scheme 50).
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Scheme 50
The transfection efficiency of mammalian cells by these FePtNPs is now under
investigation.
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General
All the reactions were monitored by TLC on commercially available precoated plates
(silica gel 60 F 254) and the products were visualized with acidic vanillin solution.
Silica gel 60, 230–400 mesh, was used for column chromatography, unless otherwise
stated. EtP refers to light petroleum, bp 40–60 °C and EtOAc to ethylacetate.. 1H and
13C NMR spectra were recorded at 400, 200 and 100, 50 MHz, respectively. Melting
points were measured on a microscopic apparatus and are uncorrected. FTIR spectra
were recorded in KBr pellets or in CDCl3 solutions. Mass spectra were measured with a
Shimadzu QP5050 or by FAB (m-nitrobenzyl alcohol as matrix) or by ESI using JEOL
MStation JMS700.
THF was distilled from sodium in the presence of the blue colour of benzophenone
kethyl, toluene was distilled from sodium, CH2Cl2 was distilled from CaH2 and MeOH
from Mg.
Commercial available reagents, catalysts and ligands were used as obtained, unless
otherwise stated, from freshly opened container without further purifications.
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Synthesis of 2-(4,7,10-tris(2-tert-butoxy-2-oxoethyl)-1,4,7,10-
tetraazacyclododecan-1-yl)acetic acid (1)
1,4,7,10-tetraazacyclododecane-1,4,7-tris(tert-butylacetate) (4)
To a solution of tetraazacyclododecane (1.50 g, 8.72 mmol) and Na(CH3COO) (2.14 g,
26.13 mmol) in dimethylacetamide (31 mL), tert-butylbromoacetate (5.10 g, 26.13
mmol) was added. The white suspension was stirred for 20 days, then the precipitate
was filtered and dried to give 4 as a white solid in 55% yield. 1H NMR, 200 MHz ,
CDCl3, δ: 1.44 (s, 9H, tBu); 1.45 (s, 18H, tBu); 2.82-2.96 (m, 12H, CH2); 3.03-3.12 (m,
4H, CH2); 3.28 (s, 2H, CH2); 3.36 (s, 4H, CH2); 10.00 (s, 1H, NH). 13C NMR, 50 MHz,
CDCl3, δ: 28.1 (6C, CH3); 28.2 (3C, CH3); 47.5, 49.2, 51.3, 58.2 ( 2C, CH2); 81.6 (1C,
N-CH2); 81.8 ( 2C, N-CH2); 169.6 ( 1C, CO); 170.5 ( 2C, CO).
N-(benzylcarboxymethyl)-1,4,7,10-tetraazacyclododecane-N’,N’’,N’’’-triacetic acid tri-
tert-butyl ester (5)
Compound 4 (2.38 g, 7.44 mmol) was added to a suspension of 60% NaH in DMF,
after 2 hours stirring, benzylbromoacetate (2 g, 8.7 mmol) was added dropwise below 0
°C. The reaction mixture was stirred for 27 h at room temperature (r.t.), then a solution
of 5% citric acid was added and the mixture extracted with chloroform. The product
obtained was purified by flash chromatography with 8/1= CH2Cl2/MeOH as eluent to
give 5 in 67% yield. 1H NMR, 200 MHz , DMSO-d6, δ: 1.40 (bs, 18H); 1.44 (s, 9H);
2.43-1.94 (bs, 6H); 3.29-2.71 (bs, 7H); 3.31 (s, 2H); 3.46–3.39 (m, 2H); 5.13 (s, 2H);
7.35 (s, 5H). 13C NMR (DMSO-d6) (d, ppm): 31.2; 50.5; 52.3; 52.6; 53.8; 57.1; 58.3;
75.3; 85.7; 85.7; 128.7; 129.8; 144.7; 172.9; 174.3.
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2-(4,7,10-tris(2-tert-butoxy-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid
(1)
A mixture of 5 (0.83 g, 1.25 mmol) and 10% Pd/C (0.11 g) was hydrogenated in
methanol under a positive H2 atmosphere for 6 h. The catalyst was removed by
filtration, and the filtrate was evaporated to yield the modified DOTA macrocycle 1 in
50% yield without further purification. 1H NMR, 200 MHz , CDCl3, δ: 1.40 (s, 9H);
1.41 (s, 18H); 2.64 (bs, 4H); 2.72 (bs, 4H); 2.87 (bs, 4H); 3.33 (bs, 4H); 3.36 (s, 6H);
3.46 (m, 2H); 13C NMR, 200 MHz, DMSO, δ: 36.83, 36.88, 56.09; 58.59; 60.78; 61.88;
64.61; 65.63; 89.53; 179.30. MALDI-MS (m/z) for [M+H]+: 572.6. ESI-MS (m/z) for
[M+H]+: 573.4.
Synthesis of 4-((4,7,10-tris(2-tert-butoxy-2-oxoethyl)-1,4,7,10-
tetraazacyclododecan-1-yl)methyl)benzoic acid (2)
Benzyl 4-(chloromethyl)benzoate (6)
4-chloromethylbenzoic acid (500 mg, 2.93 mmol) was suspended in 3.8 mL of benzylic
alcohol and three drops of concentrated sulfuric acid. The reaction mixture was stirred
at 64°C for 3h, then diluted with CH2Cl2 and a saturated solution of NaHCO3 was added
until neutral pH. The two phases where separated and the organic layer was washed
with water (3x50mL), dried over Na2SO4, filtered and the solvent removed under
vacuum. The oil yielded was purified by flash chromatography with 10/1=EtP/EtOAc
as eluent to give benzyl derivative 6 in 34% yield. 1H NMR, 200 MHz , CDCl3, δ: 4.61
(s, 2H, CH2); 5.37 (s, 2H, CH2); 7.36-7.48 (m, 7H, Harom); 8.07 (d, 2H, J = 8.4 Hz,
Harom).
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Tert-butyl-2,2',2''-(10-(4-(benzyloxycarbonyl)benzyl)-1,4,7,10-tetraazacyclodode
cane-1,4,7-triyl)triacetate (7)
NN
NN
O
OBut
O
OBut
O
ButO
OBn
O
7
1,4,7,10-tetraazacyclododecane-1,4,7-tris(tert-butylacetate) 4 (100 mg, 0.19 mmol) and
K2CO3 (68 mg, 0.49 mmol) were suspended in 4 mL of CH3CN and the mixture was
stirred at 60°C for 15 min. At this temperature the benzyl ester of 4-
chloromethylbenzoic acid 6 (55 mg, 0.21 mmol) was added dropwise over 1 h. After
48 h, the yellow suspension obtained was filtered through celite and concentrated to
obtain an oil which was used in the subsequent reaction without further purification, 7.
1H NMR, 200 MHz, C6D6, δ: 1.30 (s, 18H, tBu); 1.34 (s, 9H, tBu); 2.46-2.50 (m, 4H,
CH2); 2.76-2.83 (m, 10H, CH2); 3.14 (s, 4H, CH2); 3.28 (s, 2H, CH2); 3.30 (s, 2H,
CH2); 5.16 (s, 2H, CH2); 7.03-7.18 (m, 5H, Harom); 7.36 (d, 2H, J = 8.0 Hz, Harom); 8.15
(d, 2H, J = 8.0 Hz, Harom).
4-((4,7,10-tris(2-tert-butoxy-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-
yl)methyl)benzoic acid (2)
NN
NN
O
OBut
O OBu
t
O
ButO
2
OH
O
7 (67 mg, 0.09 mmol) was dissolved in 1.9 mL of absolute ethanol, added with 10%
Pd/C (26 mg) and hydrogenated at 50 psi of H2 for 60 h. The catalyst was removed by
filtration, the filtrate evaporated, and the crude purified by flash chromatography with
8/1→5/1=CH2Cl2/MeOH as eluent to obtain benzyl derivative 2 in 50% yield (from 4 to
2). 1H NMR, 400 MHz, CDCl3, δ: 1.42 (s, 9H, tBu); 1.45 (s, 18H, tBu); 2.00-3.22 (m,
12H, CH2); 3.22-3.40 (m, 4H, CH2); 3.47(s, 2H, CH2); 4.43 (s, 1H, OH); 7.45 (d, 2H, J
= 7.8 Hz, Harom); 8.05 (d, 2H, J = 7.8 Hz, Harom). 13C NMR, 50 MHz, CDCl3, δ: 27.8,
27.9 (3C, CH3); 28.1 (6C, CH3); 49.2, 49.7, 50.5 (2C, CH2); 51.2 (4C, CH2); 51.9, 55.9,
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59.3 (2C, CH2); 81.8, 82.1, 82.4, 83.1 (1C, N-CH2); 88.8 (3C, C(CH3)3); 129.5 (2C,
CHarom); 130.2 (3C, CHarom and Carom); 140.9 (1C, Carom); 169.3, 169.9, 172.2, 173.2
(1C, CO). IR: 3426, 2971, 2930, 2837, 1731, 1715, 1369, 1230, 1163 cm-1. MS:
(MALDI-ToF) M+.= 673.105 (100%).
Synthesis of 5-tert-butoxy-5-oxo-4-(4,7,10-tris(2-tert-butoxy-2-oxoethyl)-1,4,7,10-
tetraazacyclododecan-1-yl)pentanoic acid (3)
5-(benzyloxy)-2-bromo-5-oxopentanoic acid (8)
To a suspension of L-glutamic acid-5-benzylester (1.50 g, 6.48 mmol) and sodium
bromide (2.27 g, 22.08 mmol) in a 1N solution of bromidric acid, cooled at 0°C,
sodium nitrite (0.79 g, 11.45 mmol) was added portionwise. The yellow solution was
stirred at this temperature for 2 h and finally 560 μL of 98% sulfuric acid was added,
followed by diethylether. The water phase was extracted several times with Et2O and
the combined organic layers washed with brine. The crude product was purified by
flash chromatography with 1/1=EtOAc/EtP, to obtain bromo-derivative 8 in 82% yield.
1H NMR, 200 MHz, (CD3)2SO, δ: 2.00-2.40 (m, 4H, CH2); 4.38-4.50 (m, 1H, CH-Br);
5.08 (s, 2H, CH2); 5.74 (s, 1H, OH); 7.35 (m, 5H, Harom). 13C NMR, 50 MHz, CDCl3, δ:
29.3 (1C, CH2); 31.4 (1C, CH2); 44.3 (1C, C-Br); 66.6 (1C, CH2); 128.0 (1C, Carom);
128.2, 128.4 (2C, CHarom); 135.3 (1C, Carom); 172.0, 173.3 (1C, CO).
5-benzyl 1-tert-butyl 2-bromopentanedioate (9)
A solution of tert-butyltrichloroacetimidate (TBTA) (2.20 mL, 12.05 mmol) in 8 mL of
cyclohexane was added dropwise to another solution of 8 (1.70 g, 5.63 mmol) in 7 mL
of CHCl3. During the addition a white precipitate formed, which was dissolved by the
addition of DMA followed by boron trifluoridiethyl etherate (120 μL, 0.56 mmol) as a
catalyst. The reaction mixture was stirred for three days at r.t. then concentrated and the
remaining DMA phase was extracted with hexane (3x10mL). The hexane phase was
evaporated and the crude product product was purified by flash chromatography with
20/1=EtOAc/EtP followed by 10/1, to give But ester 9 in 50% yield. 1H NMR, 200
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MHz, (CD3)2SO), δ: 1.47 (s, 9H, CH3); 2.20-2.50 (m, 2H, CH2); 2.52-2.60 (m, 2H,
CH2); 4.24 (dd, 1H, J1 = 6.0 Hz, J2 = 8.2 Hz, CH-Br); 5.13 (s, 2H, CH2); 7.36 (m, 5H,
Harom).
5-benzyl 1-tert-butyl 2-(4,7,10-tris(2-tert-butoxy-2-oxoethyl)-1,4,7,10-tetraaza
cyclododecan-1-yl)pentanedioate (10)
OButO
OBn
O
NN
NN
O
OBut
O OBu
t
O
ButO
10
To a solution of 4 (918 mg, 1.79 mmol) in 31 mL of dry CH3CN, K2CO3 (740 mg, 5.36
mmol) was added. The reaction mixture was stirred at 60 °C for 10 min before adding
dropwise, over a period of 40 min, a solution of 9 (1.14 g, 3.58 mmol) in 15 mL of dry
CH3CN. After 42 h under stirring at 60° C the yellow solution was filtered throw celite
and concentrated. The residue was chromatographed with 20/1=CH2Cl2/MeOH
followed by 8/1 to obtain 10 in 59% yield. Melting point: 145°C. 1H NMR, 200 MHz,
CDCl3, δ: 1.45 (s, 36H, CH3); 1.90-3.60 (m, 27H); 5.07 (s, 2H, CH2); 7.33 (m, 5H,
Harom).
5-tert-butoxy-5-oxo-4-(4,7,10-tris(2-tert-butoxy-2-oxoethyl)-1,4,7,10-
tetraazacyclododecan-1-yl)pentanoic acid (3)
10 (100 mg, 0.127 mmol) was dissolved in 2.8 mL of absolute ethanol and to this
solution 37 mg of 10% Pd (C) were added. The reaction mixture was hydrogenated for
two days, filtered over cotton wool pad and the filtrate concentrated to give 3 with 79%
yield without further purification. Melting Point = 180-182°C. 1H NMR, 400 MHz,
CD3OD, δ: 1.49 (s, 9H, CH3); 1.50 (s, 18H, CH3); 1.53 (s, 9H, CH3); 1.98-2.30 (m,
8H); 2.46-2.88 (m, 11H); 2.90-3.20 (m, 4H); 3.42-3.6 (m, 4H). 13C NMR, 100 MHz,
CD3OD, δ: 28.3 (6C, CH3); 28.1 (6C, CH3); 33.3 (1C, CH2); 45.2, 53.9, 54.0, 56.6, 56.9
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(12C, CH2); 61.3 (1C, CH); 82.9 (2C, C(CH3)3), 83.0, 83.6 (1C, C(CH3)3); 174.6, 174.7,
176.5, 176.7 (1C, CO). MS IR: 3422, 2974, 2929, 2840, 1726, 1362, 1223, 1166 cm-1. :
ESI(MS) M+.=701, 723 (100%); CI, 56(100%), 157, 600.
Synthesis of 3-(9H-purin-6-ylthio)acrylic acid, PTA (14)
To a suspension of 6-mercaptopurine (11) (1.00 g, 5.88 mmol) in 35 mL of anhydrous
methanol, a freshly prepared 1.17 M solution of MeONa in MeOH (5.03 mL) was
added with continuous stirring until complete solution formed. Propiolic acid (0.36 mL,
5.88 mmol) was dissolved in a 5.00 mL portion of the 1.17 M solution of MeONa in
MeOH, and added to the solution of 6-MP. The reaction mixture was refluxed overnight
under a nitrogen atmosphere. Addition of 3% HCl to the mixture, until pH 2, caused the
formation of a precipitate which was recollected by filtration, washed with water and
dried. NMR control of the crude product reveal apart from the desired product, the
presence of some residual 11. A saturated solution of NaHCO3 was added to the residue
under stirring to give a suspension. After filtration, HCl 1N was added to the solution
causing the precipitation of pure PTA 14 which was isolated by filtration as single Z
isomer in 43% yield. Mp 235°C, dec. 1H NMR, 400 MHz, DMSO-d6, δ: 6.26 (d, 1H,
J=10.0 Hz, C=CH-S); 8.53 (s, 1H, CHarom); 8.74 (d, 1H, J=10.0Hz, C=CH-CO); 13.69
(s, 1H, NH); 8.79 (s, 1H, CHarom). 13C NMR, 100 MHz, DMSO-d6, δ: 117.2 (1C, C=C),
137.5 (1C, Carom);, 144.7 (1C, CHarom); 151.8 (1C, C=C); 156.3 (1C, Carom), 161.9 (1C,
CHarom); 167.8 (1C, CO). IR, KBr: 1569; 1597; 1681; 3462 cm-1.
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Methyl 3-(9H-purin-6-ylthio)acrylate (17)
To a suspension of 6-MP (11) (1.00 g, 5.88 mmol) in 45 mL of dry MeOH, 3.5 mL of a
1.67 M solution of MeONa (5.88 mmol) were added under stirring, until a complete
dissolution of 11. 1.8 mL of ethylpropiolate (17.6 mmol) were then added and the
reaction mixture was refluxed for 15 h, diluted with 50 mL of a saturated solution of
NH4Cl and extracted with EtOAc. The combined organic layers were washed with
water, dried over Na2SO4, filtered and evaporated to give adduct 17 in 14% yield as a
mixture 77/23 of isomers cis and trans. 1H NMR, 200 MHz, DMSO-d6, δ: 3.75 (s, 6H,
O-CH3(cis+trans)); 6.39 (d, 1H, J= 10.2 Hz, S-CHcis); 6.54 (d, 1H, J = 16.0 Hz, S-CHtrans);
8.59 (s, 2H, CHarom(cis+trans)); 8.84 (s, 2H, CHarom(cis+trans)); 8.86 (d, 1H, J = 8.8 Hz, CHcis-
CO ); 8.89 (d, 1H, J =14.6 Hz, CHtrans-CO); IR (KBr), cm-1: 3366 (stretch. N-H), 1701
(stretch. C=O), 1567 (bend. N-H).
Synthesis of methyl 4-propioloylbenzoate (20)
Methyl 4-(1-hydroxyprop-2-ynyl)benzoate (19)
OH
O
O
19
To a solution of methyl-4-formylbenzoate (1.00 g, 6.10 mmol) in 25mL of dry THF, a
0.5 M solution of ethynyl magnesium bromide in THF (12.2 mL, 6.10 mmol) at -78°C
in 20 min. After the addition the reaction was stirred at -78°C for 50min, at r.t. for 2 h,
and finally neutralized with a saturated solution of NH4Cl, extracted with Et2O
(3x40mL) and dried over Na2SO4. The crude product was purified by flash
chromatography with 3/1=EtP/EtOAc as eluent, to give 19 in 69% yield. 1H NMR, 200
MHz, CDCl3, δ: 2.70 (d, 1H, J = 2.2 Hz, C≡C-H); 3.92 (3H, CH3);. 5.53 (dd, 1H, J =
2.2 e 6.2 Hz, CH-OH); 7.63 (d, 2H, J =8.8 Hz, Harom); 8.06 (d, 2H, J = 8.8 Hz, Harom).
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Methyl 4-propioloylbenzoate (20)
To a solution of derivative 19 (0.80 g, 4.21 mmol) in 15 mL of CH2Cl2 at 0°C, TEMPO
(0.01 g, 0.84mmol) followed by trichloroisocianuric acid (TCICA) (1.07 g, 4.63 mmol)
were added. The resulting suspension was maintained at 0°C for 5 min and at r.t. for 40
min. The reaction mixture was diluted with CH2Cl2 and then filtered through celite. The
filtrate was washed with a saturated solution of Na2CO3 (2x25 mL), a 1N solution of
HCl (25 mL) and finally with water (25 mL). The solution was dried over Na2SO4 and
the solvent removed under vacuum to obtain derivative 20 in 97% yield. 1H NMR, 200
MHz, CDCl3, δ: 3.51 (s, 1H, C≡C-H); 3.96 (s, 3H, CH3); 8.15-8.25 (m, 4H, CHarom). IR
(CHCl3), cm-1: 3215 (stretch.C≡C-H), 2095 (stretch. C≡C), 1717 (stretch. O-C=O),
1633 (stretch. C=O).
Synthesis of methyl 8-(9H-purin-6-ylthio)-6-oxooct-7-enoate (25)
Ethyl 6-oxohexanoate (22)
To a solution of ethyl-6-hydroxy-hexanoate (2.00 mL, 12.30 mmol) in 32 mL of
CH2Cl2, trichloroisocianuric acid (2.90 g, 12.30 mmol) was added. After 10 min under
stirring, TEMPO (0.020 g, 0.12 mmol) was added and the reaction stirred for 3 min.
After dilution with CH2Cl2, the mixture was filterd through celite and the filtrate
washed with a saturated solution of Na2CO3 (3x40 mL), 40mL of 1N HCl and finally
with water. After drying over Na2SO4, filtration and evaporation aldehyde 22 was
obtained in 98% yield without further purification. 1H NMR, 200 MHz, CDCl3, δ: 1.37
(t, 3H, J = 7.0Hz, CH2CH3); 1.42-1.68 (m, 4H); 2.19-2.23 (m, 2H, CH2-COO); 2.25-
2.42 (m, 2H, CH2-CHO); 4.04 (q, 2H, J =7.4 Hz, CH2CH3); 9.70 (t, 1H, J = 1.6 Hz,
CHO). IR (CDCl3), cm-1: 2827, 2724 (stretch. H-C=O), 1720 (stretch. C=O), 1390
(bend. H-C=O).
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Ethyl 6-hydroxyoct-7-ynoate (23)
To a solution of 22 (1.90 g, 12.00 mmol) in 25 mL of anhydrous THF at -78°C and
under nitrogen atmosphere, a 0.5 M solution of etynyl magnesium bromide in THF
(24.00 mL, 12.00 mmol). The reaction mixture was stirred at -78°C for 50 min, and at
r.t. for 1 h, then was neutralized by the addition of a saturated solution of NH4Cl and
extracted with diethyl ether (3x40 mL). The recollected organic layers were dried over
Na2SO4, filtered and the solvent removed. The crude product was purified by flash
chromatography with 3/1=EtP/EtOAc as eluent, to give alcohol 23 in 43% yield. 1H
NMR, 200 MHz, CDCl3, δ: 1.25 (t, 3H, J = 7.1, CH2CH3); 1.40-1.90 (m, 6H); 2.32 (at,
2H, J = 7.4 Hz, CH2-COO); 2.45 (d, 1H, J = 2.2 Hz, C≡C-H); 4.13 (q, 2H, J = 7.0 Hz,
CH2CH3); 4.38 (dt, 1H, J = 1.80 Hz, J = 6.0 Hz, CH-OH).
Ethyl 6-oxooct-7-ynoate (24)
To a solution of 23 (0.60 g, 3.30 mmol) in 10 mL of CH2Cl2 at 0°C, TEMPO (0.01 g,
0.84 mmol) followed by trichloroisocianuric acid (TCICA) (0.84 g, 3.63 mmol) were
added. The resulting suspension was maintained at 0°C for 40 min and at r.t. for 16 h.
The reaction mixture was diluted with CH2Cl2 and then filtered through celite. The
filtrate was washed with a saturated solution of Na2CO3 (2x35 mL), a 1N solution of
HCl (35 mL) and finally with water (35 mL). The solution was dried over Na2SO4 and
the solvent removed under vacuum to obtain derivative 24 in 99% yield without further
purification. 1H NMR, 200 MHz, CDCl3, δ: 1.25 (t, 3H, J = 7.1, CH2CH3); 1.55-1.80
(m, 4H); 2.32 (at, 2H, CH2-C(O)O); 2.62 (at, 2H, CH2-C=O); 3.13 (s, 1H, C≡C-H); 4.13
(q, 2H, J = 7.0 Hz, CH2CH3). IR (CDCl3), cm-1: 3297 (stretch.C≡C-H), 2097 (stretc.
C≡C), 1727 (stretch. C=O estereo), 1683 (stretch, C=O aldeidico).
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Methyl 8-(9H-purin-6-ylthio)-6-oxooct-7-enoate (25)
To a suspension of 6-mercaptopurine (11) (0.22 g, 1.28 mmol) in 10 mL of anhydrous
methanol, a freshly prepared 5.1 M solution of MeONa in dry MeOH (0.25 mL, 1.28
mmol) was added with continuous stirring until complete solution formed. 24 (0.70 g,
3.85 mmol) was dissolved in a 2.00 mL of MeOH and added.and added to the solution
of 6-MP. The reaction mixture was stirred at r.t. overnight under a nitrogen atmosphere.
A saturated solution of NH4Cl was added to the mixture, which was then extracted
with EtOAc, washed with water and dried. The crude product was purified by flash
chromatography with 13/1=CHCl3/MeOH to obtain derivative 25 in 47% yield as a
mixture 80/20 of cis and trans isomers. 1H NMR, 200 MHz, DMSO-d6, δ: 1.14 (t, 6H,
J = 7.0 Hz, CH2CH3(cis+trans)); 1.23-1.65 (m, 8H, C-CH2CH2-C(cis+trans)); 2.05-2.40 (m, 4H,
CH2-COO(cis+trans)); 2.42-2.70 (m, 4H, CH2-CO(cis+trans)), 4.01 (q, 4H, J = 7.0 Hz,
CH2CH3(cis+trans)); 6.75 (d, 1H, J = 19.0 Hz, S-CHtrans); 6.79 (d, 1H, J = 10.0 Hz, S-
CHcis); 8.56 (s, 2H, CHarom(cis+trans)); 8.70 (d, 1H, J = 10.0 Hz, CHcis-CO); 8.80 (s, 2H,
CHarom(cis+trans)); 8.85 (d, 1H, J = 19.0 Hz, CHtrans-CO). 13C NMR, 200 MHz, DMSO-d6,
δ: 14.1, 23.0, 24.0, 33.3, 42.0 (10C, Calif(cis+trans)); 59.6 (2C, OCH2(cis+trans)); 121.9 (2C,
C=C(cis+trans)); 144.5 (2C, C=C(cis+trans)); 121.9, 135.0, 135.7, 151.2, 151.4 (10
Carom(cis+trans)); 172.5 (2C, COO(cis+trans)); 196.4 (1C, C=C-CO(trans)); 199.2 (1C, C=C-
CO(cis)). IR (KBr), cm-1: 3462 (stretch. N-H), 1731 (stretch. O-C=O), 1669 (stretch.
C=O), 1594 (stretch. C=C), 1569 (bend. N-H). ESI-MS, m/z: 357 (M+Na +); 335
(M+H+). ESI-MS, m/z: 333 (M-H-)
Synthesis of 6-(9H-purin-6-ylthio)-4-oxohex-5-enoic acid (27)
4-Tert-butoxy-4-oxobutanoic acid (28)
A suspension of succinic anhydride (5.00 g, 50.00 mmol) in 30 mL of dry toluene was
manteined under a nitrogen atmosphere and reacted in sequence with N-
hydroxysuccinimide (1.73 g, 15.00 mmol), 4-dimethylaminopyridine (DMAP, 0.61 g,
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5.00 mmol), dry tert-butanol (14.00 mL, 150.00 mmol) and triethylamine (TEA, 2.09
mL, 15.00 mmol). The mixture was stirred for 30 min at r.t., and heated at reflux for 24
h. After cooling, ethyl acetate (80 mL) was added, the organic phase washed with a
10% citric acid solution (3x80 mL) and brine (2x60 mL), dried on Na2SO4 and
concentrate under reduced pressure. The crude product (7.00 g), was purified by flash
cromathography with 2/5=ethyl acetate/dichloromethane, to give acid 28 in 73% yield,
as a pale yellow solid. Mp 50°C. 1H NMR, 200 MHz, CDCl3, δ: 1.44 (s, 9H, tBu); 2.69-
2.48 (m, 4H, CH2). IR, CDCl3: 1716; 1746; 3450-2550 cm-1.
Tert-butyl 4-(methoxy(methyl)amino)-4-oxobutanoate (30)
To a suspension of 28 (1.00 g, 5.74 mmol) in dry DMF, HBTU (2.18 g, 5.74 mmol) and
DIPEA (2.00 mL, 11.50 mmol) were added, and the mixture stirred at r.t. for 10 min.
Finally, a solution Wienreb’s amine 29 (0.56 mg, 5.74 mmol) in dry DMF (15 mL) was
added. After stirring at r.t. for 3 h, the mixture was diluted with H2O (50 mL) and
extracted with CHCl3 (3x40 mL). The combined organic phases were dried on Na2SO4
and concentrated under reduced pressure, to give 30 in 76% yield, used without further
purification in the next step . 1H NMR, 200 MHz, CDCl3, δ: 1.45 (s, 9H, tBu); 2.50-
2.75 (m, 4H, CH2); 3.71 (s, 3H, OCH3); 3.18 (s, 3H, NCH3). IR, CDCl3: 1658; 1718 cm-
1.
tert-butyl 4-oxohex-5-ynoate(31)
A solution of 30 (0.15 g, 0.70 mmol) in dry THF (25 mL) was kept under a nitrogen
atmosphere, cooled at -78 °C and, after adding of a 0.5 M solution of ethynyl
magnesium bromide in THF (7.00 mL, 3.50 mmol), stirred at -78 °C for 30 min and at
r.t. for 3 h. Then, the mixture was quenched adding Et2O (60mL), ice and a solution of
1M KH2PO4 (150mL), under vigorous stirring. After extraction with Et2O (3x50 mL),
the combined organic phases were washed subsequently with 1M KH2PO4 (1x150 mL),
satured Na2CO3 (2x150mL) and brine (3x150 mL), dried over Na2SO4 and concentrated
under reduced pressure to give ynoate 31 in 47% yield as a pure solid. 1H NMR, 200
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MHz, CDCl3, δ: 1.44 (s, 9H, tBu); 2.56 (t, 2H, J=6.4 Hz, CH2); 2.87 (t, 2H, J=6.4 Hz,
CH2); 3.24 (s, 1H, C≡CH). 13C NMR, 50 MHz, CDCl3, δ: 28.1 (3C, CH3); 30.4 (1C,
CH2); 40.2 (1C, CH2); 78.9 (2C, C≡C); 81.0 (1C, C(CH3)3); 170.7, 184.9 (1C, CO).
tert-butyl 6-(9H-purin-6-ylthio)-4-oxohex-5-enoate (32)
To a suspension of 11 (0.19 g, 1.10 mmol) in 10 mL of anhydrous MeOH, maintained
under a nitrogen atmosphere, a freshly prepared 0.65 M solution of MeONa in dry
MeOH (1.70 mL, 1.10 mmol) was added with continuous stirring until complete
solution. To this solution, 31 (0.20 g, 1.10 mmol) in dry MeOH (4 mL), was added and
the mixture stirred at r.t. overnight. The mixture was diluted with saturated NH4Cl (30
mL) and extracted with AcOEt (3x30 mL). The combined organic phases were dried
over Na2SO4 and concentrate under reduced pressure. The crude product (0.72 g) was
washed with EtP and purified by flash chromatography with 15/1=CHCl3/MeOH, to
give 32 in 84% yield as a 75/25 mixture of E/Z isomers. 1H NMR, 200 MHz, DMSO, δ:
1.37 (s, 9H, tBu); 2.5 (at, 4H, J=6.6 Hz, CH2(E+Z)); 2.84 (at, 4H, J=6.4 Hz, CH2(E+Z));
6.82 (d, 1H, J=16.0 Hz, S-CHE); 6.86 (d, 1H, J=9.8 Hz, S-CHZ); 8.57 (s, 2H,
CHarom(E+Z)); 8.73 (d, 1H, J=9.8 Hz, CHZ-CO); 8.83 (s, 2H, CH arom(E+Z)); 8.91 (d, 1H,
J=16.6 Hz, CHE-CO). 13C NMR, 50 MHz, DMSO, Z + E, δ: 27.7, 28.8 (3C, C(CH3)3);
35.2, 37.4 (2C, CH2); 79.6 (2C, C(CH3)3); 121.8 (2C, C=C); 126.5 (2C, Carom); 134.8,
135.7 (2C, C Carom); 144.4 (2C, C=C); 151.0, 151.3 (2C, CHarom); 171.0 (2C, COO);
194.9 (1C, CO); 197.4 (1C CO). Elementary analysis for C15H18N4O3S: Calc.: C,
53.88%; H, 5.43%; N, 16.75%; Found: C, 53.67%; H, 5.39%; N, 16.38%.
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6-(9H-purin-6-ylthio)-4-oxohex-5-enoic acid (27)
A solution of tert-butyl 6-(9H-purin-6-ylthio)-4-oxohex-5-enoate 32 (0.05 g, 0.19
mmol) in TFA (2.5 mL) was stirred at r.t. for 2 h. Compound 27 was obtained as pure
product as unique Z isomer in 84% yield by simple evaporation of the excess of TFA.
1H NMR, 200 MHz, DMSO-d6, δ: 2.52 (at, 2H, J=7.0 Hz, CH2), 2.86 (at, 2H, J=6.2 Hz,
CH2), 6.88 (d, 1H, J=9.8 Hz, S-CHZ=C), 8.59 (s, 1H, CHarom), 8.74 (d, 1H, J=10.4 Hz,
C=CH-CO), 8.83 (s, 1H, CHarom). 13C NMR, 50 MHz, DMSO-d6, δ: 27.8, 37.4 (1C,
CH2); 121.9 (1C, C=C); 134.8 (1C, Carom); 144.4 (1C, C=C); 151.2 (2C, CHarom); 157.3
(1C, Carom); 173.3 (1C, COOH); 197.6 (1C, COOH). IR, KBr: 1546; 1664; 1709; 3546;
2470-3550 cm-1.
Synthesis of Methyl 4-((9H-purin-6-yl)disulfanyl)butanoate (41)
Dimethyl 4,4'-disulfanediyldibutanoate (35)
S
S
O
O
O
O
35
To a suspension of dithiobutirric acid 34 (1.50 g, 6.29 mmol) in 35 mL of MeOH, 0.5
mL of H2SO4(96%) were added and the mixture was refluxed for 1 h. The reaction was
then neutralized with a saturated solution of NaHCO3 and extracted with CH2Cl2 (3x40
mL). After anhydrification over Na2SO4 the solvent was removed under vacuum to give
disulfide 35 in 96% yield. 1H NMR, 200 MHz, CDCl3, δ: 2.01 (aq, 4H, J = 6.90 Hz, C-
CH2-C); 2.42 (at, 4H, J = 7.30 Hz, CH2-CO); 2,68 (at, 4H, J = 7.2 Hz, CH2-S); 3.65 (s,
6H, CH3).
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Dimethyl 4,4’-thiolsolfonyldibutanoate (38)
To a solution of 35 (1.55 g, 5.83 mmol) in 30 mL of CH2Cl2, m-chloroperbenzoic acid
(70%) (1.58 g, 6.41 mmol) in 27 mL of CH2Cl2 was added at 0°C. The reaction mixture
was stirred for 10 min at 0°C then at r.t. for 90 min.
Another portion of m-chloroperbenzoic acid (70%) (2.15 g, 8.70 mmol) in 35 mL of
CH2Cl2 was added at 0°C, and the suspension stirred for 10 min at 0°C, for 2 h at 30°C
and for 15h at r.t. The reaction mixture was diluted with 40 mL of CH2Cl2, washed with
a saturated solution of Na2S2O3 (3x60 mL), and Na2CO3 (3x60 mL).The organic phase
was dried over Na2SO4, filtered and evaporated. The crude product was purified by
column chromatography utilizing Florisil and 12/1=CHCl3/MeOH as eluent to give 38
in 65 % yield. 1H NMR (200 MHz, CDCl3), δ: 1.96-2.30 (m, 4H, C-CH2-C); 2.38-2.60
(m, 4H, CH2-CO); 3.19 (at, 2H, J = 7.20 Hz, CH2-S); 3.42 (at, 2H, J = 7.50 Hz, CH2-
SO2); 3.68 (s, 3H, CH3); 3.69 (s, 3H, CH3).
Methyl 4-((9H-purin-6-yl)disulfanyl)butanoate (41)
To a solution of thiolsulfonate 38 (0.70 g, 2.35 mmol) in 17 mL of dry DMF a solution
of 6-MP (11) (0.40 g, 2.35 mmol) in 28 mL of dry DMF was added dropwise followed
by 0.64 mL of dry TEA. The reaction mixture was heated at 60°C for 18 h, neutralized
with NH4Cl and extracted with EtOAc (6x40 mL). The recombined organic layers were
washed with H2O (5x30 mL), dried over Na2SO4, filtered and evaporated. The crude
product was purified by column chromatography with 15/1= CHCl3/MeOH to give
disulfide 41 in 27% yield. 1H NMR, 200 MHz, CD3OD, δ: 2.05 (aq, 2H, J = 7.1 Hz, C-
CH2-C); 2.53 (at, 2H, J = 7.2 Hz, CH2-CO); 2.97 (at, 2H, J = 7.0 Hz, CH2-S); 3.65 (s,
3H, CH3); 8.37 (s, 1H, CHarom); 8.92 (s, 1H, CHarom), 1H NMR, 200 MHz, CDCl3, δ:
2.05 (aq, 2H, J = 7.2 Hz, C-CH2-C); 2.50 (at, 2H, J = 7.3 Hz, CH2-CO); 2.95 (at, 2H, J
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= 7.0 Hz, CH2-S); 3.62 (s, 3H, CH3); 8.41 (s, 1H, CHarom); 8.90 (s, 1H, CHarom). 13C
NMR, 200 MHz, CD3OD, δ: 24.1 (1C, C-CH2-C); 32.5 (1C, CH2-CO); 38.4 (1C, CH2-
CS); 51.9 (1C, CH3); 130.4 (1C, Carom); 142.7 (1C, CHarom); 150.5 (1C, Carom); 152.1
(1C, CHarom); 159.5 (1C, Carom); 173.46 (1C, CO). IR (KBr), cm-1: 3452 (stretch. N-H),
1737 (stretch. C=O), 1566 (bend. N-H). MS: m/z: 284 (M+·, 12), 252 (M- CH3OH, 8),
152 (6-MP, 100), 119 (6-MP- SH·, 30).
Synthesis of benzyl 4-((9H-purin-6-yl)disulfanyl)butanoate (42)
Benzyl 4,4'-disulfanediyldibutanoate (36)
S
S
BnO
O
BnO
O
36
To a suspension of dithiobutirric acid 34 (1.50 g, 6.29 mmol) in 7.81 mL of benzyl
alcohol, 0.5 mL of H2SO4(96%) were added and the mixture was stirred at 64°C for 1 h.
The reaction was then neutralized with a saturated solution of NaHCO3 and extracted
with CH2Cl2 (3x40 mL). After anhydrification over Na2SO4 the solvent was removed
under vacuum and distillation to remove the excess of BnOH. The crude product was
purified by column chromatography with 2/3=EtP/CH2Cl2 followed by 1/2 and finally
1/3 to give disulfide 36 in 73% yield. 1H NMR, 200MHz, CDCl3, δ: 2.03 (aq, J =
6.8Hz, 4H, C-CH2-C); 2.48 (at, 4H, J = 7.2Hz, CH2-CO); 2.69 (at, J = 7.2Hz, 4H, CH2-
S); 5.12 (s, 4H, Ar-CH2),7.33-7.39 (m, 10H, Harom).
Dibenzyl 4,4’-tiolsolfonyldibutanoate (39)
To a solution of 36 (1.00 g, 2.34 mmol) in 25 mL of CH2Cl2, m-chloroperbenzoic acid
(70%) (0.63 g, 2.57 mmol) in 27 mL of CH2Cl2 was added at 0°C. The reaction mixture
was stirred for 10 min at 0°C then at r.t. for 90 min. Another portion of m-
chloroperbenzoic acid (70%) (0.63 g, 2.57 mmol) in 7 mL of CH2Cl2 was added at 0°C,
and the suspension stirred for 10 min at 0°C and for 5 h at r.t. The reaction mixture was
diluted with 50 mL of CH2Cl2, washed with a saturated solution of Na2S2O3 (3x60 mL),
and Na2CO3 (3x60 mL).The organic phase was dried over Na2SO4, filtered and
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evaporated. The crude product was purified by column chromatography with
3/1=EtP/EtOAc as eluent to give 39 in 48% yield. 1H NMR, 200MHz, CDCl3, δ: 2.20-
2.30 (m, 4H, C-CH2-C); 2.47-2.60 (m, 4H, CH2-CO); 3.15 (at, 2H, J = 7.1Hz, CH2-S);
3.38 (at, 2H, J = 7.60Hz, CH2-SO2); 5.13 (s, 4H, Ar-CH2); 7.28-7.39 (m, 10H, Ar). 13C
NMR, 200 MHz, CDCl3, δ: 19.1 (1C, C-CH2-C); 24.9 (1C, C-CH2-C); 31.7 (1C, CH2-
C-S); 32.3 (1C, CH2-CO); 35.3 (1C, CH2-CO); 61.0 (1C, CH2-SO2); 66.4 (2C, CH2-
OCO); 128.1, 128.4 (10C, CHarom); 135.3 (1C, Carom); 135.4 (1C, Carom); 171.4 (1C,
CO); 171.8 (1C, CO).
Benzyl 4-((9H-purin-6-yl)disulfanyl)butanoate (42)
N
N NH
N
S
S
OBn
O
42
To a solution of thiolsulfonate 39 (0.50 g, 1.11 mmol) in 12 mL of dry DMF a solution
of 6-MP (11) ) (0.19 g, 1.11mmol) in 20 mL of dry DMF was added dropwise followed
by K2CO3 (0.36 g, 1.11 mmol). The reaction mixture was heated at 60°C for 20 h,
neutralized with NH4Cl and extracted with EtOAc (6x40 mL). The recombined organic
layers were washed with H2O (5x30 mL), dried over Na2SO4, filtered and evaporated.
The crude product was purified by column chromatography with 5/2=EtOAc/CH2Cl2 to
give disulfide 42 in 26% yield. 1H NMR, 200 MHz, CDCl3, δ: 2.08 (aq, 2H, J = 7.20Hz,
C-CH2-C); 2.59 (at, 2H, J = 7.30Hz, CH2-CO); 8.31 (s, 1H, CHarom);8.89 (s, 1H,
CHarom). IR (KBr), cm-1: 3434 (stretch. NH), 1731 (stretch. C=O), 1560 (bend. NH).
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Synthesis of Tert-butyl 4,4'-disulfanediyldibutanoate (37)
To a solution of dithiobutirric acid 34 (0.12 g, 0.50 mmol) in 8 mL of toluene dry, 0.36
mL of oxalyl chloride (4.20 mmol) were added dropwise at 8°C. The reaction mixture
was stirrred at 8°C for 1 h, the solvent was removed and the crude product dissolved in
CH2Cl2 dry. A solution of tert-butyl alcohol (0.6 mL, 6.25 mmol) and TEA (0.121 mL,
0.88 mmol) in dry CH2Cl2 was added to the solution and stirred at 10°C for 4 h. The
mixture was then diluted with CH2Cl2 and washed with a saturated solution of NH4Cl
(3x15 mL), dried over Na2SO4 and evaporated. The crude product was purified by
column chromatography with 30/1=EtP/EtOAc as eluent to obtain derivative 37 in 18%
yield. 1H NMR, 400 MHz, CD3OD, δ: 1.44 (s, 18H, C(CH3)3); 1.97 (aq, 4H, J =7.2 Hz,
C-CH2-C); 2.34 (at, 4H, J =7.2 Hz, CH2-CO); 2.70 (at, 4H, J = 7.2 Hz, CH2-S).
Synthesis of 3-((9H-purin-6-yl)disulfanyl)undecanoic acid (44)
To solution of 11-mercaptoundecanoic acid (0.79 g, 3.61 mmol) in dry toluene (5 mL),
cooled to -15 °C, a solution of SO2Cl2 (0.28 mL, 1.81mmol) in dry toluene (1.5 mL)
was added. This mixture was stirred at r.t. for 15 min and nitrogen was bubbled inside
to eliminate residual traces of SO2 and HCl. Before undergoing the next reaction we
verified the effective formation of sulfenyl chloride product by titration with
cyclohexene. This allowed us verifying the actual formation of the expected sulfenic
species and estimating a 46% yield for the first reaction. The so obtained sulfenyl
chloride was reacted with a suspension of 6-MP 11 in dry pyridine at 84 °C, for 2 h.
The mixture was cooled at r.t., diluted with water and acidified to pH 5 with 3% HCl.
The acid aqueous layer was extracted several times with EtOAc and the combined
organic phase dried and concentrated. The resulting crude product was purified by flash
cromathography with 25/1→15/1=CH2Cl2/MeOH to obtain acid 44 in 64% yield. 1H
NMR, 200 MHz, CD3OD, δ: 1.73-1.80 (m, 16H, CH2); 2.27 (at, 2H, J = 7.2 Hz, CH2);
6.18 (t, 2H, J = 7.2 Hz, CH2); 8.44 (s, 1H, CHarom); 8.78 (s, 1H, CHarom). 13C NMR, 50
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MHz, DMSO-d6, δ: 24.5, 27.7, 28.1, 28.5, 28.7, 28.8, 33.6, 38.1 (CH2); 142.0, 151.7
(1C, CHarom); 174.5 (1C, COOH).
Synthesis of 2’-Deoxy-5’-O-[bis(4-methoxyphenyl)phenylmethyl]-5-fluoro-3’-O-(3-
carboxypropanoyl)uridine (47)
2’-deoxy-5’-O-[bis(4-methoxyphenyl)phenylmethyl]-5-fluorouridine (46)
2’-Deoxy-5-fluorouridine 45 (0.50 g, 2.03 mmol) was evaporated three times with 3 mL
of pyridine dry and then redissolved in 7 mL of anhydrous pyridine. 4,4’-
Dimethoxytriphenylmethyl chloride (1.03 g, 3.05 mmol) in pyridine dry (7 mL) was
added dropwise at 0 °C under stirring. The reaction mixture was stirred at room
temperature for 16 h. The solution was poured onto 50 mL of ice containing 5%
NaHCO3, extracted with dichloromethane, dried over anhydrous Na2SO4, and
evaporated. The crude product was purified by column chromatography using
30/1=CH2Cl2/MeOH as eluent obtaining 46 in 62% yield.
1H NMR, 200MHz, CDCl3, δ: 2.60-2.20 (m, 2H, 2’-H2); 3.41-3.32 (m, 2H, 5’-H2), 3.76
(s, 6H, OCH3), 4.20-4.12 (m, 1H, 4’-H), 4.60-4.45 (m, 1H, 3’-H), 6.31 (at, 1H, J=6.2,
1’-H), 6.90-6.78 (m, 4H, CHarom), 7.5-7.15 (m, 9H, Harom),7.84 (d, 1H, J=4.4, 6-H,F);
13C NMR, 200MHz, CDCl3, δ: 41.1 (1C, 2’-C), 55.3 (2C, CH3), 63.4 (1C, 5’-C), 72.0
(1C, 3’-C), 85.6 (1C, 1’-C), 86.5 (1C, Cquat), 87.1 (1C, 4’-C), 113.2 (4H, CHarom), 123.7,
124.4, 126.9, 127.8, 129.8, (10C, Carom+ 6-C), 135.2, 135.0 (2C, Cquat), 140.4 (d, 1C, J =
236.1Hz, 1-CF), 144.0 (1C, Cquat), 148.9 (1C, 4-CO), 157.1, 156.6 (2C, Cquat-OCH3),
158.5 (1C, 2-CO).
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2’-Deoxy-5’-O-[bis(4-methoxyphenyl)phenylmethyl]-5-fluoro-3’-O-(3-
carboxypropanoyl)uridine (47)
To a solution of 46 (0.25 g, 0.46 mmol) in 6 mL of CH2Cl2 dry, DMAP (0.08 g, 0.68
mmol) followed by succinic anhydride (0.18 g, 1.83 mmol) were added under nitrogen
atmosphere. The reaction mixture was stirred for 18 h at r.t., poured onto a solution of
5% NaHCO3 (50 mL), acidified with 1M HCl to pH 3, and then extracted with CH2Cl2.
The combined organic layers were washed with water, dried over Na2SO4 and the
solvent removed to give ester 47 in 90% yield without further purification. 1H NMR,
400MHz, (CD3)2CO, δ: 2.60-2.40 (m, 6H, 2’-H2 + CH2CH2); 3.58-3.33 (m, 2H, 5’-H2),
3.78 (s, 6H, OCH3), 4.22-4.19 (m, 1H, 4’-H), 5.50-5.43 (m, 1H, 3’-H), 6.28 (at, 1H, J =
6.2 Hz, 1’-H), 6.91-6.89 (m, 4H, CHarom), 7.50-7.24 (m, 9H, Harom), 7.88 (d, 1H, J = 6.8
Hz, 6-H,F). 13C NMR, 100 MHz, (CD3)2CO, δ : 29.4, 30.2 (2C, Succ-CH2), 38.2 (C-2),
55.4 (2C, OCH3), 64.5 (C-5), 75.4 (C-3), 84.6 (C-4), 85.7 (C-1), 87.6 (C-Ph3), 113.9
(2C, Carom), 124.6 (C-6), 127.6 (1C, Carom), 128.6 (1C, Carom), 128.7 (1C, Carom), 130.8
(2C, Carom), 136.1, 136.3 (2C, Carom), 141.3 (C-5), 145.6 (1C, Carom), 150.3 (C-2), 157.3
(C-4), 159.5 (2C, Carom), 172.4, 173.4 (2C, Succ-CO). ESI-MS: m/z = 648 [M]+.
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Synthesis of 2’-deoxy-5’-O-[bis(4-methoxyphenyl)phenylmethyl]-4-(bis(4-
methoxyphenyl)(phenyl)methylamino)-2',2'-difluoro-3’-O-(3-
carboxypropanoyl)cytidine (50)
2’-deoxy-5’-O-[bis(4-methoxyphenyl)phenylmethyl]-4-(bis(4-
methoxyphenyl)(phenyl)methylamino)-2', 2'-difluorocytidine(49)
Gemcitabine 48 (0.37 g, 1.43 mmol) was evaporated three times with 2 mL of pyridine
dry and then redissolved in 20 mL of anhydrous pyridine. 4,4’-
dimethoxytriphenylmethyl chloride (1.52 g, 4.49 mmol) in pyridine dry (20 mL) was
added dropwise at 0 °C under stirring. The reaction mixture was stirred at room
temperature for 16 h. The solution was poured onto 50 mL of ice containing 5%
NaHCO3, extracted with dichloromethane, dried over anhydrous Na2SO4, and
evaporated. The crude product was purified by column chromatography using
15/1=CH2Cl2/MeOH as eluent obtaining 49 in 62% yield. 1H NMR, 200MHz, CDCl3,
δ: 3.38-3.52 (m, 2H, 5’-H2), 3.69-3.73 (m, 12H, OCH3), 4.02-4.06 (m, 1H, 4’-H), 4.40-
4.45 (m, 1H, 3’-H), 4.88 (d, 1H, J=7.6, Hvinyl), 6.30-6.42 (m, 1H, 1’-H), 6.70-6.81 (m,
8H, Harom); 7.01-7.32 (m, 20H, Harom), 7.57 (d, 1H, J=7.6, Hvinyl); 13C NMR, 200MHz,
CDCl3, δ: 55.3 (4C, CH3), 61.2 (1C, 5’-C), 70.4 (1C, 3’-C), 80.4 (2C, Cquat), 84.5 (1C,
1’-C), 86.7 (1C, 4’-C), 95.5 (1C, Cvinyl); 113.2, 113.6, 127.4, 127.8, 128.3, 128.4, 129.9,
130.2 (14C, Carom+ 6-C), 135.0, 135.1, 135.7, 136.1 (4C, Cquat), 141.0 (1C, Cvinyl), 144.2,
144.8 (2C, Cquat), 155.1 (1C, CO); 158.4, 158.5 (4C, Cquat-OCH3), 165.3 (1C, 2-CO).
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2’-deoxy-5’-O-[bis(4-methoxyphenyl)phenylmethyl]-4-(bis(4-
methoxyphenyl)(phenyl)methylamino)-2',2'-difluoro-3’-O-(3-carboxypropanoyl)cytidine
(50)
To a solution of 49 (0.18 g, 0.20 mmol) in 4 mL of CH2Cl2 dry, DMAP (0.04 g, 0.30
mmol) followed by succinic anhydride (0.08 g, 0.81 mmol) were added under nitrogen
atmosphere. The reaction mixture was stirred for 24 h at r.t., poured onto a solution of
5% NaHCO3 (50 mL), acidified with 1M HCl to pH 3, and then extracted with CH2Cl2.
The combined organic layers were washed with water, dried over Na2SO4 and the
solvent removed to give ester 50 in 90% yield without further purification. 1H NMR,
400MHz, (CD3)2CO, δ: 2.60-2.70 (m, 4H, CH2CH2); 3.28-3.41 (m, 2H, 5’-H2), 3.73,
3.74, 3.75, 3.76 (s, 12H, OCH3), 4.06-4.09 (m, 1H, 4’-H), 4.92 (d, 1H, J=7.6, Hvinyl),
5.45-5.51 (m, 1H, 3’-H), 6.39 (at, 1H, J = 6.2 Hz, 1’-H), 6.73-6.82 (m, 8H, CHarom),
7.50-7.24 (m, 18H, Harom), 7.40 (d, 1H, J=7.6, Hvinyl),. 13C NMR, 100 MHz, (CD3)2CO,
δ : 28.7 (2C, Succ-CH2), 55.1, 55.2 (4C, OCH3), 60.9 (C-5), 69.7-69.8 (1C, 3’-C), 70.4
(Cquat) 78.2 (C-4), 83.5-83.7 (C-1), 86.6 (C-Ph3), 95.6 (1C, Cvinyl); 113.2, 113.5 (4C,
Carom), 123.5 (C-2), 126.8, 127.4, 127.7,127.9, 128.3, 128.5, 129.1, 129.9, 130.1 (18C,
Carom), 134.9, 135.7, 140.0 (4C, Carom), 140.8 (CH), 144.1, 144.4 (2C, Carom), 154.6
(Carom), 158.5, 158.6 (4C, Carom), 165.4 (1C, C-NH); 170.6, 175.3 (2C, Succ-CO). ESI-
MS: m/z = 967[M]+.
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Synthesis of 3-(5-carboxypentylamino)benzo[e][1,2,4]triazine 1,4-dioxide (57)
3-aminobenzo[e][1,2,4]triazine 1-oxide (53)
2-Nitroaniline (6.00 g, 43.50 mmol) and cyanamide (7.40 g, 176.20 mmol) were heated
with stirring at 100°C until a deep red melt formed. The reaction was cooled at 50 °C
and 22 mL of concentrated HCl was added dropwise. The reaction mixture was warmed
at 100 °C, stirred for 4h, then made strongly alkaline by the addiction of 70 mL 30%
solution of NaOH. After the solution was heated again for 3h, cooling crystals formed.
These were collected and washed with water (120 mL) and diethylether (100 mL) to
give 3-amino-1,2,4-benzotriazine-1-oxide 53 in 78% yield. 1H NMR, 200 MHz ,
C6D6SO, δ: 7.28-7.38 (m, 3H, Harom e NH2); 7.53 (d, J = 8.2 Hz, 1H, Harom); 7.78 (m,
1H, Harom); 8.13 (d, J = 8.8 Hz, 1H, Harom).
3-hydroxybenzo[e][1,2,4]triazine 1-oxide (54)
A solution of 53 (5.35 g, 33.02 mmol) in 62 mL of trifluoroacetic acid (TFA) was
cooled at 5°C. Over a period of 15’ sodium nitrite (2.51 g, 36.33 mmol) was added
portionwise. The reaction mixture was stirred at r.t. for 4h, poured onto ice/water,
stirred 30 min, filtered, washed with water and dried to give 3-hydroxy-1,2,4-
benzotriazine-1-oxide 54. 1H NMR, 200 MHz, CDCl3, δ: 7.72-7.81 (m, 1H, Harom);
7.98-8.01 (m, 2H, Harom); 8.40 (d, J = 8.8 Hz, 1H, Harom).
3-chlorobenzo[e][1,2,4]triazine 1-oxide (52)
Chloride 52 was obtained by adding 0.4 mL of DMF and 82.5 mL of phosphorous
oxychloride (7 eq.) directly to 54. The reaction mixture was refluxed for 1h, then
poured on ice and filtered. The crude product was recristyllized from methanol to give
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chloride 52 in 60% yield. 1H NMR, 200 MHz, CDCl3, δ: 7.72-7.81 (m, 1H, Harom); 7.98-
8.01 (m, 2H, Harom); 8.40 (d, J = 8.8 Hz, 1H, Harom). 1H NMR, 200 MHz, C6D6SO, δ:
7.90 (t, J = 7.0 Hz, 1H, Harom); 8.04-8.20 (m, 2H, Harom); 8.37 (d, J = 8.8 Hz, 1H, Harom).
3-(6-methoxy-6-oxohexylamino)benzo[e][1,2,4]triazine 1-oxide (55)
To a solution of methyl-6-aminohexanoate (10.08 g, 55.09 mmol) in 250 mL of CH2Cl2
was added a solution of 52 (3.36 g, 18.56 mmol) and TEA (5.20 mL, 37.12 mmol) in
100 mL CH2Cl2. The reaction mixture was stirred for 116h at r.t. and distilled to dryness
in vacuo. The residue was purified by flash chromatography with 50/1= CH2Cl2 /MeOH
as eluent to yield 1-oxide 55 in 75% yield. 1H NMR, 200 MHz, CDCl3, δ: 1.38-1.51 (m,
2H, CH2); 1.61-1.76 (m, 4H, CH2); 2.33 (t, J = 7.2 Hz, 2H, CH2); 3.51 (m, 2H, CH2);
3.65 (s, 3H, CH3); 5.39 (m, 1H, NH); 7.27 (dt, J1 = 8.5 Hz, J2 = 1.5 Hz, 1H, Harom);
7.55-7.72 (m, 2H, Harom); 8.24 (dd, J1 = 8.6 Hz, J2 = 1.2 Hz, 1H, Harom). 13C NMR, 50
MHz, CDCl3, δ: 24.5, 26.3, 28.9, 33.8, 41.0 (1C, CH2); 51.4 (1C, CH3); 120.6, 124.6,
126.3 (1C, CHarom); 130.6 (1C, Carom.); 135.3 (1C, CHarom.); 148.6, 158.8 (1C, Carom.);
173.8 (1C, CO).
3-(6-methoxy-6-oxohexylamino)benzo[e][1,2,4]triazine 1,4-dioxide (56)
50% H2O2 (7.5 mL) was diluted with 37.5 mL MeOH and dried on Na2SO4 overnight to
increase its oxidizing properties. A solution of dried H2O2 in MeOH (1.25 mL) was
added to a stirred solution of trifluoroacetic anhydride (2.6 mL) in 7.2 mL of dry
CH2Cl2 at 5°C. The mixture was stirred for 10 min at r.t. then cooled to 5°C before
adding a solution of 55 (300 mg, 1.03 mmol) and trifluoroacetic acid (720 µL) in 7.2
mL dry CH2Cl2. After 4 days under stirring at r.t. the red solution was diluted with
EtOAc and washed with a saturated solution of NaHCO3. The organic phase was dried,
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filtered and concentrated to give 1,4-dioxide 56 with 90% yield. 1H NMR, 400 MHz,
CDCl3, δ: 1.43-1.50 (m, 2H, CH2); 1.66-1.78 (m, 4H, CH2); 3.33 (t, J = 7.6 Hz, 2H,
CH2); 3.59-3.66 (m, 2H, CH2); 3.67 (s, 3H, CH3); 7.14 (s, 1H, NH); 7.51 (t, J = 8.4 Hz,
1H, Harom.); 7.88 (t, J = 7.6 Hz, 1H, Harom.); 8.29 (d, J = 8.0 Hz, 1H, Harom.); 8.33 (t, J =
8.8 Hz, 1H, Harom.). 13C NMR, 50 MHz, CDCl3, δ: 24.6, 26.3, 29.3, 33.9, 41.4 (1C,
CH2); 51.7 (1C, CH3); 117.2, 121.6, 127.0, 130.4 (1C, C Harom.); 136.0, 138.1, 149.7
(1C, Carom); 173.8 (1C, CO). IR: 3401, 3244, 2952, 1737, 1620, 1597, 1412, 1384,
1357, 1177, 1088, 719 cm-1.MS: (CI) M+.= 306; 55 (100%); 65, 90 (70%); 289 (30%);
175 (50%) (51); 90 (70%); .
3-(5-carboxypentylamino)benzo[e][1,2,4]triazine 1,4-dioxide (57)
a) 37% HCl (1.4 mL, 13.65 mmol) was added to a solution of 56 (120 mg, 0.39
mmol) in 2 mL of dioxane. The reaction mixture was stirred at r.t. for 48h,
concentrated and purified by flash chromatography with 12/1 CH2Cl2/MeOH to obtain
57 in 83% yield.
b) 1M LiOH (3.9 mL, 3.90 mmol) was added to a solution of 56 (120 mg, 0.39
mmol) in 1/1=THF/MeOH (4 mL/4 mL). The reaction mixture was stirred for 5’, then
1M HCl was added until pH 5 and the aqueous phase was extracted with EtOAc (8x30
mL). Combined organic layers were dried, filtered and evaporated to give acid 57 in
98% yield without further purification.
1H NMR, 400 MHz, (CD3)2SO), δ: 1.31-1.33 (m, 2H, CH2); 1.51-1.55 (m, 2H, CH2);
1.59-1.63 (m, 2H, CH2); 2.19-2.23 (m, 2H, CH2); 3.35-3.40 (m, 2H, CH2); 7.52-7.57
(m, 1H, Harom.); 7.90-7.94 (m, 1H, Harom.); 8.12 (d, J = 8.4 Hz, 1H, Harom.); 8.19 (d, J =
8.4 Hz, 1H, Harom.); 8.27-8.30 (m, 1H, Harom.). 13C NMR, 50 MHz, (CD3)2SO), δ: 24.3,
25.8, 28.5, 33.7, 41.4 (1C, CH2); 116.8, 121.1, 126.8 (1C, C Harom.); 129.8 (1C, Carom.);
135.4 (1C, CHarom.); 138.1, 149.7 (1C, Carom.); 174.4 (1C, CO). IR: 3439, 3249, 2924,
1617, 1594, 1410, 1365, 1315, 1119, 1080, 721 cm-1. MS: (ESI-MS) M+.= 292 (CI): 55
(100%); 57 (55%), 99 (45%); 175 (35%); 276 (20%).
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Synthesis of 3-(6-(4-((3-
carboxypropyl)disulfanyl)butanamido)hexylamino)benzo[e][1,2,4]triazine 1,4-
dioxide (61)
3-(6-(tert-butoxycarbonylamino)hexylamino)benzo[e][1,2,4]triazine 1-oxide (58)
A solution of 6-t-butyloxycarbamoylhexylamine (0.13 g, 6.11 mmol) in CH2Cl2 was
added to a stirred solution of 52 (0.37 g, 2.04 mmol) and TEA (0.57 mL, 4.08 mmol) in
CH2Cl2 (100 mL), and the solution was stirred at r.t. for 96 h. The solvent was
evaporated and the residue chromatographed, eluting with 1/1=EtOAc/EtP, to give 1-
oxide 58 in 65% yield. 1H NMR, 400 MHz, (CD3)2SO), δ: 1.38–1.43 (m, 4 H, CH2);
1.44 [s, 9 H, C(CH3)3]; 1.48–1.54 (m, 2 H, CH2); 1.64–1.72 (m, 2H, CH2); 3.10–3.13
(m, 2H, CH2N), ); 3.51 (dd, J ¼ 6.8, 6.6 Hz, 2 H, CH2N), 4.55 (br s, 1 H, OCONH);
5.34 (br s, 1 H, NH); 7.27 (dd, J ¼ 8:0, 7.5 Hz, 1 H,H 7); 7.59 (d, J = 8.5 Hz, 1 H, H5);
7.70 (dd, J = 8:2, 7.2 Hz, 1 H, H6);8.26 (d, J ¼ 8:6 Hz, 1 H, H 8). Anal. calc. for
C18H27N5O3: C, 59.8;H, 7.5; N, 19.4; found: C, 59.6; H, 7.7; N, 19.2%.
3-(6-(tert-butoxycarbonylamino)hexylamino)benzo[e][1,2,4]triazine 1,4-dioxide (59)
50% H2O2 (7.5 mL) was diluted with 37.5 mL MeOH and dried on Na2SO4 overnight to
increase its oxidizing properties. A solution of dried H2O2 in MeOH (1.25 mL) was
added to a stirred solution of trifluoroacetic anhydride (2.6 mL) in 7.2 mL of dry
CH2Cl2 at 5°C. The mixture was stirred for 10 min at r.t. then cooled to 5°C before
adding a solution of 58 (300 mg, 1.03 mmol) and trifluoroacetic acid (720 µL) in 7.2
mL dry CH2Cl2. After 4 days under stirring at r.t. the red solution was diluted with
EtOAc and washed with a saturated solution of NaHCO3. The organic phase was dried,
filtered and concentrated to give 1,4-dioxide 59 with 99% yield. 1H NMR, 400 MHz,
(CD3)2SO), δ: 1.25-1.31 (m, 2H, CH2); 1.32-1.40 (m, 13H, CH2, C(CH3)3); 1.56–1.61
(m, 2H, CH2), 2.87-2.92 (m, 2H, CH2N), 3.32-3.39 (m, 2H, CH2N), 6.76 (br s, 1H, NH),
7.53-7.57 (m, 1 H, H7), 7.91-7.95 (m, 1H, H6), 8.12 (d, J = 8.5 Hz, 1H, H5), 8.19 (d, J
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= 8.5 Hz, 1 H, H8), 8.30 (dd, J = 6.3, 6.1 Hz, 1H, OCONH). Anal. calc. for
C18H27N5O4.1/4H2O: C, 56.6; H, 7.3; N, 18.3; found: C, 56.8; H, 7.3; N, 16.8%.
3-(6-aminohexylamino)benzo[e][1,2,4]triazine 1,4-dioxide (60)
59 was then dissolved in MeOH and gaseous HCl was bubbled inside for 2’. The
yellow solution was stirred for 17 h at r.t., diluted with water and extracted several
times with CHCl3. The aqueous phase was basified by adding of a saturated solution of
NaHCO3 and extracted many times with CHCl3. These final recollected organic layers,
once dried and concentrated, gave the amine 60 in 55% yield. 1H NMR, 400 MHz,
(CD3)2SO), δ: 1.35-1.50 (m, 6H, CH2), 1.70-1.76 (m, 2 H, CH2), 2.70 (t, J = 6:8 Hz, 2
H, CH2N), 3.60 (t, J = 7.1 Hz, 2 H, CH2N), 7.13 (s, 1 H, NH), 7.48-7.52 (m, 1 H, H 7’),
7.87-7.90 (m, 1 H, H 6’), 8.29 (d, J = 8.6 Hz, 1 H, H 5’), 8.34 (d, J = 8.5 Hz, 1 H, H
8’). Anal. calc. for C13H19N5O2: C, 56.3; H, 6.9; N, 25.3; found: C, 56.3;H, 6.8; N,
22.2%.
3-(6-(4-((3-carboxypropyl)disulfanyl)butanamido)hexylamino)benzo[e][1,2,4]triazine
1,4-dioxide (61)
Dithiobutirric acid 34 (1 eq.) was activated by adding to its solution in dry DMF,
HBTU (1 eq.) and DIPEA (2 eq.). After stirring for 10’ this solution was added to
another of 60 (1 eq.) in dry DMF. The reaction mixture was stirred for 6h, acidified
with 1N HCl to pH 5 and diluted with CHCl3. The organic phase was washed with
water and the crude product purified in a TLC plate with 15/1=CH2Cl2 /MeOH to obtain
61 (55%). 1H NMR, 400 MHz, (CD3)2SO), δ: 1.25-1.53 (m, 8H, CH2), 1.71-1.74 (m,
2H, CH2), 1.98-2.05 (m, 4H, CH2), 2.30-2.43 (m, 2H, CH2), 2.43 (t, J = 6:8 Hz, 2 H,
CH2), 2.70-2.74 (m, 4H, CH2), 3.24-3.27 (m, 2 H, CH2), 3.59-3.61 (m, 2H, CH2), 5.93
(br s, 1H, NH), 6.05 (br s, 1H, NH); 7.48-7.52 (m, 1 H, H 7’), 7.87-7.90 (m, 1 H, H 6’),
8.26-8.29 (m, 2 H, Harom).
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Synthesis of 4-(2,2-dimethyl-5,6-dioxo-3,4,4a,5,6,10b-hexahydro-2H-
benzo[h]chromen-3-yloxy)-4-oxobutanoic acid (64)
3-hydroxy-2,2-dimethyl-4,4a-dihydro-2H-benzo[h]chromene-5,6(3H,10bH)-dione (62)
O
O
O
OH
62
Lapachol 63 (0.35 g, 1.47 mmol) was treated with MCPBA (ca. 65%) (0.43 g, 1.76
mmol) in 10 mL of dry CH2Cl2 at r.t. for 24 h. The reaction mixture was diluted with a
saturated solution of NaHCO3 , the organic layer was separated and the aqueous phase
extracted with CH2Cl2. The combined organic layers were washed with water, dried
over Na2SO4, filtered and the solvent evaporated. The crude was purified by column
chromatography with 4/1=hexane/EtOAc to give 62 in 57% yield. mp 203–205°C. 1H
NMR, 400 MHz, CDCl3, δ: 1.45 (s, 3H, CH3), 1.53 (s, 3H, CH3), 1.90 (s, 1H, OH), 2.64
(dd, 1H, J = 26 and 5.7 Hz, H-4), 2.82 (dd, 1H, J = 2.6 and 5.3 Hz, H-4), 3.91 (dd, 1H,
J = 5.7 and 5.3 Hz, H-3), 7.60-7.66 (m, 3H, Harom), 8.02 (d, 1H, J = 6.2 Hz, Harom). 13C
NMR, 400 MHz, CDCl3, δ: 21.0, 22.6, 23.2, 69.0, 79.7, 110.0, 124.3, 128.8, 130.1,
131.0, 132.0, 135.0, 161.2, 178.6, 179.4. IR: 1700, 1630 (CO) cm-1.
4-(2,2-dimethyl-5,6-dioxo-3,4,4a,5,6,10b-hexahydro-2H-benzo[h]chromen-3-yloxy)-4-
oxobutanoic acid (64)
To a solution of 62 (0.07 mg, 0.27 mmol) in 7 mL of dry CH2Cl2, succinic anhydride
(0.08 g, 0.81 mmol) and DMAP (0.10 g, 0.81 mmol) were added and the resulting
mixture stirred at r.t. for 18 h and poured onto ice/water/NaHCO3. The suspension was
acidified to pH 5 and extracted with CH2Cl2 (3x30mL). The recollected organic phases
were washed with a saturated solution of NaHCO3 (1x50mL) and water (1x50mL), then
dried to give 64 in 92% yield without further purification. 1H NMR, 200 MHz, CDCl3,
δ: 1.43 (s, 3H, CH3), 1.48 (s, 3H, CH3), 2.62-2.74 (m, 6H, H-4 and CH2), 5.17 (t, 1H, J
= 4.8 Hz, H-3), 7.53 (dt, J = 1.0 and 6.4 Hz 1H, Harom), 7.64 (dt, J = 1.6 and 6.0 Hz 1H,
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Harom), 7.84 (dd, J = 1.0 and 6.0 Hz 1H, Harom), 7.64 (dt, J = 1.4 and 6.6 Hz 1H, Harom).
13C NMR, 400 MHz, CDCl3, δ: 22.5, 23.2, 24.9, 29.0, 29.7, 69.4, 79.7, 109.9, 124.3,
128.8, 130.0, 131.0, 134.9, 137.4, 171.2, 179.2.
Synthesis of (Z)-5-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenoxy)-5-oxopentanoic
acid (72)
3-(tert-butyldimethylsilyloxy)-4-methoxybenzaldehyde (66)
To a solution of isovanillin (4.00 g, 26.32 mmol) in 30 mL of dry DMF, DIPEA (9.10
mL, 52.61 mmol) and TBDMSCl (6.35 g, 42.13 mmol) were added. The reaction
mixture was stirred at r.t. for 4 h, diluted with water and EtP. The phases were
separated and the water layer was extracted twice with EtP (2x100mL). The combined
organic phases were washed with a saturated solution of NaHCO3 (1x100mL) and
water (6x100mL), then dried over Na2SO4, filtered and concentrated under vacuum.
The crude product was purified by flash chromatography with 80/1=CH2Cl2/EtP to give
66 in 99% yield. 1H NMR, 200 MHz , CDCl3, δ: 0.17 (s, 6H, CH3); 1.00 (s, 9H, tBu);
3.89 (s, 3H, OCH3); 6.95 (d, J=8.3 Hz, 1H, Harom); 7.37 (d, J=1.8 Hz, 1H, Harom); 7 .48
(dd, J1=8.3 Hz, J2=1.8 Hz, 1H, Harom); 9.82 (s, 1H, CHO).
(3,4,5-trimethoxyphenyl)methanol (68)
A solution of 3,4,5-trimethoxybenzaldehyde (4.00 g, 20.41 mmol) in 40 mL of dry
MeOH was chilled to 0 °C and NaBH4 (0.94 g, 24.70 mmol) was added in small
portions over 1 h. The resulting mixture was stirred overnight at r.t. and concentrated.
The crude product was partitioned between Et2O and water. The aqueous layer was
extracted with Et2O (3x100 mL) and combined organic phases dried and evaporated to
obtain 68 in 88% yield. 1H NMR, 200 MHz , CDCl3, δ: 3.81 (s, 3H, OCH3); 3.83 (s,
6H, OCH3); 4.60 (s, 2H, CH2); 6.57 (s, 2H, Harom).
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5-(bromomethyl)-1,2,3-trimethoxybenzene(69)
To a solution of 68 (3.02 g, 15.25 mmol) in 20 mL of dry CH2Cl2, cooled to -5 °C, a
solution of PBr3 (3.05 g, 11.29 mmol) in 10 mL of dry CH2Cl2 was added dropwise.
The reaction mixture was stirred at the same temperature for 45 min, poured onto ice,
neutralized with NaHCO3 and stirred for 1h. The water phase was extracted with
CH2Cl2 (5x100mL) and the recollected organic layers were washed with brine
(2x150mL) and dried to obtain 69 in 96% yield. 1H NMR, 200 MHz , CDCl3, δ: 3.81 (s,
3H, OCH3); 3.83 (s, 6H, OCH3); 4.60 (s, 2H, CH2); 6.57 (s, 2H, Harom).
Triphenyl(3,4,5-trimethoxybenzyl)phsphonium bromide(67)
A solution of triphenylphosphine (3.94 g, 14.17 mmol) in 11 mL of toluene was added
to a solution of 69 (3.75 g, 14.42 mmol) in 16 mL of toluene. The reaction mixture was
stirred for 24 h at r.t. and the white precipitate formed filtered and dried to give the
phosphonium salt 67 in 66% yield. 1H NMR, 200 MHz , D2O, δ: 3.27 (s, 6H, OCH3);
3.54 (s, 3H, OCH3); 4.46 (d, J = 14.2 Hz, 2H, P-CH2); 6.03 (d, J = 2.6 Hz 2H, Harom);
7.38-7.50 (m, 12H, Harom); 7.60-7.76 (m, 3H, Harom).
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(Z)-tert-butyl(2-methoxy-5-(3,4,5-trimethoxystyryl)phenoxy)dimethylsilane (70)
A homogeneous suspension of triphenylphsphonium bromide 67 (1.00 g, 1.91 mmol)
in 60 mL of dry THF under nitrogen was cooled to -23 °C and retained at that
temperature for 2 h. Butyllithium 1.6 M in hexane (1.23 mL, 1.91 mmol) was added
dropwise, the resultant orange solution was stirred at the same temperature for 1 h and
finally aldehyde 66 (0.53 g, 1.99 mmol) was added dropwise. The reaction mixture was
stirred at -23 °C for 4 h and at r.t. for 18 h, ice-water was added and the two phases
separated. The aqueous phase was washed with Et2O (3x75mL) and the ethereal
solution added to the THF layer. The combined organic phase was washed with water
(3x75mL), dried over Na2SO4, filtered and the solvent eliminated. The crude product
was purified by flash chromatography with 15/1=EtP/EtOAc to isolate both the Z-70
and the E-70 stilbenes in 61 and 20% yield respectively. 1H NMR, 200 MHz , CDCl3, Z,
δ: 0.05 (s, 6H, CH3); 0.94 (s, 9H, CH3); 3.70 (s, 6H, OCH3); 3.77 (s, 3H, OCH3); 3.83
(s, 3H, OCH3); 6.44 (d, J=2.2 Hz, 2H, Harom); 6.49 (s, 2H, Harom); 6.71-6.90 (m, 3H,
Harom).
(Z)-2-methoxy-5-(3,4,5-trimethoxystyryl)phenol (65)
To a solution of Z-70 (0.45 g, 1.03 mmol) in 11 mL of dry THF, cooled to 0 °C,
TBAF.3H2O (0.34 g, 1.06 mmol) dissolved in 4 mL of dry THF was added. The
reaction mixture was stirred at r.t. for 20 min, then ice was added followed by ether and
the organic layer was washed with water (3x30 mL). The residue was chromatographed
with 3/2=EtP/EtOAc to give Combretastatin A-4 65 in 77% yield. 1H NMR, 200 MHz ,
CDCl3, δ: 3.69 (s, 6H, OCH3); 3.83 (s, 3H, OCH3); 3.86 (s, 3H, OCH3); 5.56 (s, 1H,
OH); 6.43 (AB system, J=12.3 Hz, 2H, Harom); 6.52 (s, 2H, Harom); 6.70-6.82 (m, 2H,
Harom); 6.92 (d, J=1.8 Hz, 1H, Harom).
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(Z)-5-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenol)-5-oxopentanoic acid (72)
To a solution of 65 (0.12 g, 0.38 mmol) in 3 mL of dry CH2Cl2, glutaric anhydride (0.70
g, 0.57 mmol) was added and the resulting mixture stirred at r.t. for 16 h then refluxed
for 24 h and poured onto ice/water/NaHCO3. The suspension was acidified to pH 5 and
extracted with CH2Cl2 (3x30mL). The recollected organic phases were washed with a
saturated solution of NaHCO3 (1x50mL) and water (1x50mL), then dried to give 72 in
50% yield without further purification. 1H NMR, 200 MHz, CDCl3, δ: 2.05 (q, 2H, J
=7.1 Hz, CH2); 2.51 (t, 2H, J=7.1 H, CH2); 2.59 (t, 2H, J=7.1 Hz, CH2) (3.70 (s, 6H,
OCH3); 3.80 (s, 3H, OCH3); 3.83 (s, 3H, OCH3); 6.45 (s, 2H, Harom); 6.50 (s, 2H, Harom);
6.76 (d, J=8.4 Hz, 1H, Harom); 6.99 (d, J=1.8 Hz, 1H, Harom); 7.12 (dd, J1=8.4 Hz e
J2=1.8 Hz, 1H, Harom). 13C NMR, 50 MHz , CDCl3, δ: 20.0, 32.7, 32.9 (1C, CH2); 55.9
(1C, OCH3), 56.0 (2C, OCH3); 60.9 (1C, OCH3); 105.7 (2C, CHarom); 111.8 (1C, Carom);
122.9, 127.7 (1C, CHarom); 128.4, 129.3 (1C, CHvinil); 129.9 (1C, CHarom); 132.4, 136.9,
139.1, 150.0 (1C, Carom); 152.8 (2C, Carom); 170.6, 177.8 (1C, CO).
Synthesis of (Z)-2-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenoxy)-acetic acid (73)
Tert-butyl 2-(5-formyl-2-methoxyphenoxy)acetate (74)
To a solution of 3-hydroxy-4-methoxybenzaldehyde (1.50 g, 9.89 mmol) in 55 mL of
dry CH3CN, was added K2CO3 (3.40 g, 24.67 mmol). The mixture was stirred at 58 °C
for 7 min under nitrogen, then a solution of t-butylbromoacetate (2.31 g, 9.84 mmol) in
36 mL of dry CH3CN was added dropwise in 15 min.. The reaction mixture was stirred
for 2 h at 60 °C and overnight at r.t. before adding a saturated solution of NH4Cl and
extracting with Et2O. The organic phase was washed with water, dried, filtered and
concentrated to give 74 with 88% yield. 1H NMR, 200 MHz , CDCl3, δ: 1.46 (s, 9H,
tBu); 3.95 (s, 3H, OCH3); 4.63 (s, 2H, OCH2); 6.98 (d, 1H, J=8.1 Hz, Harom); 7.47 (dd,
J1=8.1 Hz, J2=1.8 Hz, 1H, Harom); 9.85 (s, 1H, CHO); 13C NMR, 50 MHz , CDCl3, δ:
28.1 (3C, CH3); 56.2 (1C, OCH3); 66.0 (1C, OCH2); 82.6 (1C, C(CH3)3); 110.9 (2C,
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CHarom); 127.1 (1C, CHarom); 129.7, 147.7, 154.5 (1C, Carom); 167.0 (1C, COO); 190.2
(1C, CHO).
(Z)-tert-butyl 2-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenoxy)acetate (75)
A homogeneous suspension of 67 (0.10 g, 1.91 mmol) in 60 mL of dry THF under
nitrogen was cooled to -23 °C and retained at that temperature for 2 h. Butyllithium 1.6
M in hexane (1.20 mL, 1.91 mmol) was added dropwise, the resultant orange solution
was stirred at the same temperature for 1 h and finally aldehyde 74 (0.53 g, 1.99 mmol)
was added dropwise. The reaction mixture was stirred at -23 °C for 4 h and at r.t. for 18
h, ice-water was added and the two phases separated. The aqueous phase was washed
with Et2O (3x75mL) and the ethereal solution added to the THF layer. The combined
organic phase was washed with water (3x75mL), dried over Na2SO4, filtered and the
solvent eliminated. The crude product was purified by flash chromatography with
3/1=EtP/EtOAc to give both the Z-75 and the E-75 stilbenes in 13 and 15% yield
respectively. 1H NMR, 200 MHz , CDCl3, Z, δ: 1.41 (s, 9H, tBu); 3.68 (s, 6H, OCH3);
3.82 (s, 3H, OCH3); 3.84 (s, 3H, OCH3); 4.39 (s, 2H, OCH2); 6.45 (AB system, J = 12.2
Hz, 2H, Hvinyl); 6.47 (s, 2H, Harom); 6.70-6.95 (m, 3H, Harom).
(Z)-2-(2-methoxy-5-(3,4,5-trimethoxystyryl)phenoxy)acetic acid (73)
O
O
O
O
O
OH
O
73
1M LiOH (2.40 mL, 2.42 mmol) was added to a solution of Z-75 (0.10 g, 0.24 mmol) in
a 1/1=THF/MeOH mixture (8 mL). The reaction mixture was stirred for 2 h, then 1M
HCl was added until pH 5 and the aqueous phase was extracted with EtOAc (8x30 mL).
Combined organic layers were dried, filtered and evaporated to give acid 73 in 83%
yield without further purification. 1H NMR, 400 MHz , CD3OD, δ: 3.66 (s, 6H, OCH3);
3.71 (s, 3H, OCH3); 3.81 (s, 3H, OCH3); 3.81 (s, 2H, OCH2); 6.48 (AB system, J = 12.0
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Hz, 2H, Harom); 6.55 (s, 2H, Harom); 6.86-6.88 (m, 1H, Harom); 6.91 (d, J = 1.2 Hz, 1H,
Harom). 13C NMR, 100 MHz , CDCl3, δ: 57.0 (3C, OCH3), 61.3 (1C, OCH3); 67.2 (1C,
OCH2); 108.0 (2C, CHarom); 114.0 (1C, Carom); 116.8, 124.5, (1C, CHarom); 130.7, 130.8
(1C, CHvinil); 131.7 (1C, CHarom); 134.3, 139.3, 149.1, 151.0 (1C, Carom); 154.9 (2C,
Carom); 171.0 (1C, CO). IR: 1124; 1236; 1510; 1577; 1739; 3439 cm-1.
Synthesis of Pentanedioicacid mono-[3-(5-ethoxycarbonyl-6-methyl-2-thioxo-
1,2,3,4-tetrahydropyrimidn-4-yl)-phenyl] ester (77)
(3-Hydroxy-phenyl)-6-methyl-2-thioxo-1,2,3,4,-tetrahydropyrimidine-5-carboxylic acid
ethyl ester (76)
To a mixture of 3-hydroxybenzaldehyde (0.85 g, 7.00 mmol) and thiourea (1.60 g,
21.00 mmol), a solution of ethyl acetoacetate (0.89 mL, 7.00 mmol) in 45 mL of THF
dry and Yb(OTf)3.xH2O (0.50 g) were added under nitrogen. The suspension was
refluxed for 7 h, then diluted with EtOAc and washed with water for 5 times. The
organic phase was dried, filtered and evaporated and the crude product was purified by
column chromatography with 2/1=cyclohexane/EtOAc as eluent to give 76 in 44%
yield. Mp 184–186°C. 1H NMR,: 1.14 (t, J=7.5 Hz, 3H, OCH2CH3); 2.30 (s, 3H, CH3);
4.03 (q, J=7.5 Hz, 2H, OCH2CH3); 5.11 (d, J=3.5 Hz, 1H, CH); 6.61–6.69 (m, 3H,
Harom); 7.06–7.17 (m, 1H, Harom); 9.45, 9.62, 10.31 (3 brs, 3H, NH and OH). 13C NMR
,200 MHz , C6D6SO, δ: 14.0, 17.2 (1C, CH3); 54.0 (1C, CH); 59.6 (1C, CH2); 100.8
(1C, C=C); 113.3, 114.6, 117.0, 129.5 (1C, CHarom); 144.8, 144.9 (1C, Carom); 157.5
(1C, C=C); 165.2 (1C, CO); 174.2 (1C, C=S). IR (KBr) 3300; 3180; 2900–2600; 1670;
1655; 1620; 1575 cm-1.
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Pentanedioicacid mono-[3-(5-ethoxycarbonyl-6-methyl-2-thioxo-1,2,3,4-
tetrahydropyrimidn-4-yl)-phenyl] ester (77)
N
H
NH
O
S
O
O
O
OH
O
77
Glutaric anhydride (0.18 g, 1.56 mmol) was added to a suspension of 76 (0.11 g, 0.39
mmol) in 10 mL of dry CH2Cl2. The resulting solution was stirred for 24 h at r.t. under
nitrogen, then refluxed for 27 h, poured onto a saturated solution of NaHCO3 and
acidified to pH 5. The aqueous mixture was extracted with CHCl3 and then the organic
layer extracted with sat. NaHCO3 solution and water. The recollected aqueous phase
was extracted with EtOAc and CHCl3 to give acid 77 in 56% yield, without further
purification. 1H NMR, 400 MHz , CD3OD, δ: 1.14 (t, J=7.5 Hz, 3H, OCH2CH3); 2.01
(qq, J=4.4 Hz, 2H, CH2); 2.30 (s, 3H, CH3); 2.43 (t, J=4.4 Hz, 2H, CH2); 2.64 (t, J=4.4
Hz, 2H, CH2); 4.05 (q, J=7.5 Hz, 2H, OCH2CH3); 5.28 (s, 1H, CH); 7.01–7.07 (m, 2H,
Harom); 7.20–7.24 (m, 1H, Harom); 7.28 (t, J=7.8 Hz, 1H, Harom); 9.45, 9.62, 10.31 (3 brs,
3H, NH and OH). 13C NMR, 400 MHz , CD3OD, δ: 13C NMR ,200 MHz , C6D6SO, δ:
14.5, 17.7 (1C, CH3); 21.2, 33.7, 34.0 (1C, CH2); 56.0 (1C, CH); 61.4 (1C, CH2); 102.8
(1C, C=C); 121.1, 122.3, 125.1, 130.7 (1C, CHarom); 146.1, 146.4 (1C, Carom); 152.3
(1C, C=C); 167.1 (1C, COO); 173.2 (1C, C=S); 176.3 (1C, COO); 176.6 (1C, COOH).
Synthesis of 4-(3-carboxymethoxy-phenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydro-
pyrimidine-5-carboxylic acid ethyl ester (80)
(3-formyl-phenox)-acetic acid tert-butyl ester(78)
To a solution of 3-hydroxybenzaldehyde (1.00 g, 8.20 mmol) in 45 mL of dry CH3CN,
K2CO3 was added (2.83 g, 20.49 mmol). The mixture was stirred at 58 °C for 10 min
under nitrogen, then a solution of t-butylbromoacetate (1.92 g, 9.84 mmol) in 30 mL of
dry CH3CN was added dropwise in 10 min.. The reaction mixture was stirred for 2 h at
60 °C before adding a saturated solution of NH4Cl and extracting with Et2O. The
organic phase was washed with water, dried, filtered and concentrated to give 78 with
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90% yield. 1H NMR, 200 MHz , CDCl3, δ: 1.49 (s, 9H, tBu); 4.59 (s, 2H, OCH2); 7.18–
7.55 (m, 4H, Harom); 9.85 (s, 1H, CHO).
4-(3-tert-Butoxycarbonylmethoxy-phenyl)-2-thioxo-1,2,3,4,-tetrahydro-pyrimidine-5-
carboxylic acid ethyl ester (79)
To a mixture of 78 (1.28 g, 5.42 mmol) and thiourea (1.24 g, 16.27 mmol), a solution of
ethyl acetoacetate (0.69 mL, 5.42 mmol) in 30 mL of THF dry and Yb(OTf)3.xH2O
(0.50 g) were added under nitrogen. The suspension was refluxed for 12 h, then diluted
with EtOAc and washed with water for 5 times. The organic phase was dried, filtered
and evaporated and the crude product was purified by column chromatography with
10/1=cyclohexane/EtOAc as eluent to give 79 in 15% yield (recovering 23% of
aldehyde). 1H NMR, 200 MHz, CDCl3, δ: 1.16 (t, J=7.4 Hz, 3H, OCH2CH3); 1.48 (s,
9H, tBu); 2.35 (s, 3H, CH3); 4.08 (q, J=7.4 Hz, 2H, OCH2CH3); 4.45 (s, 2H, OCH2);
5.17 (d, J=3.5 Hz, 1H, CH); 6.65–6.95 (m, 3H, Harom); 7.08–7.22 (m, 1H, Harom); 7.56,
8.08 (2 brs, 2H, NH). 13C NMR, 100 MHz, CD3OD, δ: 13.7, 17.5 (1C, CH3); 27.6 (3C,
CH3); 59.7 (1C, CH); 59.9 (1C, CH2); 65.1 (1C, CH2); 81.7 (1C, Cquat); 101.5 (1C,
C=C); 112.9, 113.2, 119.4, 128.9 (1C, CHarom); 143.3, 143.7 (1C, Carom); 157.4 (1C,
C=C); 164.6 (1C, COO); 167.3 (1C, COO); 173.1 (1C, C=S).
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4-(3-carboxymethoxy-phenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydro-pyrimidine-5-
carboxylic acid ethyl ester (80)
TFA (5.0 mL) was added to a solution of 79 (0.14 g, 0.34 mmol) in 5 mL of CH2Cl2.
The reaction mixture was stirred at r.t. for 1 h, concentrated and purified by flash
chromatography with 7/1=hexane/EtOAc to obtain 80 in 50% yield. 1H NMR, 400
MHz , CD3OD, δ: 1.17 (t, J=7.2 Hz, 3H, OCH2CH3); 2.34 (s, 3H, CH3); 4.09 (q, J=7.2
Hz, 2H, OCH2CH3); 4.63 (s, 2H, OCH2); 5.30 (s, 1H, CH); 6.81–6.89 (m, 2H, Harom);
6.92 (d, J=7.8 Hz, 1H, Harom); 7.24 (t, J=7.8 Hz, 1H, Harom). 13C NMR, 100 MHz,
CD3OD, δ: 14.5, 17.7 (1C, CH3); 56.2 (1C, CH); 61.3 (1C, CH2); 65.9 (1C, CH2); 103.0
(1C, C=C); 114.3, 114.8, 120.7, 130.8 (1C, CHarom); 146.0, 146.3 (1C, Carom); 159.6
(1C, C=C); 167.2 (1C, COO); 172.6 (1C, COOH); 176.2 (1C, C=S).
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6-MP release from 14, 27, 43
Quantification of 6-MP release from prodrugs was evaluate via HPLC on a C18 Vydac
column with a gradient concentration from 95% A to 5% A in 30 min.
A = H2O+TFA 0.1%, pH=2-3
B = MeOH
Compounds were revealed at 323nm.
Peptide Synthesis
Peptide synthesis was performed with a MultiSynTech Syro automated multiple peptide
synthesizer (Witten, Germany). Protected L-amino acid, coupling reagents (DIPEA and
HBTU), NovaSyn TGR resin (crosslinked polystyrene and polyethylene glycol carrying
a Rink linker) was purchased from Novabiochem. Side chain protecting groups were
trityl for His, 2,2,4,6,7-pentamethyldihydro-benzofuran-5-sulfonyl for Arg, tert-butyl
ether for Ser and Tyr, tert-butyl ester for Asp and Glu, and tert-butyloxycarbonyl for
Trp. All tetra-branched peptides were built using two consecutive Fmoc-Lys(Fmoc)-
OH coupling steps to form the branched core. Peptides were synthesized using Fmoc-
Lys(Dde)-OH as the first amino acid on Novasyn TGR resin, then the second
aminoacid was Fmoc–PEG–OH. Two coupling steps with Fmoc-Lys(Fmoc)-OH were
used to build the core and the tetramer was synthesized using Boc-Arg(Pbf)-OH as the
final amino acid of the neurotensin sequence.
Operatively, a mixture of 5 eq. of Fmoc protected aminoacid, 5 eq. of HBTU dissolved
in DMF and 10 eq. of DIPEA were added to the resin beads. The reaction was
automatically performed at r.t. for 40 minutes and the coupling step repeated twice.
After each aminoacid addition the Fmoc protecting group was removed with a 40%
solution of piperidine in DMF and extensively washed with DMF before adding the
next one. All tetrameric peptides were built employing two consecutive Fmoc-
Lys(Fmoc)-OH coupling steps to form the branched core.
The Dde protective group was removed using 2% hydrazine in DMF (v/v) for 10 min at
room temperature and the free amino group was coupled with Fmoc–PEG–OH. The
Fmoc group was then removed to enable coupling with Functional Unit.
Peptides were cleaved from the resin and deprotected with 95% TFA, 2.5% TIS and 2.5
% H2O (v/v). The mixture was stirred for 1h at r.t. and the solution removed by
filtration. This sequence was repeated teice. After the addition of cold diethylether the
peptide precipitated. The crude was centrifuged and the solution removed to eliminate
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the impurities. After three washings, dendrimer was dissolved in 0.5 % of acetic acid,
freezed and liophylized.
Unrelated analogues were synthesized analogously and the N-terminus was acetylated
before the conjugation steps. HPLC purification was performed on a C18 Vydac
column and revealed at 280 nm. Water (A) containing 0.1% TFA and methanol (B)
were used as eluents, gradients of B in 30 min were run at flow rates of 0.8 ml/min and
4 ml/min for analytical and preparatory procedures, respectively. The gradient used is:
from 80% to 1% of A. All compounds were also characterized on an Ettan MALDI-
TOF mass spectrometer (Amersham Biosciences, Buckinghamshire, UK). As an
example: [NT(8-13)4-47] 85. HPLC: tR = 28.42 min (1-80% B); tR = 22.21 min (1-70%
B). MALDI-ToF m/z: [M]+ 4723.93 (calcd 4725.64).
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Synthesi of 2,2-dimethyl-5,6-dioxo-3,4,5,6-tetrahydro-2H-benzo[h]chromen-3-yl 4-
(2-mercaptoethylamino)-4-oxobutanoate (96)
2-(tritylthio)ethanamine (94)
Triphenylmethanethio chloride (0.56 g, 2.00 mmol) was dissolved in 1 mL of dry
CH2Cl2. To this solution cysteamine hydrochloride (0.26 g, 2.30 mmol) and TFA (0.40
mL) were added to form a dark red brown solution. The reaction mixture was stirred at
r.t. for 2 h under argon, then 1N NaOH (3mL) was added. The oil obtained was diluted
with CH2Cl2 (150 mL) and a saturated solution of NaHCO3 (150 mL). The two phases
were separated and the aqueous layer was extracted with CH2Cl2 (3x50mL). The
combined organic layers were washed with water (3x100mL), dried over Na2SO4,
filtered and evaporated. The crude product was purified by flash chromatography with
6/1=Hexane/Ethylacetate as eluent to give thioether 94 in 99% yield. 1H NMR, 400
MHz, CDCl3, δ: 2.36 (t, J=6.5 Hz, 2H), 2.63 (t, J=6.5 Hz, 2H), 7.23-7.25 (m, 3H),
7.26-7.34 (m, 6H), 7.48-7.50 (m, 6H). ESI-MS: [M+Na]+: 342.5.
2,2-dimethyl-5,6-dioxo-3,4,5,6-tetrahydro-2H-benzo[h]chromen-3-yl 4-oxo-4-(2-
(tritylthio)ethylamino)butanoate (95)
Compound 94 (0.28 g, 0.44 mmol) and 64 (0.08 g, 0.49 mmol) were dissolved in 8 mL
of DMSO. The solution was degassed with argon and cooled to 0 °C before adding
HBTU (0.21 g, 0.56 mmol) and DIPEA (0.24 g, 1.79 mmol). The reaction mixture was
then stirred at r.t. for 64 h, concentrated and, after the addition of EtOAc, washed with
HCl 1M and water. The resulting solution was dried over Na2SO4, filtered and
concentrated to give the desired derivative 95 in 99% yield without further purification.
1H NMR, 400 MHz, CDCl3, δ: 1.43 (s, 3H, CH3), 1.48 (s, 3H, CH3), 2.36 (t, J=6.5 Hz,
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2H), 2.62-2.74 (m, 8H, H-4 and CH2), 5.17 (t, 1H, J = 4.8 Hz, H-3), 7.23-7.25 (m, 3H),
7.26-7.34 (m, 6H), 7.48-7.50 (m, 6H), 7.53 (dt, J = 1.0 and 6.4 Hz 1H, Harom), 7.64 (dt,
J = 1.6 and 6.0 Hz 1H, Harom), 7.84 (dd, J = 1.0 and 6.0 Hz 1H, Harom), 7.64 (dt, J = 1.4
and 6.6 Hz 1H, Harom).
2,2-dimethyl-5,6-dioxo-3,4,5,6-tetrahydro-2H-benzo[h]chromen-3-yl 4-(2-
mercaptoethylamino)-4-oxobutanoate (96)
Compound 95 (0.45 g, 0.68 mmol) was dissolved in 7 mL of CH2Cl2 and TFA (1.80
mL, 15.00 mmol) was added, followed by TIPS (240 µL, 1.13 mmol). The mixture was
stirred under argon for 32h. The solvent was removed under vacuum and the residue
was purified by washing with hexane (3 times) and Et2O (4 times) to obtain thiol 96
with 98% yield. 1H NMR, 400 MHz, CDCl3, δ: 1.43 (s, 3H, CH3), 1.48 (s, 3H, CH3),
2.36 (t, J=6.5 Hz, 2H), 2.62-2.74 (m, 8H, H-4 and CH2), 5.17 (t, 1H, J = 4.8 Hz, H-3),
7.53 (dt, J = 1.0 and 6.4 Hz 1H, Harom), 7.64 (dt, J = 1.6 and 6.0 Hz 1H, Harom), 7.84 (dd,
J = 1.0 and 6.0 Hz 1H, Harom), 7.64 (dt, J = 1.4 and 6.6 Hz 1H, Harom). ESI(MS): 682.2.
Synthesis of 26,26,26-triphenyl-2,5,8,12-tetraoxa-25-thiahexacosan-1-ol (99)
12-(tritylthio)dodecan-1-ol (97)
Triphenylmethanethiol (26.41 g, 95.54 mmol) was dissolved in EtOH/toluene (67
mL/67 mL). To this solution 10 mL of NaOH 12M (4.78 g, 119.43 mmol) and a
solution of 11-Bromo-1-undecanol (20.00 g, 79.62 mmol) in EtOH/toluene (33 mL/33
mL) were added. The red mixture was stirred at 60°C for 4h, then the solvent was
removed. The oil obtained was diluted with CH2Cl2 (150 mL) and a saturated solution
of NaHCO3 (150 mL). The two phases were separated and the aqueous layer was
extracted with CH2Cl2 (3x50mL). The combined organic layers were washed with water
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(3x100mL), dried over Na2SO4, filtered and evaporated. The crude product was purified
by flash chromatography with 6/1=hexane/EtOAc as eluent to give thioether 97 in 99%
yield. PM=446.6 1H NMR, 400 MHz, CDCl3, δ: 1.30-1.42 (m, 18H, CH2); 1.52-1.59
(m, 2H, CH2); 2.13 (t, J=7.2 Hz, 2H, CH2); 3.64 (t, J=6.4 Hz, 2H, CH2); 7.18-7.25 (m,
3H, Harom); 7.26-7.46 (m, 12H, Harom).
12-(tritylthio)dodecyl methanesulfonate (98)
TEA (22.00 mL, 159.20 mmol) was added to a solution of 97 (35.60 g, 79.60 mmol) in
140 mL CH2Cl2 at 0°C. At this temperature Methanesulfonyl chloride (9.2 mL, 119.4
mmol) was added dropwise by a syringe. The reaction mixture was allowed to go to
room temperature, stirred for 3h and then diluted with CH2Cl2. The solution was
washed with a saturated solution of NaHCO3 (4x100 mL) and water (2x100mL). The
organic phase was dried over Na2SO4, filtered and the solvent evaporated. The crude
product was purified by flash chromatography starting with 80/1 and gradually going to
5/1 =Hexane/Ethylacetate as eluent to give sulfonyl derivative 98 in 80% yield. PM=
524.24 1H NMR, 400 MHz, CD3OD , δ: 1.23-1.35 (m, 16H, CH2); 1.70-1.80 (m, 2H,
CH2); 2.16 (t, J=7.6 Hz, 2H, CH2); 3.08 (s, 3H, CH3); 4.26 (t, J=6.4 Hz, 2H, CH2);
7.24-7.26 (m, 3H, Harom); 7.30-7.33 (m, 6H, Harom). 7.41-7.44 (m, 6H, Harom).
26,26,26-triphenyl-2,5,8,12-tetraoxa-25-thiahexacosan-1-ol (99)
S
9
99
O
HO
4
To tetraethyleneglycol (TEG) (160.00 mL, 932.80 mmol), 50% aq. NaOH (2.45 g,
62.20 mmol) was added. The resulting mixture was heated at 90°C for 1h under argon,
then allowed to return to r.t. and poured onto 98 (32.60 g, 62.20 mmol). The reaction
was stirred under argon at 90°C for 24, extracted with 5/1=Hexane/EtOAc (6x100 mL)
and concentrated. The residue was purified by flash chromatography with 5/1=
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Hexane/EtOAc → EtOAc as eluent to yield alcohol 99 in 58% yield. 1H NMR, 400
MHz, CDCl3, δ: 1.10-1.39 (m, 16H, CH2); 1.53-1.58 (m, 2H, CH2); 2.14 (t, J=7.2 Hz,
2H, CH2); 2.64 (m, 1H, OH); 3.44 (t, J=6.8 Hz, 2H, CH2); 3.46-3.72 (m, 16H, CH2);
7.18-7.29 (m, 9H, Harom); 7.39-7.40 (m, 6H, Harom).
Synthesis of 28-mercapto-4,4-dimethyl-6,9,12,16-tetraoxa-4-azoniaoctacosan-4-
ium-1-sulfonate (103)
26,26,26-triphenyl-2,5,8,12-tetraoxa-25-thiahexacosyl methanesulfonate (100)
TEA (1.30 mL, 9.63 mmol) was added to a solution of 99 (3.00 g, 4.82 mmol) in 9 mL
of CH2Cl2 at 0°C. At this temperature methanesulfonyl chloride (0.60 mL, 7.68 mmol)
was added dropwise by a syringe. The reaction mixture was allowed to go to room
temperature, stirred for 3h and then diluted with CH2Cl2. The solution was washed with
a saturated solution of NaHCO3 (4x100 mL) and water (2x100mL). The organic phase
was dried over Na2SO4, filtered and the solvent evaporated to give sulfonyl derivative
100 in 89% yield. 1H NMR, 400 MHz, CDCl3, δ: 1.10-1.39 (m, 16H, CH2); 1.53-1.58
(m, 2H, CH2); 2.05 (t, J=7.0 Hz, 2H, CH2); 3.08 (s, 3H, CH3); 3.44 (t, J=7.0 Hz, 2H,
CH2); 3.56-3.72 (m, 12H, CH2); 3.76 (t, J=2.8 Hz, 2H, CH2); 4.38 (t, J=2.8 Hz, 2H,
CH2); 7.16-7.20 (m, 3H, Harom); 7.22-7.29 (m, 6H, Harom); 7.39-7.42 (m, 6H, Harom).
N,N-dimethyl-26,26,26-triphenyl-2,5,8,12-tetraoxa-25-thiahexacosan-1-amine (101)
Dimethylamine hydrochloride (34.95 g, 428.00 mmol) and KOH were stirred as a
mixture of solids in a flask connected by a canula to another flask with a solution of 100
(3.00 g, 4.28 mmol) in 100 mL of dry THF. The dimethylamine was bubbled as a gas
into the solution for 5h, the reaction mixture was then stirred overnight. The solvent
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was removed under reduced pressure and the crude product dissolved in CH2Cl2 and
washed with water (6 times). The organic phase was dried over Na2SO4, filtered and the
solvent evaporated to give dimethylamine derivative 101 in 85% yield. 1H NMR, 400
MHz, CDCl3, δ: 1.40 (m, 18H, CH2); 2.14 (t, J=7.3 Hz, 2H, CH2); 2.53 (t, J=5.8 Hz,
2H, CH2); 2.84 (s, 6H, N(CH3)2); 3.44 (t, J=6.8 Hz, 2H, OCH2); 3.56-3.65 (m, 14H,
CH2), 7.16-7.20 (m, 3H, Harom); 7.22-7.29 (m, 6H, Harom); 7.39-7.42 (m, 6H, Harom).13C
NMR, 400 MHz, CDCl3, δ: 26.10, 28.60, 29.02, 29.19, 29.41, 29.48, 29.56, 29.65,
32.04, 45.81, 58.77, 66.36, 69.23, 70.07, 70.40, 70.61, 71.55, 126.49, 127.79, 129.62,
145.10.
27,27-dimethyl-1,1,1-triphenyl-15,19,22,25-tetraoxa-2-thia-27-azoniatriacontan-27-
ium30sulfonate (102)
An anhydrous acetone solution (100 mL) of compound 101 (2.20 g, 3.38 mmol) and
1,3-propanesultone (0.32 g, 6.44 mmol) was stirred at r.t. for 3h. The reaction mixture
was filtered, and the resulting solid was washed with hexane/EtOAc=4/1 (8 times) and
dried under vacuum to afford sulfonyl derivative 102 in 85% yield. 1H NMR, 400 MHz,
CDCl3, δ: 1.40 (m, 18H, CH2); 2.12 (t, J=7.3 Hz, 2H, SCH2); 2.26 (m, 2H, CH2); 2.88
(t, J=6.7 Hz, 2H, CH2); 3.23 (s, 6H, N(CH3)2); 3.42 (t, J = 6.8 Hz, 2H, OCH2); 3.56-
3.71 (m, 14H, CH2); 3.78 (m, 2H, NCH2); 3.94 (m, 2H, OCH2); 7.16-7.20 (m, 3H,
Harom); 7.22-7.29 (m, 6H, Harom); 7.39-7.42 (m, 6H, Harom). ESI(MS): 794.6 [M+Na]+
28-mercapto-4,4-dimethyl-6,9,12,16-tetraoxa-4-azoniaoctacosan-4-ium-1-sulfonate
(103)
Compound 102 (0.60 g, 0.77 mmol) was dissolved in 8 mL of CH2Cl2 and TFA (1.80
mL, 15.54 mmol) was added, followed by TIPS (240 µL, 1.16 mmol). The mixture was
stirred under argon overnight. The solvent was removed under vacuum and the residue
was purified by washing with Hexane (7 times) and Et2O (twice) to obtain thiol 103
with 74% yield. 1H NMR, 400 MHz, CDCl3, δ: 1.40 (m, 18H, CH2); 2.26 (brs, 2H,
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CH2); 2.49 (q, J=7.2 Hz, 2H, HSCH2); 2.90 (brs, 2H, CH2); 3.04 (s, 6H, N(CH3)2); 3.41
(t, J=6.8 Hz, 2H, OCH2); 3.52-3.79 (m, 16H, CH2); 3.91 (m, 2H, OCH2). ESI(MS):
552.4 [M+Na]+.
Synthesis of 16-(tritylthio)hexadecan methanesulfonate (108)
16-bromohexadecan-1-ol (106)
To a solution of hexadecane-1,16-diol (0.75 g, 2.90 mmol) in 7.5 mL of cyclohexane,
HBr (7.5 mL) was added. The reaction mixture was refluxed for 6h, then diluted with
hexane and washed with a saturated solution of NaHCO3 (3x50 mL) and water. The
organic layer was dried over Na2SO4, filtered and evaporated to give bromide 106 in
99% yield. 1H NMR, 400 MHz, CDCl3, δ: 1.25-1.42 (m, 22H, CH2); 1.49-1.55 (m, 4H,
CH2); 1.80 (m, 2H, CH2); 3.39 (t, J=6.8 Hz, 2H, OCH2); 3.62 (t, J=6.8 Hz, 2H, BrCH2).
12-Tritylthio hexadecan-1-ol (107)
Triphenylmethanethiol (1.58 g, 5.73 mmol) was dissolved in EtOH/toluene (10 mL/10
mL). To this solution 0.6 mL of NaOH 12M (0.29 g, 7.16 mmol) and a solution of 106
(0.93 g, 2.58 mmol) in EtOH/toluene (4 mL/4 mL) were added. The red mixture was
stirred at 60°C for 4h, then the solvent was removed. The oil obtained was diluted with
CH2Cl2 (150 mL) and a saturated solution of NaHCO3 (150 mL). The two phases were
separated and the aqueous layer was extracted with CH2Cl2 (3x50mL). The combined
organic layers were washed with water (3x100mL), dried over Na2SO4, filtered and
evaporated. The crude product was purified by flash chromatography with
3/1=hexane/EtOAc as eluent to give thioether 107 in 30% yield. 1H NMR, 400 MHz,
CDCl3, δ: 1.15-1.42 (m, 22H, CH2); 1.49-1.55 (m, 4H, CH2); 1.80 (m, 2H, CH2); 2.05
(t, J=6.8 Hz, 2H, CH2); 3.03 (t, J=6.8 Hz, 2H, OCH2); 7.18-7.25 (m, 3H, Harom); 7.26-
7.46 (m, 12H, Harom).
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16-(tritylthio)hexadecan methanesulfonate (108)
TEA (0.22 mL, 1.16 mmol) was added to a solution of 107 (0.40 g, 0.78 mmol) in 10
mL of CH2Cl2 at 0°C. At this temperature methanesulfonyl chloride (0.09 mL, 1.16
mmol) was added dropwise by a syringe. The reaction mixture was allowed to go to
room temperature, stirred for 5h and then diluted with CH2Cl2. The solution was
washed with a saturated solution of NaHCO3 (4x20 mL) and water (2x20mL). The
organic phase was dried over Na2SO4, filtered and the solvent evaporated to give
sulfonyl derivative 108 in 64% yield. 1H NMR, 400 MHz, CDCl3, δ: 1.15-1.42 (m,
26H, CH2); 1.80 (m, 2H, CH2); 2.08 (t, J=6.8 Hz, 2H, SCH2); 3.00 (s, 3H, CH3); 4.22 (t,
J=8.8 Hz, 2H, OCH2); 7.16-7.20 (m, 3H, Harom); 7.22-7.29 (m, 6H, Harom); 7.39-7.42 (m,
6H, Harom).
Synthesis of 3-((13-mercaptotridecyl)dimethylammonio)propane-1-sulfonate (104)
Tritylthio-13-(dimethylamino)tridecane-1-thiol (109)
Dimethylamine hydrochloride ( 28.00 g, 343.35 mmol) and KOH were stirred as a
mixture of solids in a flask connected by a canula to a solution of 98 (1.80 g, 3.43
mmol) in 50 mL of dry THF. The dimethylamine was bubbled as a gas into the solution
for 8h under vigorous stirring, the reaction mixture was then stirred overnight. The
solvent was removed under reduced pressure and the crude product dissolved in CH2Cl2
and washed with water (6 times). The organic phase was dried over Na2SO4, filtered
and the solvent evaporated to give dimethylamine derivative 109 in 98% yield. 1H
NMR, 400 MHz, CDCl3, δ: 1.15-1.28 (m, 16H, CH2); 1.36-1.38 (m, 2H, CH2); 2.12 (t,
J=7.6 Hz, 2H, SCH2); 2.33 (s, 6H, CH3); 2.34-2.38 (m, 2H, CH2); 7.18-7.35 (m, 10H,
Harom); 7.35-7.50 (m, 5H, Harom).
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Tritylthio-3-((13-mercaptotridecyl)dimethylammonio)propane-1-sulfonate (111)
An anhydrous acetone solution (80 mL) of compound 109 (1.60 g, 3.38 mmol) and 1,3-
propanesultone (0.78 g, 6.42 mmol) was stirred overnight at r.t.. The reaction mixture
was filtered, and the resulting solid was washed with hexane/EtOAc=4/1 (8 times) and
dried under vacuum to afford sulfonyl derivative 111 in 75% yield. 1H NMR, 400 MHz,
CD3OD, δ: 1.15-1.42 (m, 16H, CH2); 1.72-1.80 (m, 2H, CH2); 2.10-2.30 (m, 4H, CH2);
2.51-2.55 (m, 2H, CH2); 2.88 (t, J=6.7 Hz, 2H, CH2); 3.07 (s, 6H, N(CH3)2); 3.20-3.30
(m, 2H, CH2); 3.48-3.54 (m, 2H, CH2); 7.16-7.20 (m, 3H, Harom); 7.22-7.29 (m, 6H,
Harom); 7.39-7.42 (m, 6H, Harom). 13C NMR, 400 MHz, CDCl3, δ: 19.1, 22.5, 23.5, 26.1,
28.4, 28.8, 29.0, 29.2, 29.3, 31.8, 42.9, 43.9, 47.6, 50.5, 53.4, 62.9, 64.3, 66.1, 68.8,
126.3, 127.6, 129.4, 144.8. ESI(MS) : 618.4 [M+Na]+.
3-((13-mercaptotridecyl)dimethylammonio)propane-1-sulfonate (104)
Compound 111 (0.45 g, 0.75 mmol) was dissolved in 7 mL of CH2Cl2 and TFA (1.80
mL, 15.00 mmol) was added, followed by TIPS (240 µL, 1.13 mmol). The mixture was
stirred under argon for 32h. The solvent was removed under vacuum and the residue
was purified by washing with hexane (3 times) and Et2O (4 times) to obtain thiol 104
with 98% yield. 1H NMR, 400 MHz, CDCl3, δ: 1.19-1.39 (m, 14H, CH2); 1.54-1.78 (m,
4H, CH2); 2.18-2.30 (m, 2H, CH2); 2.49 (q, J=7.2 Hz, 2H, HSCH2); 2.90 (brs, 2H,
CH2); 3.10-3.23 (s, 6H, N(CH3)2); 3.24-3.30 (m, 2H, CH2); 3.58-3.74 (m, 2H, CH2).
ESI(MS): 354.2 [M+Na]+.
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Synthesis of 3-((16-mercaptohexadecyl)dimethylammonio)propane-1-sulfonate
(105)
Tritylthio-16-(dimethylamino)hexadecane-1-thiol (110)
Dimethylamine hydrochloride (4.08 g, 50.00 mmol) and KOH were stirred as a mixture
of solids in a flask connected by a canula to a solution of 108 (0.30 g, 0.50 mmol) in 10
mL of dry THF. The dimethylamine was bubbled as a gas into the solution for 8h under
vigorous stirring, the reaction mixture was then stirred overnight. The solvent was
removed under reduced pressure and the crude product dissolved in CH2Cl2 and washed
with water (6 times). The organic phase was dried over Na2SO4, filtered and the solvent
evaporated to give dimethylamine derivative 110 in 96% yield. 1H NMR, 400 MHz,
CDCl3, δ: 1.15-1.42 (m, 26H, CH2); 1.80 (m, 2H, CH2); 2.12 (t, J=7.2 Hz, 2H, SCH2);
2.40 (s, 6H, CH3); 2.49 (t, J=7.6 Hz, 2H, OCH2); 7.18-7.35 (m, 10H, Harom); 7.35-7.50
(m, 5H, Harom).
Tritylthio-3-((16-mercaptohexadecyl)dimethylammonio)propane-1-sulfonate (112)
An anhydrous acetone solution (10 mL) of compound 110 (0.26 g, 0.48 mmol) and 1,3-
propanesultone (0.11 g, 0.90 mmol) was stirred overnight at r.t.. The reaction mixture
was filtered, and the resulting solid was washed with hexane/EtOAc=4/1 (8 times) and
dried under vacuum to afford sulfoxide derivative 112 in 63% yield. 1H NMR, 400
MHz, CD3OD, δ: 1.15-1.42 (m, 30H, CH2); 2.10-2.30 (m, 4H, CH2); 2.55-2.65 (m, 2H,
CH2); 2.88 (t, J=6.7 Hz, 2H, CH2); 3.07 (s, 6H, N(CH3)2); 3.48-3.54 (m, 4H, CH2);
7.16-7.20 (m, 3H, Harom); 7.22-7.29 (m, 6H, Harom); 7.39-7.42 (m, 6H, Harom). ESI(MS):
688.4 [M+Na]+.
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3-((16-mercaptohexadecyl)dimethylammonio)propane-1-sulfonate (105)
Compound 112 (0.20 g, 0.30 mmol) was dissolved in 2 mL of CH2Cl2 and TFA (0.70
mL, 6.00 mmol) was added, followed by TIPS (100 µL, 0.45 mmol). The mixture was
stirred under argon for 32h. The solvent was removed under vacuum and the residue
was purified by washing with hexane (7 times) and Et2O (twice) to obtain thiol 105
with 79% yield. 1H NMR, 400 MHz, CDCl3, δ: 1.19-1.39 (m, 26H, CH2); 1.54-1.78 (m,
4H, CH2); 2.18-2.30 (m, 2H, CH2); 2.49 (q, J=7.2 Hz, 2H, HSCH2); 2.90 (brs, 2H,
CH2); 3.10-3.35 (s, 10H, N(CH3)2 + CH2); 3.58-3.74 (m, 2H, CH2). ESI(MS): 446.2
[M+Na]+.
Synthesis of 23-mercapto-3,6,9,12-tetraoxatricosyl-2,6-bis(2,6-
diaminohexanamido)hexanoate (116)
methyl 16-(tert-butoxycarbonylamino)-6-(4-(tert-butoxycarbonylamino)butyl)-
2,2,24,24-tetramethyl-4,7,15,22-tetraoxo-3,23-dioxa-5,8,14,21-tetraazapentacosane-9-
carboxylate (113)
L-Lysine methyl ester dihydrochloride (2.33 g, 10.00 mmol) was suspended in 83 mL
of EtOAc. TEA (3.00 mL, 22.00 mmol) was added, followed by Boc-Lys(Boc)-
OH.DCHA (12.60 g, 22.00 mmol). The mixture was stirred under argon for 2 minutes
and then cooled to 0°C. Hydroxybenzotriazole (HOBt, 2.97 g, 22.00 mmol) and
dicyclohexyl carbodiimmide (DCC, 4.54 g, 22.00 mmol) were added simultaneously as
a mixture of solids. The reaction mixture was allowed to warm at rt and stirred for 24h.
The precipitate was removed by filtration and discarded. The filtrate was washed with a
saturated solution of NaHCO3 (3x100 mL) and water (1x100mL). The organic phase
was dried over Na2SO4, filtered and concentrated to give a white solid. This residue was
purified by flash chromatography with 30/1=CH2Cl2/MeOH to obtain G1(COOMe) 113
with 97% yield. 1H NMR, 400 MHz, CDCl3, δ: 1.35-1.85 (m, 54H, CH2 and CH3);
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2.94-2.99 (m, 4H, CH2NH); 2.94-3.20 (m, 4H, CH2NH); 3.47-3.52 (m, 2H, CH2NH);
3.71 (s, 3H, CH3); 4.08-4.13 (m, 1H, CH); 4.25-4.39 (m, 2H, CH); 4.75 (br s, 1H, NH-
Boc); 4.90 (br s, 1H, NH-Boc); 5.55 (br s, 1H, NH-Boc); 5.90 (br s, 1H, NH-Boc); 6.92
(br s, 1H, CONH); 7.35 (br s, 1H, CONH).
16-(tert-butoxycarbonylamino)-6-(4-(tert-butoxycarbonylamino)butyl)-2,2,24,24-
tetramethyl-4,7,15,22-tetraoxo-3,23-dioxa-5,8,14,21-tetraazapentacosane-9-carboxylic
acid (114)
1M NaOH (26.60 mL, 26.60 mmol) was added to a solution of 113 (7.50 g, 9.20 mmol)
in 375 mL of CH2Cl2 at 0°C, under argon atmosphere. The reaction mixture was then
stirred at r.t. for 24h, concentrated and, after the addition of water (200 mL), acidified
to pH 3 with aqueous NaHSO4. The product was extracted with EtOAc (5x150 mL) and
washed with water and brine. The resulting solution was dried over Na2SO4, filtered
and concentrated to give the desired dendrimer 114 in 95% yield. 1H NMR, 400 MHz,
(CD3)2CO), δ: 1.35-1.85 (m, 54H, CH2 and CH3); 2.94-2.99 (m, 4H, CH2NH); 2.94-
3.20 (m, 4H, CH2NH); 3.47-3.52 (m, 2H, CH2NH); 3.71 (s, 3H, CH3); 4.08-4.13 (m,
1H, CH); 4.25-4.39 (m, 2H, CH); 4.75 (br s, 1H, NH-Boc); 4.90 (br s, 1H, NH-Boc);
5.55 (br s, 1H, NH-Boc); 5.90 (br s, 1H, NH-Boc); 6.92 (br s, 1H, CONH); 7.35 (br s,
1H, CONH).
Tritylthio-23-mercapto-3,6,9,12-tetraoxatricosyl-2,6-bis(2,6-
diaminohexanamido)hexanoate (115)
G1-COOH 114 (1.00 g, 1.25 mmol) was dissolved in 15 mL of CH2Cl2 and cooled to
0°C under argon. DMAP (0.05 g, 0.40 mmol) was added, followed by DCC (0.403 g,
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1.94 mmol). The mixture was stirred under argon for 10 minutes. A solution of 99
(0.554 g, 0.89 mmol) in 8 mL of CH2Cl2 was added. The reaction mixture was allowed
to warm at rt and stirred for 24h. The solvent was removed under vacuum and the
residue was purified by flash chromatography with 80/1=CH2Cl2/MeOH as eluent to
obtain G1-conjugate 115 with 99% yield. 1H NMR, 400 MHz, CDCl3, δ: 1.10-1.95 (m,
73H, CH2 and CH3); 2.12 (t, J=7.2 Hz, 2H, CH2); 2.84-3.15 (m, 6H, CH2NH); 3.43 (t,
J=6.8 Hz, 2H, CH2); 3.55-3.73 (m, 16H, CH2); 4.06-4.12 (m, 1H, CH); 4.25-4.30 (m,
2H, CH); 4.75 (br s, 1H, NH-Boc); 4.90 (br s, 1H, NH-Boc); 5.55 (br s, 1H, NH-Boc);
5.90 (br s, 1H, NH-Boc); 6.60 (br s, 1H, CONH); 6.92 (br s, 1H, CONH); 7.15-7.29 (m,
9H, Harom); 7.39-7.40 (m, 6H, Harom).
23-mercapto-3,6,9,12-tetraoxatricosyl-2,6-bis(2,6-diaminohexanamido)hexanoate
(116)
Compound 115 (0.25 g, 0.18 mmol) was dissolved in 10 mL of CH2Cl2 and TFA (1
mL) was added, followed by triisopropylsilane (TIPS) (60 µL). The mixture was stirred
under argon for 24h. The solvent was removed under vacuum and the residue was
washed with Hexane (6 times) and Et2O (twice) to obtain G1-conjugate 116 with 99%
yield. 1H NMR, 400 MHz, CD3OD, δ: 1.00-1.95 (m, 36H, CH2 and CH3); 2.50 (t, J=7.2
Hz, 2H, CH2); 2.90-2.93 (m, 4H, CH2NH2); 3.15-3.26 (m, 2H, CH2); 3.41-3.47 (m, 2H,
CH2); 3.56-3.81 (m, 16H, CH2); 3.96 (br s, 1H, CH); 4.43 (br s, 1H, CH); 4.79 (br s,
1H, CH).
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Synthesis of Gold (~ 2 nm) nanoparticles
C5 AuNP were prepared by following the Brust-Schiffrin two-phase method using 1-
pentanethiol as capping ligands.
Operatively a solution of tetrabutylammonium bromide (TOAB, 4.20 g, 7.62 mmol) in
150 mL of toluene was mixed with a solution of HAuCl4 (2.00 g, 5.08 mmol) in 150
mL of water. The mixture was stirred for 10 min while the toluene layer became red.
Pentanethiol (0.74 g, 7.11 mmol) was then added and the reaction stirred for 10 min,
cooled and a solution of NaBH4 (3.84 g, 101.60 mmol) in 12 mL of water was added
dropwise. The two-phase mixture was stirred overnight at r.t., then separated and the
organic layer was evaporated at 30 °C under vacuum, diluted with CH2Cl2 and the
AuNPs precipitated by the addition of diethyl ether. After washing several times with
ethanol the C5 AuNPs were dried and stored at r.t.
To fabricate 117, 118, 119 and 120 via ligand place exchange reaction, 30 mg of C5 NP
were mixed with 100 mg of 103, 104, 105 and 116 respectively in dichloromethane (10
mL). The solution was stirred at room temperature for 24 h. Solvent was removed by
rotary evaporator and the nanoparticles were washed with diethyl ether (20 mL x 5).
The nanoparticles were further purified by dialysis in MiliQ water using SnakeSkin
pleated dialysis tubing (10,000 MWCO) for 1 day.
Preparation and characterization of AuNPZwit complexes (AuNPZwit-dye/drug
conjugates)
In order to prepare AuNPZwit complexes, solvent displacement method was carried
out using water and acetone. An acetone solution of each guest compound (10 mg) and
aqueous solution of 117 (80 μM) were well mixed. Acetone was then removed by
rotary evaporator or slow evaporation at room temperature. During the evaporation of
acetone, some guest compounds were entrapped in interior of AuNPZwit due to
hydrophobic interaction and the rest of guest compounds were precipitated out. The
mixture was then filtered using a vacuo filter (0.2 μm pore) to remove the precipitate.
For further purification, the AuNPZwit 117 complexes solution was washed with
distilled water and centrifuged with Amicon Ultra-4 tube (10,000 MWCO) several
times (2 mL x~5 times) until no absorbance of guest molecules in filtrate was detected
by spectrophotometer.
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Synthesis of 2-(2-(2-(3-mercaptopropoxy)ethoxy)ethoxy)ethyl 2,6-bis(2,6-
diaminohexanamido)hexanoate (122)
13-oxo-3,6,9-trioxa-12-thiatetradecyl 16-(tert-butoxycarbonylamino)-6-(4-(tert-
butoxycarbonylamino)butyl)-2,2,24,24-tetramethyl-4,7,15,22-tetraoxo-3,23-dioxa-
5,8,14,21-tetraazapentacosane-9-carboxylate (124)
G1-COOH (114) (1.00 g, 1.25 mmol) was dissolved in 15 mL of CH2Cl2 and cooled to
0°C under argon. DMAP (0.05 g, 0.40 mmol) was added, followed by DCC (0.40 g,
1.94 mmol). The mixture was stirred under argon for 10 minutes. A solution of 123
(0.554 g, 0.89 mmol) in 8 mL of CH2Cl2 was added. The reaction mixture was allowed
to warm at rt and stirred for 24 h. The solvent was removed under vacuum and the
residue was purified by flash chromatography with 80/1=CH2Cl2/MeOH followed by
20/1 to obtain G1-conjugate 124 with 99% yield. 1H NMR, 400 MHz, CDCl3, δ: 1.30-
1.95 (m, 56H, CH2 and CH3); 2.30 (s, 3H, CH3); 2.86-3.00 (m, 6H, CH2NH); 3.24-3.30
(m, 2H, CH2S); 3.48-3.73 (m, 14H, CH2); 4.06-4.12 (m, 1H, CH); 4.25-4.30 (m, 2H,
CH); 4.75 (br s, 1H, NH-Boc); 4.90 (br s, 1H, NH-Boc); 5.55 (br s, 1H, NH-Boc); 5.90
(br s, 1H, NH-Boc); 6.60 (br s, 1H, CONH); 6.92 (br s, 1H, CONH).
2-(2-(2-(2-mercaptoethoxy)ethoxy)ethoxy)ethyl 16-(tert-butoxycarbonylamino)-6-(4-
(tert-butoxycarbonylamino)butyl)-2,2,24,24-tetramethyl-4,7,15,22-tetraoxo-3,23-dioxa-
5,8,14,21-tetraazapentacosane-9-carboxylate (125)
Compound 124 (0.20 g, 0.19 mmol) was dissolved in 5 mL of CH2Cl2 and TFA (1 mL)
was added, followed by triisopropylsilane (TIPS) (40 µL). The mixture was stirred
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under argon overnight. The solvent was removed under vacuum and the residue was
washed with Hexane (7 times) and Et2O (twice) to obtain G1-conjugate 125 with 99%
yield. 1H NMR, 400 MHz, CD3OD, δ: 1.30-1.95 (m, 20H, CH2 and CH3); 2.30 (s, 3H,
CH3); 2.86-3.00 (m, 6H, CH2NH); 3.24-3.30 (m, 2H, CH2S); 3.48-3.73 (m, 12H, CH2);
3.85 (t, 2H, CH2); 3.90-4.00 (m, 1H, CH); 4.20-4.35 (m, 1H, CH); 4.35-4.50 (m, 1H,
CH).
2-(2-(2-(3-mercaptopropoxy)ethoxy)ethoxy)ethyl 2,6-bis(2,6-
diaminohexanamido)hexanoate (122)
Compound 125 (0.12 g, 0.19 mmol) was dissolved in 10 mL of MeOH, the solution was
cooled at 0°C and acetyl chloride (0.22 g, 2.85 mmol) was added slowly under argon
atmosphere. The reaction mixture was allowed to rise automatically to r.t. and stirred
for 3h. The solvent was removed under reduced pressure to obtain thiol 122 with 86%
yield. 1H NMR, 400 MHz, CD3OD, δ: 1.40-2.00 (m, 20H, CH2 and CH3); 2.58 (t, 2H,
CH2); 2.88-3.02 (m, 6H, CH2NH); 3.22-3.28 (m, 2H, CH2); 3.55-3.73 (m, 12H, CH2);
3.89-3.93 (m, 2H, CH2); 3.95-4.09 (m, 2H, CH); 4.30-4.50 (m, 1H, CH). ESI(MS):
609.5 [M+Na]+.
Synthesis of N-(2-(2-(2-aminoethylamino)ethylamino)ethyl)-4-((4-(3,4-
dihydroxyphenethylamino)-4-oxobutyl)disulfanyl)butanamide (126) and N1-(2-(2-
(2-aminoethylamino)ethylamino)ethyl)-N10-(3,4-
dihydroxyphenethyl)decanediamide (127)
N1, N2, N3-tris(tert-butoxycarbonyl)-triethylenetetramine (131)
To a solution of triethylenetetramine (1.00 g, 6.84 mmol) in 80 mL of dry MeOH at -78
°C under N2, ethyltrifluoroacetate (0.97 g, 6.84 mmol) was added dropwise over 45
mins. Stirring was continued for another 45 min at -78 °C, the temperature was
increased to 0 °C and the mixture was further stirred for 1h. Without isolation of the
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mono-trifluoroacetamide derivative obtained, the remaining amino groups were
protected by dropwise addition of di-tert-butyl dicarbonate (5.56 g, 25.64 mmol) in 10
mL of dry MeOH over 30 min at 0 °C. The reaction was then allowed to go to r.t. and
stirred for 20 h before removing the solvent. The residue was dissolved in CH2Cl2 and
washed with a saturated solution of NaHCO3 and water. The organic layer was dried,
filtered and evaporated. The crude residue was purified by column chromatography
with 50/1= CH2Cl2/MeOH as eluent to give the protected oligoethyleneamine in 90%
yield. The next reaction was carried out directly on a solution of thw fully protected
compound (3.00 g, 6.00 mmol) in 79 mL of MeOH where potassium carbonate (0.88 g
in 7.6 mL of H2O) was added and refluxed for 20 h. The solvent was removed under
reduced pressure and the residue was diluted with CH2Cl2 and washed with H2O. The
organic layer was dried over Na2SO4 and concentrated to yield the crude product, that
was then purified by column chromatography with 80/20/1= CH2Cl2/MeOH/NH4OH as
eluent to obtain amine 131 with 30% yield. 1H NMR, 400 MHz, CDCl3, δ: 1.39 (s, 2H,
NH2), 1.43 (s, 27H, C(CH3)3), 2.79 (bt, 2H, CH2NH2), 3.23–3.30 (m, 10H, CH2N and
CH2NH).
4-((4-(2,5-dioxopyrrolidin-1-yloxy)-4-oxobutyl)disulfanyl)butanoic acid (129)
To a solution of dithiodibutyric acid 34 (2.00 g, 8.40 mmol) in dry THF (15 mL), N-
hydroxysuccinimide (1.16 g, 10.08 mmol) was added followed by a solution of DCC
(1.77 g, 8.57 mmol) in 5 mL of dry THF at 0°C. The mixture was stirred for 15 min,
then DMAP (0.01, 0.08 mmol) was added. The reaction mixture was allowed to go to
r.t. and stirred overnight. The white precipitate was filtered and the solvent was
removed from the filtrate to give a residue that was then dissolved in CH2Cl2 and
washed with water. The organic layer was dried over Na2SO4, filtered and evaporated.
The crude product obtained was purified by flash chromatography with
1/1=EtOAc/CH2Cl2 as eluent to give activated acid 129 in 72% yield. 1H NMR, 400
MHz, CD3OD, δ: 1.98 (quintet, J=7.2 Hz, 2H, CH2); 2.14 (quintet, J=7.2 Hz, 2H, CH2);
2.42 (t, J=7.2 Hz, 2H, CH2); 2.72-2.89 (m, 10H, CH2).
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10-(2,5-dioxopyrrolidin-1-yloxy)-10-oxodecanoic acid (130)
Sebacic acid 128 (2.00 g, 9.89 mmol) was dissolved in dry THF (25 mL). To this
solution N-hydroxysuccinimide (1.36 g, 11.87 mmol) was added followed by a solution
of DCC (2.02 g, 10.09 mmol) in 5 mL of dry THF at 0°C. The mixture was stirred for
15 min, then DMAP (0.01 g, 0.08 mmol) was added. The reaction mixture was allowed
to go to r.t. and stirred for 7 h. The white precipitate was filtered and the solvent was
removed from the filtrate to give a residue that was then re-dissolved in CH2Cl2 and
washed with water. The organic layer was dried over Na2SO4, filtered and evaporated
and the crude product obtained was purified by flash chromatography with
1/2=EtOAc/CH2Cl2 as eluent to give activated acid 130 in 72% yield. 1H NMR, 400
MHz, CDCl3, δ: 1.20-1.42 (m, 12H, CH2); 1.55 (quintet, J=7.2 Hz, 2H, CH2); 1.70
(quintet, J=7.2 Hz, 2H, CH2); 2.30 (t, J=7.2Hz, 2H, CH2); 2.30 (t, J=7.2Hz, 2H, CH2);
2.56 (t, J=7.2Hz, 2H, CH2); 2.80 (s, 4H, CH2).
8,11-bis(tert-butoxycarbonyl)-2,2-dimethyl-4,15-dioxo-3-oxa-19,20-dithia-5,8,11,14-
tetraazatetracosan-24-oic acid (132)
TEA was added to a solution of 131 (0.20 g, 0.45 mmol) in DMF/H2O (5 mL/5 mL),
until pH 9 is reached. This basic solution was then added to a solution of 129 (0.15 g,
0.45 mmol) in 15 mL of DMF. The reaction mixture was stirred for 18 h under argon,
then poured onto water and extracted with EtOAc (6x100 mL). The recollected organic
layers were washed with water, dried over Na2SO4, filtered and concentrated. The
residue was purified by flash chromatography with 25/1=CH2Cl2/MeOH → 15/1 as 
eluent to yield amide 132 in 98% yield. 1H NMR, 400 MHz, CD3OD, δ: 1.43 (s, 9H,
CH3); 1.47 (s, 18H, CH3); 1.96-2.01 (m, 5H, CH2 + NH); 2.29-2.31 (m, 2H, CH2); 2.42
(t, J=7.2 Hz, 2H, CH2); 2.69-2.76 (m, 4H, CH2); 3.18 (t, J=6.0 Hz, 2H, CH2); 3.26-3.37
(m, 10H, CH2).
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8,11-bis(tert-butoxycarbonyl)-2,2-dimethyl-4,15-dioxo-3-oxa-5,8,11,14-
tetraazatetracosan-24-oic acid (133)
TEA was added to a solution of 131 (0.20 g, 0.45 mmol) in DMF/H2O (5 mL/5 mL),
until pH 9 is reached. This basic solution was then added to another solution of 130
(0.15 g, 0.45 mmol) in 11 mL of DMF. The reaction mixture was stirred for 18 h under
argon, then poured onto water and extracted with EtOAc (6x100 mL). The recollected
organic layers were washed with water, dried over Na2SO4, filtered and concentrated.
The residue was purified by flash chromatography with 50/1=CH2Cl2/MeOH as eluent
to yield amide 133 in 99% yield. 1H NMR, 400 MHz, CDCl3, δ: 1.20-1.30 (m, 12H,
CH2); 1.43 (s, 9H, CH3); 1.47 (s, 18H, CH3); 1.52-1.61 (m, 1H, NH); 2.13 (at, J=7.2 Hz,
2H, CH2); 2.30 (t, J=7.2 Hz, 2H, CH2); 3.18-3.45 (m, 12H, CH2).
Dopamine-8,11-bis(tert-butoxycarbonyl)-2,2-dimethyl-4,15-dioxo-3-oxa-19,20-dithia-
5,8,11,14-tetraazatetracosan-24-oic amide (134)
Compound 132 (0.37 g, 0.56 mmol) and dopamine hydrochloride (0.10 g, 0.61 mmol)
were dissolved in 10 mL of DMSO. The solution was degassed under argon and cooled
to 0 °C before adding HBTU (0.26 g, 0.70 mmol) and DIPEA (380 µL, 2.22 mmol).
The reaction mixture was then stirred at r.t. for 64 h, concentrated and, after the
addition of EtOAc washed with HCl 1M and water. The resulting solution was dried
over Na2SO4, filtered and concentrated to give the desired dopamine derivative 134 in
79% yield without further purification. 1H NMR, 400 MHz, (CD3)2CO, δ: 1.43 (s, 9H,
CH3); 1.47 (s, 18H, CH3); 1.95-2.01 (m, 4H, CH2); 2.24-2.28 (m, 24H, CH2); 2.61-2.72
(m, 4H, CH2); 3.19 (t, J=6.0 Hz, 2H, CH2); 3.26-3.37 (m, 10H, CH2)¸6.51 (dd, J1 =8.0
Hz, J2 =1.8 Hz, 1H, Harom); 6.32-6.68 (m, 2H, Harom).
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Dopamine-,11-bis(tert-butoxycarbonyl)-2,2-dimethyl-4,15-dioxo-3-oxa-5,8,11,14-
tetraazatetracosan-24-oic amide (135)
Compound 133 (0.28 g, 0.44 mmol) and dopamine hydrochloride (0.08 g, 0.49 mmol)
were dissolved in 8 mL of DMSO. The solution was degassed with argon and cooled to
0 °C before adding HBTU (0.21 g, 0.56 mmol) and DIPEA (0.24 g, 1.79 mmol). The
reaction mixture was then stirred at r.t. for 64 h, concentrated and, after the addition of
EtOAc, washed with HCl 1M and water. The resulting solution was dried over Na2SO4,
filtered and concentrated to give the desired dopamine derivative 135 in 99% yield
without further purification. 1H NMR, 400 MHz, CDCl3, δ: 1.21-1.29 (m, 12H, CH2);
1.35-1.59 (m, 31H, CH3 + CH2); 2.11-2.17 (m, 4H, CH2); 2.62 (at, J=7.2 Hz, 2H, CH2);
3.19 (bs, 2H, CH2); 3.27-3.41 (m, 10H, CH2); 6.51 (d, J=8.0 Hz, 1H, Harom); 6.66-6.75
(m, 2H, Harom).
N-(2-(2-(2-aminoethylamino)ethylamino)ethyl)-4-((4-(3,4-dihydroxyphenethylamino)-4-
oxobutyl)disulfanyl)butanamide (126)
Compound 134 (0.34 g, 0.43 mmol) was dissolved in 15 mL of CH2Cl2 and TFA (5.00
mL, 43.17 mmol) was added. The mixture was stirred under argon for 4 h, then the
solvent was removed under vacuum and the residue was purified by washing with
Hexane (7 times) and Et2O (twice) to obtain amine 126 with 90% yield. 1H NMR, 400
MHz, CD3OD, δ: 1.87-2.03 (m, 4H, CH2); 2.25 (t, J=7.2 Hz, 2H, CH2); 2.34 (t, J=7.2
Hz, 2H, CH2); 2.64 (at, J=7.2 Hz, 2H, CH2); 2.71 (at, J=7.2 Hz, 2H, CH2); 3.25 (bs, 2H,
CH2); 3.27-3.41 (m, 14H, CH2); 6.51 (d, J=8.0 Hz, 1H, Harom); 6.66-6.75 (m, 2H,
Harom).
Experimental Section
142
N1-(2-(2-(2-aminoethylamino)ethylamino)ethyl)-N10-(3,4-
dihydroxyphenethyl)decanediamide (127)
Compound 135 (0.34 g, 0.45 mmol) was dissolved in 15 mL of CH2Cl2 and TFA (5.00
mL, 43.17 mmol) was added. The mixture was stirred under argon for 4 h. The solvent
was removed under vacuum and the residue was purified by washing with Hexane (3
times) and Et2O (twice) to obtain amine 127 in 99% yield. PM=466
1H NMR, 400 MHz, CD3OD, δ: 1.21-1.29 (m, 8H, CH2); 1.51-1.62 (m, 4H, CH2); 2.13
(t, J=7.2 Hz, 2H, CH2); 2.22 (t, J=7.6 Hz, 2H, CH2); 2.61-2.69 (m, 2H, CH2); 3.23 (bs,
2H, CH2); 3.27-3.41 (m, 12H, CH2); 6.51 (d, J=8.0 Hz, 1H, Harom); 6.66-6.75 (m, 2H,
Harom).
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Synthesis of FePt (~ 4 nm) nanoparticles99
One typical synthetic procedure is as follows: under airless condition, platinum
acetylacetonate (197 mg, 0.5 mmol), 1,2-hexadecanediol (390 mg, 1.5 mmol), and
dioctylether (20 ml) were mixed and heated to 100°C. Oleic acid (0.16 ml, 0.5 mmol),
oleyl amine (0.17 ml, 0.5 mmol), and Fe(CO)5 (0.13 ml, 1 mmol) were added, and the
mixture was heated to reflux (297°C). The refluxing was continued for 30 min. The
heat source was then removed, and the reaction mixture was allowed to cool to room
temperature. The inert gas protected system could be opened to ambient environment at
this point. The black product was precipitated by adding ethanol (40 ml) and separated
by centrifugation. Yellow-brown supernatant
was discarded. The black precipitate was dispersed in hexane (25 ml) in the presence of
oleic acid (0.05 ml) and oleyl amine (0.05 ml) and precipitated out by adding ethanol
(20 ml) and centrifuging. The product was dispersed in hexane (20 ml), centrifuged to
remove any unsolved precipitation (almost no precipitation was found at this stage), and
precipitated out by adding ethanol (15 ml) and centrifuging. The materials were
redispersed and stored in hexane solution.
Synthesis of water soluble FePtNPs 136 and 137, 5 mg of oleic acid and oleylamine
stabilized FePt NPs were mixed with 10 mg of deprotected derivative of 99 (SH-C11-
TEG-OH) in CH2Cl2. The mixture was stirred overnight then to the resulting SH-C11-
TEG-OH functionalized FePtNPs, 7.5 mg of DOP-PEI (126 or 127) were added and the
reaction mixture stirred for 2 days at 35 °C. The functionalized NPs were then purified
by multiple filtrations through a molecular weight cut-off filter and dissolved in water.
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